EP0923287A1 - Nonclassical pyrrolo 2,3-d]pyrimidine antifolates - Google Patents

Nonclassical pyrrolo 2,3-d]pyrimidine antifolates

Info

Publication number
EP0923287A1
EP0923287A1 EP97939567A EP97939567A EP0923287A1 EP 0923287 A1 EP0923287 A1 EP 0923287A1 EP 97939567 A EP97939567 A EP 97939567A EP 97939567 A EP97939567 A EP 97939567A EP 0923287 A1 EP0923287 A1 EP 0923287A1
Authority
EP
European Patent Office
Prior art keywords
eth
pyrimidin
amino
optionally substituted
ylcarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97939567A
Other languages
German (de)
French (fr)
Other versions
EP0923287A4 (en
Inventor
Christopher L. Jordan
Vinod F. Patel
Daniel J. Soose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0923287A1 publication Critical patent/EP0923287A1/en
Publication of EP0923287A4 publication Critical patent/EP0923287A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Definitions

  • the invention relates generally to the fields of pharmaceutical and synthetic organic chemistry. Specifically, the invention relates to the field of antifolate compounds which are useful in the treatment of various diseases.
  • folic acid is used by a number of cells to fuel cell replication.
  • Antifolate compounds mimic folic acid and its derived cofactors when taken up in a cell.
  • Antifolates interact with various folate requiring enzymes in cells to eventually cause the inhibition of cell replication.
  • Antifolate compounds are known to be useful in the treatment of cancer by providing a means to terminate the growth of malignant cells .
  • Classical antifolate compounds such as the multi-targeted antifolate LY 231514 (N- [4- [2- (2-amino-3H- 4-oxo-pyrrolo[2, 3-D]pyrimidin-5-yl ) ethyl] benzoyl] -L- glutamic acid)
  • FPGS folylpolyglutamate synthetase
  • DHFR dihydrofolate reductase
  • GAFT glycinamide ribonucleotide formyl transferase
  • TS thymidylate synthase
  • One way of increasing efficacy, in terms of inhibiting cell replication, is to provide an antifolate that does not contain a terminal glutamic acid moiety in the "L" configuration, thus avoiding the need for polyglutamation with FPGS.
  • the difficulty in providing such a compound is that the compound, in order to be effective in inhibiting cell replication, must still be able to effectively inhibit with other folate requiring enzymes even though it is not polyglutamated.
  • the concept of using a non-polyglutamatable inhibitor was suggested in 1983 as an approach to the design of novel DHFR inhibitors targeted against FPGS deficient tumors. See "Methotrexate Analogues. 20. Replacement of Glutamate by Longer-Chain Amino Diacids: Effects on Dihydrofolate Reductase Inhibition,
  • Non-polyglutamatable inhibitors were also described for the GARFT enzyme in "First Use of the Taylor Pteridine Synthesis as a Route to Polyglutamate Derivatives of Antifolates. 46. Side Chain Modified 5- deazafolate and 5-deazatetrahydrofolate Analogs as Mammalian Folypolyglutamate Synthetase and Glycinamide Ribonucleotide Formyl Transferase Inhibitors: Synthesis and in Vitro Biological Evaluation", Rosowsky, et al . , J ⁇ . Med. Chem. , (1992), 35(9), 1578-88.
  • the first aspect of the invention is a compound of formula (III) :
  • W and G are independently -H, optionally substituted C1-C6 alkyl, optionally substituted aryl, -NR 3 R 4 , -SR 5 , -OR 6 or halo, R 3 and R 4 are independently -H, optionally substituted Ci-Cg alkyl, or a suitable amino protecting group, or together N, R 3 and R * -" are a phthalimido group,
  • R 5 is -H, optionally substituted C1-C6 alkyl or a suitable thiol protecting group
  • R 6 is -H, optionally substituted Ci-C ⁇ alkyl or a suitable hydroxy protecting group
  • L is -R 7 -Q(a)--
  • -CH2CH CH-, -CH2C ⁇ C- and -C ⁇ CCH2 ⁇ , and when R 7 is not -C ⁇ C-, R 7 may be substituted with C1-C2 alkyl, C1-C2 hydroxyalkyl, or C1-C2 hydroxyalkyl wherein the H on the hydroxy moiety has been replaced with a hydroxy protecting group, Q is -0-, -S- or -NR 8 -, a is zero or 1,
  • R 8 is -H, optionally substituted C1-C3 alkyl, alkoxycarbonyl or phenoxycarbonyl ;
  • B is selected from the group consisting of: optionally substituted 1,2-, 1,3-, or 1,4- phenylene, optionally substituted 2,3-, 2,4-, or 2,5- thiophenediyl , optionally substituted 2,3-, 2,4-, or 2,5- furandiyl, optionally substituted 1,2-, 1,3-, or 1,4- cyclohexanediyl, and optionally substituted -CH2CH2-, -CH2CH2CH2-, or -CH2CH2CH2CH2-,
  • A) an ⁇ -amino acid residue selected from the group consisting of -alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine and -valine, OR
  • R ⁇ are each independently -H or a suitable carboxylic acid protecting group
  • R 11 is i) -COOR 10 , where R 10 is -H, optionally substituted alkyl or a suitable carboxylic acid protecting group, or ii) -H, -OH, 1-carboxyeth-l-yl , optionally substituted C1-C alkyl, optionally substituted cycloalkyl, carboxycycloalkyl, optionally substituted aryl, carboxyaryl, optionally substituted heteroaryl, optionally substituted alkyl (aryl), optionally substituted Ci-C ⁇ alkoxy, optionally substituted polycyclic, optionally substituted 5-tetrazolyl, or iii) -(CH2)e- where: e is 0, 1, 2, 3 or 4, U is -O-CH2-COOH, -S-CH2-COOH or -NR 12 R 25 ,
  • R1 is -H or a suitable amino protecting group
  • R 25 is benzoyl or carboxybenzoyl , or iv) -(CH2) e -T, where e is as above, T is phthalimido, -CO2R 10 , -SO(g)X, -NR 13 R 14 , -CONR 13 R 14 , CONHSO2R 15 , -PO3H2 or -CO- ⁇ - a ino acid residue
  • R-LO is as above, g is zero, 1, 2 or 3 , providing that when g is zero, 1 or 2 , X is optionally substituted Cj_-C6 alkyl, and when g is 3, X is -H,
  • R 13 is -H
  • R 14 is -H, optionally substituted C1-C6 alkyl
  • R 15 is optionally substituted alkyl, optionally substituted aryl, benzyl or carboxyaryl, and each R-'-'-' is independently -H or optionally substituted alkyl, and each ⁇ -amino acid residue is as above ; providing that all of R 11 is so configured such that
  • D- or L-glutamic acid is not D- or L-glutamic acid, -alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine or -valine; OR
  • each R 9 ' is independently -H or a suitable carboxylic acid protecting group
  • RU' is i) -COOR 10 ', where R 10 ' is -H, optionally substituted alkyl or a suitable carboxylic acid protecting group, ii) -H, -OH, 1-carboxyeth-l-yl , optionally substituted Ci-C ⁇ alkyl, optionally substituted cycloalkyl, carboxycycloalkyl, optionally substituted aryl, carboxy aryl, optionally substituted heteroaryl, optionally substituted aryl (alkyl), optionally substituted alkoxy, optionally substituted polycyclic, optionally substituted 5- tetrazolyl, or iii) -(CH2)e'-U ⁇ where: e' is zero, 1, 2, 3 or 4,
  • U' is -0-CH2 -COOH, -S-CH2 -COOH, or -NR 12, R 25 ',
  • R--- 2 ' is -H or a suitable amino protecting group
  • R ⁇ ' is benzoyl or carboxybenzoyl , iv) -(CH2)e'-T', where e 1 is as above,
  • T 1 is phthalimido, -CO2R 10 ', -S0( g ')X', -NR 1 'R 14 ', -CONR 13 'R 1 ' , -CONHSO2R 15 ' , -PO3H2 or -CO- ⁇ - amino acid residue, where
  • R-LO ' is as above, g' is zero, 2 or 3 , providing that when g' is zero or 2 , X' is optionally substituted C1-C alkyl, and when g' is 3, X' is -H, R 13 ' is -H,
  • R-*- 4 ' is -H, optionally substituted Ci-C ⁇ alkyl,
  • R 15 ' is optionally substituted alkyl, optionally substituted aryl, benzyl or carboxyaryl, and each R!6 ' is independently -H or optionally substituted alkyl;
  • R! is optionally substituted C3-C20 cycloalkyl or C3-C2O carboxycycloalkyl
  • R 2 is -H
  • J is optionally substituted 5-tetrazolyl or optionally substituted C1-C6 alkyl
  • y is zero or 1
  • y' is zero, 1, 2, 3, 4, 5 or 6 and R 11 is as above, and R 2 is -H;
  • j is zero, or an integer from 1 to 10
  • k is zero, or an integer from 1 to 10
  • R1 7 and R--- are independently -H or a suitable carboxylic acid protecting group
  • R 1 and R 2 are both - (CH2 ) n-COOR 17 , where n is zero, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and
  • R 17 is as defined above;
  • R 2 is:
  • R- 1 - 7 is as above, and
  • Y is selected from the group consisting of halo, nitro, amino and optionally substituted alkyl; or a pharmaceutically acceptable salt or solvate thereof.
  • a second aspect of the invention is an active ester intermediate of formula (I) :
  • a further aspect of the invention is a process to make the compounds of formula (III), or pharmaceutically acceptable salts or solvates thereof, by reacting an active ester of formula (I):
  • R 1 and R2 are as defined previously, in the presence of either a silylating agent or a suitable base.
  • a further aspect of this invention is a continuation of the process of the second aspect of the invention, further comprising a rapid work-up procedure wherein a compound or salt of formula (III) is isolated and purified by the following procedure: a) optionally adding a suitable diamine; b) adding a suitable aqueous acid; c) separating the product from its solvent; d) preparing the product physically for collecting, washing and drying; and e) collecting, washing and drying the product.
  • a further aspect of the invention is a pharmaceutical composition comprising a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, m combination with a pharmaceutically acceptable carrier, diluent or excipient.
  • a further aspect of the invention is a method of treating susceptible neoplasms in a mammal in need of such treatment comprising administering a neoplasm growth inhibiting amount of a compound of formula (III) , or a pharmaceutically acceptable salt or solvate thereof, to a mammal .
  • a further aspect of the invention is a method of treating arthritis in a mammal comprising administering an arthritis inhibiting amount of a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, to a mammal .
  • a further aspect of this invention is a method of treating psoriasis in a mammal comprising administering an arthritis inhibiting amount of a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, to a mammal.
  • alkyl refers to a fully saturated monovalent group having the stated number of carbon atoms containing only carbon and hydrogen, and which may be a straight chain or branched group. This term is exemplified by groups containing from 1-6 carbon atoms, such as, but not limited to, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, hexyl, and neohexyl . "Lower alkyl” refers to alkyl groups of from 1-3 carbon atoms .
  • cycloalkyl refers to a fully saturated monovalent ring which contains only carbon atoms in the ring.
  • the "cycloalkyl” groups used herein contain at least 3 and at most 20 carbon atoms in the ring.
  • Carboxycycloalkyl is a cycloalkyl structure that has from one to three -COOH groups in place of hydrogen (s) normally attached to carbon atoms in the ring.
  • C ⁇ -C6 alkoxy refers to a straight or branched alkyl chain having from one to six carbon atoms attached to an oxygen atom.
  • Typical C ⁇ -C6 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and the like.
  • C2 ⁇ C alkenyl refers to a monovalent, straight or branched chain containing only two to six carbon atoms with hydrogens attached and which contains at least one double bond.
  • Alkoxycarbonyl is the group RO-C- / where R is Ci-
  • Phenoxycarbonyl is the group PhO-C- t w ere Ph is phenyl .
  • ⁇ -Amino acid residues includes optionally substituted -alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine and -valine.
  • the preferred ⁇ -amino acid for the compounds of this invention is an ⁇ - amino acid in the L-configuration at the ⁇ carbon.
  • the amino acid residue group is bonded to the carbonyl group of Compound III through the ⁇ amino nitrogen.
  • Aryl refers to a monovalent aromatic structure.
  • aromatic refers to a structure containing one or more groups of carbon atoms in a cyclic array that contains clouds of delocalized ⁇ electrons above and below the plane of the atoms; furthermore, the ⁇ clouds must contain a total of (4q+2) ⁇ electrons, where q is any positive integer.
  • these aromatic rings can contain from six to ten carbon atoms. Within this range of possible numbers of carbon atoms present, each aromatic ring must retain its aromatic character and be sterically feasible.
  • Aromatic rings may optionally be substituted, with the proviso that only one to three of the hydrogens may be replaced.
  • heteroaryl refers to a monovalent aromatic structure containing from four to ten carbon atoms and at least one non-carbon atom selected from the group consisting of N, 0 or S, within the ring.
  • heteroaryl rings include single rings, such as pyrrolidino, pyridino, pyrimidino or fused rings such as quinolo, purino, pyrido or pyrrolo [2 , 3-d] pyrimidino .
  • An aryl (alkyl) group consists of at least one aryl group substituted with at least one alkyl group.
  • halo refers to fluoro, bromo, iodo and chloro .
  • a 5-tetrazolyl group is:
  • benzoyl refers to this structure
  • carboxybenzoyl refers to this structure
  • polycyclic refers to two or more rings that share two or more carbon atoms.
  • polycyclic compounds will be limited to monovalent ring systems that have only carbon atoms in the rings and that have either two or three rings.
  • the number of carbon atoms in each ring varies from 4 to 8.
  • substituted means one to three hydrogens on the structure have been replaced with one to three moieties independently selected from the group consisting of bromo, chloro, iodo, fluoro, C ⁇ -C6 alkyl, -N02, aryl, difluoromethoxy, and trihaloalkyl, wherein the halo can be bromo, chloro, iodo or fluoro and the alkyl is C1-C3 alkyl, with the proviso that any substituted structure must be so configured that it is sterically feasible, affords a stable structure and is capable of reacting as described herein.
  • a “pharmaceutically acceptable salt” may be any salt derived from an inorganic or organic acid that is suitable for administration as a drug.
  • the salts are derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid (giving the sulfate and bisulfate as acid salts), nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, p-toluenesulfonic acid, hexanoic acid, heptanoic acid, cyclopent
  • a “pharmaceutically acceptable solvate” refers to a form of a compound that has one or more solvent molecules clinging to the molecules of the compound and which form is suitable for administration as a drug.
  • the solvent may be water, alcohol or any common organic solvent.
  • treatment means administering an appropriate therapeutic or prophylactic amount of a compound of the present invention to a mammal.
  • effective amount means a dosage sufficient to cause a positive change in the disease state being treated.
  • positive change will vary in meaning depending on the patient, the disease and the treatment.
  • an effective amount of an oncolytic could be an amount that causes a reduction in the size of a cancerous tumor, or where no reduction in tumor size occurs, an effective amount of an oncolytic could be defined simply as that amount that causes a decrease in analgesic consumption for the patient suffering from cancer.
  • protecting group refers to a group affixed to a substrate group for the purpose of preventing the substrate group from reacting at the wrong time or with a non-targeted reagent to yield an undesired product.
  • amino protecting group refers to substituents on an amino group commonly employed to block or protect the amino functionality while allowing other unprotected functional groups on the compounds to react .
  • amino protecting groups include the for yl group, the trityl group, the t-butoxy carbonyl (BOO group, the phthalimido group, the pivaloyl group, the trichloroacetyl group, the chloroacetyl, bromoacetyl and iodoacetyl groups, urethane- type blocking groups such as the benzoylmethylsulfonyl group, the 2-(nitro) phenylsulfenyl group, the diphenylphosphine oxide group and like amino protecting groups .
  • amino protecting group employed is not critical so long as the derivatized amino group is stable to the condition of subsequent reaction ( ⁇ ) on other positions of the intermediate molecule and can be selectively removed at the appropriate point without disrupting the remainder of the molecule including any other amino protecting group (s) .
  • Further examples of amino protecting groups can be found in the references: J. W. Barton, "Protective Groups in Organic Chemistry", J. G. W. McOmie, Ed., Plenum Press, New York, N.Y., 1973 Chapter 2; and T. W. Greene, P.G.M. Wuts, "Protective Groups in Organic Synthesis-2nd Edition", John Wiley and Sons, New York, N.Y., 1991, Chapter 7.
  • carboxylic acid protecting group refers to groups commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound.
  • carboxylic acid protecting groups include 4-n ⁇ trobenzyl, 4-methoxybenzyl, 3 , 4-d ⁇ methoxybenzyl , 2,4- dimethoxybenzyl, 2 , 4, 6-tr ⁇ methoxybenzyl, 2,4,6- tnmethylbenzyl, pentamethylbenzyl , 3,4- methylenedioxybenzyl , benzhydryl , 4,4' -dimethoxybenzhydryl , 2,2 ' ,4, 4 ' -tetramethoxybenzhydryl, methyl, ethyl, propyl, isopropyl, t-butyl, t-amyl, t ⁇ tyl, 4-methoxytr ⁇ tyl , 4,4'- dimethoxytntyl
  • carboxylic acid protecting group employed is not critical so long as the derivatized carboxylic acid is stable to the condition of subsequent reaction (s) on other positions of the molecule and can be removed at the appropriate point without disrupting the remainder of the molecule. Further examples of these groups are found in Chapter 5 of the Barton book, "Protective Groups in Organic Chemistry", and Chapter 5 of the Greene-Wuts book,
  • a related term is "protected carboxy", which refers to a carboxy group substituted with one of the above carboxy protecting groups.
  • Hydroxy protecting groups include C ⁇ -C6 alkyl, C -
  • hydroxy protecting groups can be found in the Greene-Wuts book.
  • Thiol protecting groups include benzyl, alkyl benzyl, hydroxybenzyl, acetoxybenzyl , nitrobenzyl, fluorenylmethyl , ferrocenylmethyl , diphenylmethyl, Bis (4- methoxyphenyl) methyl, 5-dibenzosuberyl, triphenylmethyl, diphenyl-4-pyridylmethyl, phenyl, 2 , 4-dinitrophenyl , t- butyl, 1-adamantyl, monothio, dithio and aminothioacetals, and thiazolidine. Further examples of thiol protecting groups can be found in the Greene-Wuts book.
  • protecting groups are chosen to perform their "protecting" function and are also chosen to be removable from the substrate group without the cleavage reaction affecting the remainder of the substrate group.
  • the compounds of this invention are herein described as embodying both the pyrrolo [2 , 3-d] pyrimidine heterocyclic ring system which ring system is numbered as follows :
  • the compounds of this invention can exist as an equilibrium mixture with their tautomeric isomers. Illustrated below are the partial structural formulae capable of undergoing tautomerism, with the equilibria among them being shown as well.
  • G , W NH2 , OH , or SH ;
  • G ' , W ' NH , 0 or S .
  • G A preferred group for G is -OH, with the understanding that the structure exists primarily in the G' keto form.
  • Preferred groups for W are -NH2 and -CH3.
  • a preferred group for L is optionally substituted -CH2CH2-.
  • Preferred groups for B are optionally substituted 1, 4-phenylene and 2 , 5-thiophenediyl .
  • Preferred groups for are as follows: -alanine,
  • amino acid residue group is bonded to the carbonyl group of Compound III through the ⁇ -amino nitrogen.
  • the group is bonded to the carbonyl group of Compound III through the preferred groups terminal nitrogen.
  • N- ⁇ [ (2 -methyl-4-hydroxypyrrolo [2 , 3- d]pyrimidin-5-yl) eth-2 -yl ] phen-4-ylcarbonyl ⁇ alanine is equivalent to N- ⁇ [ (2-methyl-3H-4-oxo-pyrrolo [2 , 3- d]pyrimidin-5-yl) eth-2 -yl] phen-4-ylcarbonyl) alanine .
  • the compounds of the present invention can be made via a process entitled "Rapid Analogue Process” or RAP.
  • the "rapid” part of the process refers to the relative rapid rate that non-classical antifolates can be synthesized, isolated and purified, when using this process.
  • R ⁇ O is selected from the group consisting of N-hydroxysuccinimidyl N-hydroxysulphosuccinimidyl and salts thereof, 2- nitrophenyl, 4-nitrophenyl and 2 , 4-dichlorophenyl, with an amine of formula (II) : HNR!R 2 ( I I )
  • Silylating agents are selected from any reagent capable of attaching a silyl group to a target group.
  • Typical silylating agents include any reagent with a trialkylsilyl group such as trimethylsilyl, triethylsilyl , triisopropylsilyl , dimethylisopropylsilyl , diethylisopropylsilyl, dimethylthexylsilyl, and t- butyldimethylsilyl, any reagent with an alkylarylsilyl group such as tribenzylsilyl , diphenylmethylsilyl , t- butylmethoxyphenylsilyl and tri-p-xylylsilyl , and any reagent with a triarylsilyl group such as triphenylsilyl .
  • a trialkylsilyl group such as trimethylsilyl, triethylsilyl , triisopropylsilyl , dimethylisopropylsilyl , diethylisopropylsilyl
  • the preferred silylating agent is a trimethyl silylating agent.
  • Typical trimethyl silylating agents include N,0- Bis (trimethylsilyl ) acetamide, allyltrimethylsilane, N,0- Bis (trimethylsilyl ) -carbamate, N, - Bis ( trimethylsilyl )methylamine, Bis (trimethylsilyl) sulfate, N, O-Bis (trimethylsilyl) trifluoroacetamide, N,N-
  • Bis (trimethylsilyl) rea trimethylsilane, ethyl trimethyl silylacetate, hexamethyldisilane, hexamethyldisilazane, hexamethyldisiloxane, hexamethyldisilylthiane, (isopropenyloxy) trimethyl silane, l-methoxy-2 -methyl-1- trimethyl-siloxy-propene, (methylthio) trimethylsilane, methyl 3-trimethylsiloxy-2-butenoate, N-methyl-N- trimethylsilylacetamide, methyl trimethylsilylacetate, N- methyl-N-trimethylsilylhepta-fluorobutyramide, N-methyl-N- trimethylsilyl-trifluoroacetamide, (phenylthio) trimethylsilane, trimethylbromosilane, trimethylchlorosilane, trimethyliodosilane, 4- trimethylsiloxy-3-penten
  • a more preferred silylating agent is N,0-bis- ( trimethylsilyl) acetamide.
  • the N,0-Bis (trimethylsilyl ) acetamide acts to protect carboxylic acid groups present, as well as any hydroxy group present, on the active ester and/or the amine of formula II.
  • trimethylsilyl protecting agent An added benefit of using a trimethylsilyl protecting agent is that the trimethylsilyl protected forms of the amine/active ester tend to be more soluble which leads to better yields in the reaction. It is also believed, without intending to be bound thereby, that the silylation of the N atoms activates the amino group towards nucleophilic attack. Protection of the carboxylic acid groups on the active ester of formula (I) and the amine of formula (II) permits the coupling of the active ester and amine to form the compounds of formula (III) .
  • the reaction takes place at a temperature preferably between about 25 C and about 100 C, more preferably between about 40 C and about 80 C, and most more preferably between about 50 C and about 60 C.
  • the reaction should take place in a solvent. Any non-reactive organic solvent such as dimethylformamide, ethyl acetate, methylene chloride, toluene or acetonitrile is suitable.
  • the preferred solvent is dimethylformamide . It takes between about 5 hours and 70 hours to make a measurable amount of product.
  • the reaction is run for about 10 hours to about 60 hours and more preferably the reaction is run for about 16 hours to about 48 hours.
  • ⁇ — ⁇ , L and B are as defined previously, with an alcohol under known conditions.
  • the active ester is a N-hydroxysuccinimide (NHS) ester
  • a compound of formula (IV) is reacted with N-hydroxysuccinimide (NHS) in a suitable solvent, such as dimethylformamide (DMF), under known conditions (such as room temperature stirring for approximately 24 hours after addition of 1,3-dicyclo- hexylcarbodimide) .
  • a suitable solvent such as dimethylformamide (DMF)
  • DMF dimethylformamide
  • the preferred active ester is a N- hydroxysuccinimide ester.
  • Compounds of formula (IV) can be made using known technology in the art of pyrrolo [ 2 , 3-d] pyrimidinyl fused ring system antifolate chemistry.
  • ⁇ -'- is the 5, 6-dihydropyrrolo [2, 3- d]pyrimidin-yl fused ring system
  • compounds of formula (IV) can be made by following the procedures described in, "The Synthesis of N- ⁇ 2-Amino-4-Substituted [ ( Pyrrolo [2 , 3- d] Pyrimidin-5-yl) Ethyl] Benzoyl ⁇ -L-Glutamic Acids as Antineoplastic Agents", Shih and Gossett, Heterocvcles . Vol. 35, No. 2, 1993.
  • Amines of formula (II) can be made by standard techniques known in the art. See for example, Organic Chemistry, pp.
  • reaction of compound (I) and compound (II) to make the compound of formula (III) can also take place in the presence of a suitable strong base.
  • suitable strong bases include NaOH, KOH, etc.
  • the preferred strong base is NaOH.
  • An advantage of the claimed process is that it includes a rapid work-up procedure wherein the compound of formula (III) is isolated from the reaction mixture by performing the following steps: a) optionally adding a suitable diamine; b) adding a suitable aqueous acid; c) separating the product from its solvent; d) preparing the product physically for collecting, washing and drying; and e) collecting, washing and drying the product.
  • a suitable diamine is any diamine capable of reacting with unreacted active ester to create a product with an amine functionality. This product with an amine functionality can then be washed out of the reaction mixture, along with unreacted HNRIR * -- .
  • One such suitable diamine is ethylene diamine. The addition of the diamine is optional, though preferred.
  • the suitable acid is a mineral acid selected from the group consisting of HCl, HBr, HI, and HF.
  • the preferred suitable acid is HCl.
  • the most preferred suitable acid is
  • aqueous HCl 1 Normal aqueous HCl .
  • Separating the product from its solvent can be done by any technique known in the art .
  • One such method is to strip the solvent from the product by heating the solvent.
  • the solvent is a high-boiling solvent
  • another solvent, or mixture of solvents can be added to form a lower-boiling azeotropic mixture which can be boiled off at a lower temperature.
  • Typical solvents used to create a lower boiling azeotropic solvent mixture can be selected from the group consisting of o-xylene, m-xylene, p-xylene, toluene, benzene, and mixtures thereof.
  • the most preferred solvent for this purpose is a mixture of o-xylene, m-xylene and p-xylene.
  • Preparing the product physically for collecting, washing and drying involves breaking up the clumped product into particles sufficiently small so that the particles may readily be collected by any suitable technique such as by filtration or evaporation. After collection, the product is washed and dried. Any method can be used to break up the product . A preferred method is sonicating the product in the presence of acid.
  • Collecting, washing, and drying can be accomplished using standard techniques in the art of organic chemistry.
  • the product can be collected by filtering it through a Buchner funnel, then washing it with water and then ether, and then drying it in a vacuum oven.
  • This invention includes pharmaceutically acceptable salts and solvates of all compounds.
  • the pharmaceutically acceptable salts of the invention are typically formed by reacting a compound of formula (III) which possesses one or more suitable acidic or basic functionalities with an equimolar or slight excess amount of base or acid.
  • the reactants generally are combined in a mutual solvent such as diethyl ether or benzene for acid addition salts, or water or alcohols for base addition salts .
  • the salt usually precipitates out of solution within about 1 hour to about 10 days, and can be isolated by filtration or other conventional means.
  • some of the compounds of the present invention may form solvates with water or common organic solvents. Such solvates are included as compounds of this invention .
  • esters may be modified to form esters, using techniques known in the art. These ester compounds typically contain C1-C4 alkyl moieties in place of the acid hydrogen. These ester intermediates are also considered to be part of the invention.
  • the compounds of the present invention may be administered to any mammal. Of all mammals, it is believed that humans will benefit the most from administration of these compounds .
  • the compounds of the present invention are antineoplastic agents.
  • An embodiment of the present invention provides a method of treating susceptible neoplasms in mammals, preferably humans, in need of such treatment.
  • the present compounds are useful in inhibiting the growth of neoplasms or "cancers", including, but not limited to, carcinoma, sarcoma, melanoma, colorectal, choriocarcinoma, prostate, leukemia, breast, squamous or small cell lung cancer, non-small cell lung cancer, ovarian, testicular, adenocarcinoma, epidermal, lymphosarcoma, pancreatic, head and neck, kidney, bone and liver cancer.
  • the compounds are tested for their ability to inhibit the growth of certain tumor cell lines and data reported as standard ICso's and Ki inhibition constants.
  • the compounds of the present invention are also useful in the treatment of psoriasis and arthritis, in mammals, preferably humans.
  • the compounds of the present invention can be administered orally, parenterally, or by means of insufflation or by insertion of a suppository.
  • the compounds can be administered individually or in combination, preferably parenterally, and usually in the form of a pharmaceutical composition.
  • Parenteral routes of administration include intramuscular, intrathecal, subcutaneous, intravenous, intra-arterial , intraorbital , intracapsular, intraspinal, and intrasternal .
  • Oral dosage forms, including tablets and capsules, contain from 1 to 3000 mg of drug per unit dosage. Isotonic saline solutions containing 1-100 mg/mL can be used for parenteral administration .
  • compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Accordingly, the present invention also includes pharmaceutical compositions comprising as active ingredient one or more compounds of formula (III) associated with at least one pharmaceutically acceptable carrier, diluent or excipient .
  • the active ingredients are usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container.
  • a carrier which can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, carrier or medium for the active ingredient.
  • the compositions can be in the form of tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum arabic, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidinone, cellulose, water, syrup, and methyl cellulose
  • the formulations can additionally include lubricating agents such as talc, magnesium stearate and mineral oil, wetting agents, emulsifying and suspending agents, preserving agents such as methyl- and propyl - hydroxybenzoates, sweetening agents or flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions are preferably formulated in a unit dosage form with each dosage normally containing from about 0.1 milligrams per square meter of body surface area (mg/M 2 ) to about 3000 mg/M 2 , more usually about 10 mg/M 2 to about 250 mg/M 2 of the active ingredient.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical excipient.
  • NMR nuclear magnetic resonance spectrum
  • IR infrared spectrum
  • UV ultraviolet spectrum
  • MS mass spectrometry
  • °C refers to degrees Celsius
  • DMF dimethylformamide
  • g refers to gram or grams
  • h refers to hour or hours
  • kPa refers to kiloPascals
  • L refers to liter or liters
  • mg refers to milligrams
  • ml refer to milliliter or milliliters
  • mol refers to moles,
  • mmol refers to millimole or millimoles
  • N refers to normal or normality
  • psi refers to pounds per square inch
  • RT refers to room temperature.
  • Step 1 Synthesis of ethyl 4 4-diethoxy-2-cyano-butanoate
  • Step 5 Synthesis of 2-methyl-3H-4-oxo-5- (trimethylsilylethyne) -pyrrolo[2, 3-d]pyrimidine
  • Step 7 Synthesis of 2-methyl-3H-4-oxo-5-(2-(4- carboxyphenyl ) ethynyl )pyrrolo [2,3-d]pyrimidine
  • Step 9 Synthesis of 4- ⁇ [2-methyl-4-oxo-3H-pyrrolo[2, 3- d]pyrimidin-5-yl]eth-2-yl ⁇ benzoic acid (N-succinimide ester) "Active Ester” (compound of formula (I))
  • Step 3 Synthesis of ⁇ 2- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl)eth-2-yl]thiophen-5-yl ⁇ carboxylic acid (N- succinimide ester) "Active Ester” (compound of formula I)
  • step 2 To a stirred solution of the carboxylic acid from Preparation 2 , step 2 (1.2 g, 3.8 mmol) and N- hydroxysuccinimide (661 mg, 5.8 mmol) in N,N- dimethyl formamide (40 mL) was added 1,3- dicyclohexylcarbodiimide (1.2 g, 5.8 mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 24 hours and then filtered to remove dicyclohexylurea.
  • Step 2 Synthesis of 2-t-butylacetamidyl-3H-4-oxo- pyrrolo [2 , 3-d] pyrimidine
  • Step 3 Synthesis of 2-t-butylacetamidyl-3H-4-oxo-5- (trimethylsilylethyne) -pyrrolo [2, 3-d]pyrimidine
  • Step 6 Synthesis of ⁇ 2-fluoro-4- [(2-t-butylacetamidyl-3H-4- oxo-pyrrolo [2, 3-d]pyrimidin-5-yl) -eth-2-yl] ⁇ benzoic acid methyl ester
  • Step 7 Synthesis of ⁇ 2-fluoro-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) -eth-2-yl] ⁇ benzoic acid:
  • Step 8 Synthesis of ⁇ 2-f luoro-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d] pyrimidin- 5 -yl) -eth-2 -yl] ⁇ benzoic acid (N- succinimide ester) :
  • Step 1 Synthesis of 4- [ (2-t-butylacetamidyl-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) -ethyn-2-yl] benzoic acid:
  • Step 4 To a solution of the acetylene from Preparation 3, Step 4 (258 mg, 1.0 mmol) and 4-iodobenzo ⁇ c acid (248 mg, 1.0 mmol) in CHCN (4 mL) was added N-O- bis (trimethylsilyl) acetamide (671 mg, 0.82 mL, 3.3 mmol) and the reaction was stirred at 40°C for 2 hours In a separate flask, a mixture of palladium(II) chloride (9 mg, 0.05 mmol) and triphenylphosphine (26 mg, 0.1 mmol) in DMF (1 mL) was stirred at RT for 90 minutes.
  • palladium(II) chloride 9 mg, 0.05 mmol
  • triphenylphosphine 26 mg, 0.1 mmol
  • Triethylamine (182 mg, 0.25 mL, 1.8 mmol) was added to acetylene mixture followed by the triphenylphosphine-palladium chloride mixture. The reaction was then refluxed for 2 hr, cooled and H;0 was added (1 mL containing 6-8 drops of IN HCl) . The resulting solid was filtered, washed with CH 3 CN and dried m vacuo. The crude product was purified by flash chromatography on silica gel (0.25% AcOH/10% MeOH/CH 2 Cl 2 ) to give 111 mg product (29%) as a tan solid.
  • Step 2 Synthesis of 4- [ (2-t-butylacetamidyl-3H-4-oxo- pyrrolo [2,3-d] yrimidin-5-yl ) -eth-2-yl]benzoic acid:
  • Step 1 To a solution of acetylene from Preparation 4, Step 1 (497 mg, 1.31 mmol) in methanol (15 mL) was added 5% Pd/C (250 mg) and the mixture was stirred under 60 psi (414 kPa) H at 50°C for 24 hours The reaction was filtered, concentrated in vacuo and triturated with methanol . The resulting solid was filtered and dried to give 232 mg product (46%) as off-white solid.
  • Step 3 Synthesis of 4- [ ⁇ 2-amino-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl) -eth-2-yl] benzoic acid:
  • Step 2 (5.76 g, 15.1 mmol) in EtOH (200 mL) was added p- toluenesulfonic acid monohydrate (6.30 g, 33.1 mmol) and the mixture was stirred at reflux for 16 hours The reaction was cooled and the resulting precipitate was filtered, washed with EtOH and dried in vacuo to give 5.22 g product as tosic acid salt (74%) .
  • a sample was dissolved in aqueous LiOH and the solution was acidified to pH 3 with IN HCl, the solid was filtered, washed with H0 and dried in vacuo to give product as a tan solid.
  • Step 4 Synthesis of 4- [ (2-amino-3H-4-oxo-pyrrolo[2,3- d]pyrimidin-5-yl) -eth-2-yl]benzoic acid (N-succinimide ester) :
  • Step 4 To a solution of acid from Preparation 4, Step 4 (10.0 g, 33.5 mmol) and N-hydroxysuccinimide (4.24 g, 36.9 mmol) in DMF (150 mL) was added 1 , 3-dicyclohexylcarbodiimide (7.61 g, 36.9 mmol) and the reaction was stirred at RT overnight. After 20 hr, the mixture was filtered and the clear solution concentrated in vacuo. The crude product was triturated with 20% iPrOH/EtOAc and filtered, then triturated again and dried in vacuo to give 10.36 g product (76%) as off-white solid.
  • active ester refers to succinimide ester made by the preparation described in any of Preparation 1, 2, 3 or 4 ; and the term amine refers to an amine of Formula II (namely: HNR---R 2 , where R 1 and R*-- are as described previously) .
  • Step 4 (75 mg, 0.19 mmol) and isopropyl amine (50 ⁇ L, 0.57 mmol) in CHCl /MeOH was stirred at room temperature under nitrogen for 2.5 hours. The reaction was concentrated in vacuo, and the crude product was sonicated in aqueous HCl and filtered. The solid was sonicated in H0, the solid was filtered and dried to give the product as an off-white solid (42 mg, 66%) .
  • Step 1 Synthesis of ⁇ -t-butyl- ⁇ -4- carboxymethylphenylsulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-y1) eth-2-y1]benzoylglutamate :
  • Step 2 Synthesis of ⁇ -t -butyl - ⁇ -4-carboxyphenylsulfonamyl- N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d] pyrimidin- 5 -yl) eth-2 - yl] benzoyl -L-glutamic acid:
  • Step 3 Synthesis of ⁇ -4-carboxyphenylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo[2,3-d]pyrimidin-5-yl)eth-2- yl]benzoyl-L-glutamic acid:
  • Step 2 Synthesis of ⁇ -t-butyl- ⁇ -3-carboxyphenylsulfonamyl- N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3 -d] pyrimidin- 5 -yl) eth-2 - yl] benzoyl -L-glutamic acid:
  • Step 3 Synthesis of ⁇ -3-carboxyphenylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl) eth-2- yl]benzoyl-L-glutamic acid:
  • the resulting dimethyl ester precursor of the above-depicted compound (61 mg, 0.12 mmol) was reacted with IN aqueous NaOH (0.36 mL, 0.36 mmol) in dioxane (3 mL) and H0 (2 mL) at 50°C for 4 hours The reaction was concentrated and the crude product was sonicated with IN aqueous HCl and the resulting solid was filtered, washed with H0, Et 0 and dried to give the product as a green solid (43 mg, 74%) .
  • Step 1 Synthesis of ⁇ -t-butyl- ⁇ -methylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl ) eth-2- yl]b ⁇ nzoyl-glutamate:
  • Step 2 Synthesis of ⁇ -methylsulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl]benzoyl-L-glutamic acid:
  • Step 1 Synthesis of dimethyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] -benzoyl-4- carboxyphenylglycinate
  • Step 2 Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl) eth-2-yl] -benzoyl-4-carboxyphenylglycine
  • Step 1 Synthesis of ⁇ -t-butyl- ⁇ -ethanesulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo[2,3-d] -pyrimidin-5-yl) eth-2- yl] benzoyl-gluta te :
  • Step 2 Synthesis of ⁇ -ethanesulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2,3-d] -pyrimidin-5-yl ) eth-2-yl]benzoyl- - glutamic acid:
  • Step 1 Synthesis of ⁇ -t-butyl- ⁇ -n-butylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo[2,3-d] -pyrimidin-5-yl)eth-2- yl]benzoyl glutamate:
  • Carboxylic acid 400 mg, 0.83 mmol
  • n- butylsulfonamide 340 mg, 2.48 mmol
  • Step 2 Synthesis of ⁇ -n-b tylsulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2, 3-d] -pyrimidin-5-yl) eth-2-yl]benzoyl-L- glutamic acid:
  • Step 2 Synthesis of 4-isopropylsulfonamyl-N-4- [ (2-amino-3H- 4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl ) eth-2-yl]benzoyl- - glutamic acid:
  • Step 1 Synthesis of ⁇ - ( -toluenesulfonamyl) -N-4- [ (2-amino-3H-4-oxo- pyrrolo[2, 3-d]pyrimidin-5-yl]eth-2-yl] -benzoyl-L-glutamic acid: Step 1: Synthesis of ⁇ -t-butyl- ⁇ - ( ⁇ -toluenesulfonamyl) -N-4- [ (2-amino-3H-4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl] eth-2-yl] - benzoyl glutamate :
  • Step 2 Synthesis of ⁇ - ( ⁇ -toluenesulfonamyl) -N-4- [ (2-amino- 3H-4-oxo-pyrrolo[2,3-d]pyrimidin-5-yl]eth-2-yl]benzoyl-L- glutamic acid:
  • Step 1 Synthesis of ⁇ -t-butyl- ⁇ -4-benzenesulfonamyl-N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2- yl] benzoyl-glutamate :
  • Step 2 Synthesis of ⁇ -4-benzenesulfonamyl-N-4- [ (2-amino-3H- 4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl) eth-2-yl] benzoyl-L- glutamic acid:
  • Carboxylic acid 500 mg, 1.03 mmol
  • methyl 2- (aminosulfonyl) benzoate 668 mg, 3.10 mmol
  • Sulfonamide Coupling Procedure for 18 hours to give the methyl benzoate ester/pivaloate ester of the above- depicted compound as a white solid (363 mg, 51%) .
  • Step 1 Synthesis of dimethyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2-yl] -benzoyl-3- carboxyphenylglycinate :
  • Step 2 Synthesis of N-4- [ ( 2 -amino -3H- 4 -oxo -pyrrolo [2 , 3- d] pyrimidin-5 -yl ) eth-2 -yl ] -benzoyl - 3 -carboxyphenylglycine :

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nonclassical pyrrolo[2,3-d]pyrimidine antifolates are described and claimed. Also described and claimed is a rapid analog process which enables a quick work-up of the antifolate which avoids costly and time-consuming chromatographic separation techniques. Also described and claimed are methods of treating susceptible neoplasms with these nonclassical antifolates. Also described and claimed are methods of treating psoriasis and arthritis with these nonclassical antifolates.

Description

NONCLASSICAL PYRROLO \ 2 .3-Dl PYRIMIDINE ANTIFOLATES
The invention relates generally to the fields of pharmaceutical and synthetic organic chemistry. Specifically, the invention relates to the field of antifolate compounds which are useful in the treatment of various diseases.
Through a mechanism of enzyme catalyzed reactions, folic acid is used by a number of cells to fuel cell replication. Antifolate compounds mimic folic acid and its derived cofactors when taken up in a cell. Antifolates interact with various folate requiring enzymes in cells to eventually cause the inhibition of cell replication. Antifolate compounds are known to be useful in the treatment of cancer by providing a means to terminate the growth of malignant cells . Classical antifolate compounds, such as the multi-targeted antifolate LY 231514 (N- [4- [2- (2-amino-3H- 4-oxo-pyrrolo[2, 3-D]pyrimidin-5-yl ) ethyl] benzoyl] -L- glutamic acid)
* the configuration around this carbon is L
(U.S. Patent No. 5,334,932), have a glutamic acid moiety in the natural or "L" configuration on one end of the molecule. Upon entry of a classical antifolate into a cell, the enzyme folylpolyglutamate synthetase (FPGS) causes a polyglutamation reaction to take place at the glutamic acid end of the antifolate. The polyglutamated antifolate then can interact with other folate requiring enzymes such as dihydrofolate reductase (DHFR) , glycinamide ribonucleotide formyl transferase (GARFT) and/or thymidylate synthase (TS) . Interaction of the polyglutamated antifolate with DHFR and/or GARFT and/or TS and/or other folate utilizing enzymes eventually leads to inhibition of cell replication. It has been observed that efficacy, in terms of inhibiting cell replication, of classical antifolates can decrease with continued use of the antifolate. One possible explanation for this observed phenomenon is that malignant cells become resistant toward classical antifolates through impaired (less efficient) polyglutamation reaction(s). As a polyglutamated antifolate interacts better with folate requiring enzymes than does a monoglutamated antifolate, this lack of polyglutamation could be sufficient to account for the decline in efficacy.
One way of increasing efficacy, in terms of inhibiting cell replication, is to provide an antifolate that does not contain a terminal glutamic acid moiety in the "L" configuration, thus avoiding the need for polyglutamation with FPGS. The difficulty in providing such a compound is that the compound, in order to be effective in inhibiting cell replication, must still be able to effectively inhibit with other folate requiring enzymes even though it is not polyglutamated. The concept of using a non-polyglutamatable inhibitor was suggested in 1983 as an approach to the design of novel DHFR inhibitors targeted against FPGS deficient tumors. See "Methotrexate Analogues. 20. Replacement of Glutamate by Longer-Chain Amino Diacids: Effects on Dihydrofolate Reductase Inhibition,
Cytotoxicity, and in Vivo Antitumor Activity", Rosowsky, et al . , J. Med. Chem. , (1983), 26, 1719-1724. In addition, several derivatives of folic acid in which the terminal L-glutamate moiety is replaced by L-ornithine have been shown to be effective inhibitors of FPGS in "Synthesis and Biological Evaluation of Nα-(5- Deaza-5, 6, 7, 8-tetrahydropteroyl) -L-ornithine" , Singh, et al . , J. Med. Chem.. (1992), 35(11), 2002-6.
Non-polyglutamatable inhibitors were also described for the GARFT enzyme in "First Use of the Taylor Pteridine Synthesis as a Route to Polyglutamate Derivatives of Antifolates. 46. Side Chain Modified 5- deazafolate and 5-deazatetrahydrofolate Analogs as Mammalian Folypolyglutamate Synthetase and Glycinamide Ribonucleotide Formyl Transferase Inhibitors: Synthesis and in Vitro Biological Evaluation", Rosowsky, et al . , J^. Med. Chem. , (1992), 35(9), 1578-88.
What are needed are pyrrolo [2 , 3-d] yrimidine non-classical antifolates, configured such that they are non-polyglutamatable, but also configured such that they can inhibit folate requiring enzymes. The first aspect of the invention is a compound of formula (III) :
where :
W and G are independently -H, optionally substituted C1-C6 alkyl, optionally substituted aryl, -NR3R4, -SR5, -OR6 or halo, R3 and R4 are independently -H, optionally substituted Ci-Cg alkyl, or a suitable amino protecting group, or together N, R3 and R*-" are a phthalimido group,
R5 is -H, optionally substituted C1-C6 alkyl or a suitable thiol protecting group, and
R6 is -H, optionally substituted Ci-Cβ alkyl or a suitable hydroxy protecting group;
L is -R7-Q(a)-- where
R7 is selected from the group consisting of -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH=CH-, -C≡C-, -CH=CHCH2~,
-CH2CH=CH-, -CH2C≡C- and -C≡CCH2~, and when R7 is not -C≡C-, R7 may be substituted with C1-C2 alkyl, C1-C2 hydroxyalkyl, or C1-C2 hydroxyalkyl wherein the H on the hydroxy moiety has been replaced with a hydroxy protecting group, Q is -0-, -S- or -NR8-, a is zero or 1,
R8 is -H, optionally substituted C1-C3 alkyl, alkoxycarbonyl or phenoxycarbonyl ;
B is selected from the group consisting of: optionally substituted 1,2-, 1,3-, or 1,4- phenylene, optionally substituted 2,3-, 2,4-, or 2,5- thiophenediyl , optionally substituted 2,3-, 2,4-, or 2,5- furandiyl, optionally substituted 1,2-, 1,3-, or 1,4- cyclohexanediyl, and optionally substituted -CH2CH2-, -CH2CH2CH2-, or -CH2CH2CH2CH2-,
A) an α-amino acid residue, selected from the group consisting of -alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine and -valine, OR
where c is zero or 1, d is zero, 1, 2, 3, 4, 5 or 6, R^ are each independently -H or a suitable carboxylic acid protecting group, and R11 is i) -COOR10, where R10 is -H, optionally substituted alkyl or a suitable carboxylic acid protecting group, or ii) -H, -OH, 1-carboxyeth-l-yl , optionally substituted C1-C alkyl, optionally substituted cycloalkyl, carboxycycloalkyl, optionally substituted aryl, carboxyaryl, optionally substituted heteroaryl, optionally substituted alkyl (aryl), optionally substituted Ci-Cβ alkoxy, optionally substituted polycyclic, optionally substituted 5-tetrazolyl, or iii) -(CH2)e- where: e is 0, 1, 2, 3 or 4, U is -O-CH2-COOH, -S-CH2-COOH or -NR12R25,
R1 is -H or a suitable amino protecting group, R25 is benzoyl or carboxybenzoyl , or iv) -(CH2)e-T, where e is as above, T is phthalimido, -CO2R10, -SO(g)X, -NR13R14, -CONR13R14, CONHSO2R15 , -PO3H2 or -CO-α- a ino acid residue, R-LO is as above, g is zero, 1, 2 or 3 , providing that when g is zero, 1 or 2 , X is optionally substituted Cj_-C6 alkyl, and when g is 3, X is -H,
R13 is -H,
R14 is -H, optionally substituted C1-C6 alkyl,
O II optionally substituted C5-C7 aryl, -CHR16NR15R16 , C-aryl f or a suitable amino protecting group,
R15 is optionally substituted alkyl, optionally substituted aryl, benzyl or carboxyaryl, and each R-'-'-' is independently -H or optionally substituted alkyl, and each α-amino acid residue is as above ; providing that all of R11 is so configured such that
is not D- or L-glutamic acid, -alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine or -valine; OR
where s', b' and C are independently zero or 1, d' is zero, 1, 2, 3, 4, 5 or 6, each R9 ' is independently -H or a suitable carboxylic acid protecting group, RU' is i) -COOR10', where R10' is -H, optionally substituted alkyl or a suitable carboxylic acid protecting group, ii) -H, -OH, 1-carboxyeth-l-yl , optionally substituted Ci-Cβ alkyl, optionally substituted cycloalkyl, carboxycycloalkyl, optionally substituted aryl, carboxy aryl, optionally substituted heteroaryl, optionally substituted aryl (alkyl), optionally substituted alkoxy, optionally substituted polycyclic, optionally substituted 5- tetrazolyl, or iii) -(CH2)e'-U\ where: e' is zero, 1, 2, 3 or 4,
U' is -0-CH2 -COOH, -S-CH2 -COOH, or -NR12,R25',
R---2 ' is -H or a suitable amino protecting group, R ^' is benzoyl or carboxybenzoyl , iv) -(CH2)e'-T', where e1 is as above,
T1 is phthalimido, -CO2R10', -S0(g')X', -NR1 'R14', -CONR13 'R1 ' , -CONHSO2R15 ' , -PO3H2 or -CO-α- amino acid residue, where
R-LO ' is as above, g' is zero, 2 or 3 , providing that when g' is zero or 2 , X' is optionally substituted C1-C alkyl, and when g' is 3, X' is -H, R13 ' is -H,
R-*-4 ' is -H, optionally substituted Ci-Cβ alkyl,
optionally substituted C5-C7 aryl, -CHR16 'NR15 ' R16 ' , O n
-C-aryl^ or a suitable amino protecting group, R15' is optionally substituted alkyl, optionally substituted aryl, benzyl or carboxyaryl, and each R!6 ' is independently -H or optionally substituted alkyl;
OR D) R! is optionally substituted C3-C20 cycloalkyl or C3-C2O carboxycycloalkyl, and
R2 is -H; OR
where J is optionally substituted 5-tetrazolyl or optionally substituted C1-C6 alkyl, y is zero or 1, y' is zero, 1, 2, 3, 4, 5 or 6 and R11 is as above, and R2 is -H;
OR
where j is zero, or an integer from 1 to 10, k is zero, or an integer from 1 to 10,
R17 and R--- are independently -H or a suitable carboxylic acid protecting group; OR
G) R1 and R2 are both - (CH2 ) n-COOR17 , where n is zero, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and
R17 is as defined above; OR
—Nχ
H) R2 is:
or
where m is zero, 1 or 2,
R-1-7 is as above, and
Y is selected from the group consisting of halo, nitro, amino and optionally substituted alkyl; or a pharmaceutically acceptable salt or solvate thereof.
A second aspect of the invention is an active ester intermediate of formula (I) :
where Θv--'- , L and B have the same definitions as above, and R60 is selected from the group consisting of N-hydroxy- succinimidyl, N-hydroxysulphosuccinimidyl and salts thereof, 2-nitrophenyl, 4-nitrophenyl and 2 , -dichlorophenyl . A further aspect of the invention is a process to make the compounds of formula (III), or pharmaceutically acceptable salts or solvates thereof, by reacting an active ester of formula (I):
where Θ^-^- , L and B and R^O are as defined previously, with an amine of formula (II) : HNR---R2 (II),
where R 1 and R2 are as defined previously, in the presence of either a silylating agent or a suitable base.
A further aspect of this invention is a continuation of the process of the second aspect of the invention, further comprising a rapid work-up procedure wherein a compound or salt of formula (III) is isolated and purified by the following procedure: a) optionally adding a suitable diamine; b) adding a suitable aqueous acid; c) separating the product from its solvent; d) preparing the product physically for collecting, washing and drying; and e) collecting, washing and drying the product. A further aspect of the invention is a pharmaceutical composition comprising a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, m combination with a pharmaceutically acceptable carrier, diluent or excipient. A further aspect of the invention is a method of treating susceptible neoplasms in a mammal in need of such treatment comprising administering a neoplasm growth inhibiting amount of a compound of formula (III) , or a pharmaceutically acceptable salt or solvate thereof, to a mammal . A further aspect of the invention is a method of treating arthritis in a mammal comprising administering an arthritis inhibiting amount of a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, to a mammal .
A further aspect of this invention is a method of treating psoriasis in a mammal comprising administering an arthritis inhibiting amount of a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, to a mammal.
The term "alkyl" refers to a fully saturated monovalent group having the stated number of carbon atoms containing only carbon and hydrogen, and which may be a straight chain or branched group. This term is exemplified by groups containing from 1-6 carbon atoms, such as, but not limited to, methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, hexyl, and neohexyl . "Lower alkyl" refers to alkyl groups of from 1-3 carbon atoms . The term "cycloalkyl" refers to a fully saturated monovalent ring which contains only carbon atoms in the ring. The "cycloalkyl" groups used herein contain at least 3 and at most 20 carbon atoms in the ring. Carboxycycloalkyl is a cycloalkyl structure that has from one to three -COOH groups in place of hydrogen (s) normally attached to carbon atoms in the ring.
The term Cχ-C6 alkoxy refers to a straight or branched alkyl chain having from one to six carbon atoms attached to an oxygen atom. Typical Cχ-C6 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and the like.
The term "C2~C alkenyl" refers to a monovalent, straight or branched chain containing only two to six carbon atoms with hydrogens attached and which contains at least one double bond. 0 I
Alkoxycarbonyl is the group RO-C- / where R is Ci-
Cβ alkyl
O
II
Phenoxycarbonyl is the group PhO-C- t w ere Ph is phenyl . α-Amino acid residues includes optionally substituted -alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine and -valine. Of these, all but glycine are chiral at the α carbon. Therefore, except for glycine, all these amino acid residues can exist in separate D and L orms or in racemic mixtures thereof . The preferred α-amino acid for the compounds of this invention is an α- amino acid in the L-configuration at the α carbon. For all of these α-amino acid residue groups the amino acid residue group is bonded to the carbonyl group of Compound III through the α amino nitrogen.
"Aryl" refers to a monovalent aromatic structure. The term "aromatic" refers to a structure containing one or more groups of carbon atoms in a cyclic array that contains clouds of delocalized π electrons above and below the plane of the atoms; furthermore, the π clouds must contain a total of (4q+2) π electrons, where q is any positive integer. For purposes of this application, these aromatic rings can contain from six to ten carbon atoms. Within this range of possible numbers of carbon atoms present, each aromatic ring must retain its aromatic character and be sterically feasible. Aromatic rings may optionally be substituted, with the proviso that only one to three of the hydrogens may be replaced.
The term "heteroaryl" refers to a monovalent aromatic structure containing from four to ten carbon atoms and at least one non-carbon atom selected from the group consisting of N, 0 or S, within the ring. Examples of heteroaryl rings include single rings, such as pyrrolidino, pyridino, pyrimidino or fused rings such as quinolo, purino, pyrido or pyrrolo [2 , 3-d] pyrimidino .
An aryl (alkyl) group consists of at least one aryl group substituted with at least one alkyl group.
The term "halo" refers to fluoro, bromo, iodo and chloro .
A 5-tetrazolyl group is: The term benzoyl refers to this structure
The term carboxybenzoyl refers to this structure
The term "polycyclic" refers to two or more rings that share two or more carbon atoms. For purposes of this application, polycyclic compounds will be limited to monovalent ring systems that have only carbon atoms in the rings and that have either two or three rings. The number of carbon atoms in each ring varies from 4 to 8.
The term "substituted" means one to three hydrogens on the structure have been replaced with one to three moieties independently selected from the group consisting of bromo, chloro, iodo, fluoro, Cχ-C6 alkyl, -N02, aryl, difluoromethoxy, and trihaloalkyl, wherein the halo can be bromo, chloro, iodo or fluoro and the alkyl is C1-C3 alkyl, with the proviso that any substituted structure must be so configured that it is sterically feasible, affords a stable structure and is capable of reacting as described herein.
The term "optionally substituted" means that the structure may or may not be substituted as described above. A "pharmaceutically acceptable salt" may be any salt derived from an inorganic or organic acid that is suitable for administration as a drug. The salts are derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid (giving the sulfate and bisulfate as acid salts), nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, p-toluenesulfonic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, lactic acid, o- (4-hydroxybenzoyl) benzoic acid, 1 , 2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2.2.2] oct-2-ene-l- carboxylic acid, glucoheptonic acid, 4 , 4 ' -methylenebis (3- hydroxy-2-naphthoic) acid, 3 -phenylpropionic acid, trimethylacetic acid, t-butylacetic acid, laurylsulfonic acid, glucuronic acid, glutamic acid, 3 -hydroxy-2 -naphthoic acid, stearic acid, muconic acid and the like.
A "pharmaceutically acceptable solvate" refers to a form of a compound that has one or more solvent molecules clinging to the molecules of the compound and which form is suitable for administration as a drug. The solvent may be water, alcohol or any common organic solvent.
The term "treatment" or "treating" means administering an appropriate therapeutic or prophylactic amount of a compound of the present invention to a mammal. The term "effective amount" means a dosage sufficient to cause a positive change in the disease state being treated. The term "positive change" will vary in meaning depending on the patient, the disease and the treatment. For example, an effective amount of an oncolytic could be an amount that causes a reduction in the size of a cancerous tumor, or where no reduction in tumor size occurs, an effective amount of an oncolytic could be defined simply as that amount that causes a decrease in analgesic consumption for the patient suffering from cancer.
The term "protecting group" refers to a group affixed to a substrate group for the purpose of preventing the substrate group from reacting at the wrong time or with a non-targeted reagent to yield an undesired product.
The term "amino protecting group" as used in the specification refers to substituents on an amino group commonly employed to block or protect the amino functionality while allowing other unprotected functional groups on the compounds to react . Examples of such amino protecting groups include the for yl group, the trityl group, the t-butoxy carbonyl (BOO group, the phthalimido group, the pivaloyl group, the trichloroacetyl group, the chloroacetyl, bromoacetyl and iodoacetyl groups, urethane- type blocking groups such as the benzoylmethylsulfonyl group, the 2-(nitro) phenylsulfenyl group, the diphenylphosphine oxide group and like amino protecting groups . The species of amino protecting group employed is not critical so long as the derivatized amino group is stable to the condition of subsequent reaction (ε) on other positions of the intermediate molecule and can be selectively removed at the appropriate point without disrupting the remainder of the molecule including any other amino protecting group (s) . Further examples of amino protecting groups can be found in the references: J. W. Barton, "Protective Groups in Organic Chemistry", J. G. W. McOmie, Ed., Plenum Press, New York, N.Y., 1973 Chapter 2; and T. W. Greene, P.G.M. Wuts, "Protective Groups in Organic Synthesis-2nd Edition", John Wiley and Sons, New York, N.Y., 1991, Chapter 7. The term "carboxylic acid protecting group" as used herein refers to groups commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound. Examples of such carboxylic acid protecting groups include 4-nιtrobenzyl, 4-methoxybenzyl, 3 , 4-dιmethoxybenzyl , 2,4- dimethoxybenzyl, 2 , 4, 6-trιmethoxybenzyl, 2,4,6- tnmethylbenzyl, pentamethylbenzyl , 3,4- methylenedioxybenzyl , benzhydryl , 4,4' -dimethoxybenzhydryl , 2,2 ' ,4, 4 ' -tetramethoxybenzhydryl, methyl, ethyl, propyl, isopropyl, t-butyl, t-amyl, tπtyl, 4-methoxytrιtyl , 4,4'- dimethoxytntyl, 4, 4' 4"- tπmethoxy-trityl , 2-phenylprop-2- yl, trimethylsilyl, t-butyldimethyl-silyl , phenacyl, 2,2,2- trichloroethyl, β- (trimethylsilyl ) -ethyl , β-(dι(n- butyl )methylsιlyl) ethyl, p-toluenesulfonyl-ethyl , 4- nitrobenzylsulfonylethyl , allyl, cmnamyl, 1- ( trimethylsilylmethyl) -prop-l-en-3-yl , and like moieties. The species of carboxylic acid protecting group employed is not critical so long as the derivatized carboxylic acid is stable to the condition of subsequent reaction (s) on other positions of the molecule and can be removed at the appropriate point without disrupting the remainder of the molecule. Further examples of these groups are found in Chapter 5 of the Barton book, "Protective Groups in Organic Chemistry", and Chapter 5 of the Greene-Wuts book,
"Protective Groups in Organic Synthesιs-2nd Edition".
A related term is "protected carboxy", which refers to a carboxy group substituted with one of the above carboxy protecting groups. Hydroxy protecting groups include Cχ-C6 alkyl, C -
C alkylthiol, aryl, aryl (alkyl), C2-C6 alkenyl, C1-C6 alkylhalide, alkylsilyl, such as, but not limited to, trimethylsilyl, triethylsilyl, tπisopropylsilyl , dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, arylsilyl, such as, but not limited to triphenylsilyl , trι-p-xylylsιlyl , heteroaryl alkylsilylalkyl . Further examples of hydroxy protecting groups can be found in the Greene-Wuts book.
Thiol protecting groups include benzyl, alkyl benzyl, hydroxybenzyl, acetoxybenzyl , nitrobenzyl, fluorenylmethyl , ferrocenylmethyl , diphenylmethyl, Bis (4- methoxyphenyl) methyl, 5-dibenzosuberyl, triphenylmethyl, diphenyl-4-pyridylmethyl, phenyl, 2 , 4-dinitrophenyl , t- butyl, 1-adamantyl, monothio, dithio and aminothioacetals, and thiazolidine. Further examples of thiol protecting groups can be found in the Greene-Wuts book.
It is understood that protecting groups are chosen to perform their "protecting" function and are also chosen to be removable from the substrate group without the cleavage reaction affecting the remainder of the substrate group.
The compounds of this invention are herein described as embodying both the pyrrolo [2 , 3-d] pyrimidine heterocyclic ring system which ring system is numbered as follows :
4
and the 5, 6-dihydropyrrolo [2 , 3-d] pyrimidine heterocyclic ring system, which is numbered in a similar manner.
In the above formulae, the compounds of this invention can exist as an equilibrium mixture with their tautomeric isomers. Illustrated below are the partial structural formulae capable of undergoing tautomerism, with the equilibria among them being shown as well.
where G , W = NH2 , OH , or SH ; G ' , W ' = NH , 0 or S .
Throughout this specification, for the purpose of convenience of expression, the ammo, hydroxyl and mercapto forms are to be described, with the corresponding designations being adopted. However, m any description, their tautomers, i.e. the lmmo, oxo and thioxo forms are understood to be included in the scope of this invention.
With all of these tautomers, it is the oxo, amino, and mercapto structures that dominate. Note that the dihydro pyrrolo [2, 3-d] pyrimidine structure has no G substituent, rather the substituent at the 4-position on the dihydro pyrrolo [2 , 3-d] yrimidine structure is H.
A preferred group for G is -OH, with the understanding that the structure exists primarily in the G' keto form.
Preferred groups for W are -NH2 and -CH3.
A preferred group for L is optionally substituted -CH2CH2-. Preferred groups for B are optionally substituted 1, 4-phenylene and 2 , 5-thiophenediyl .
Preferred groups for are as follows: -alanine,
-arginine,
-asparagine,
-aspartic acid,
-cysteine, -cystine,
-glutamine,
-glycine,
-histidine,
-hydroxyproline, -isoleucine,
-leucine,
-lysine,
-methionine,
-phenylalanine , -proline,
-serine,
-threonine,
-tryptophan,
-tyrosine, -valine,
-o-chlorophenylalanine,
-m-chlorophenylalanine,
-p-chlorophenylalanine,
- ' -methanesulfonyl glutamine, -N' -triphenylmethyl glutamine,
-phenylglycine,
-thien-2 -ylglycine,
-o-carboxyphenylglycine,
-m-carboxyphenylglycine , -p-carboxyphenylglycine, -o-hydroxyphenylglycine ,
-m-hydroxyphenylglycine,
-p-hydroxyphenylglycine ,
-eyelohexylglycine, -2 ' -carboxycyclohexylglycine,
-3 ' -carboxycyclohexylglycine.
-4 ' -carboxycyclohexylglycine,
-o-nitrophenylglycine,
-m-nitrophenylglycine, -p-nitrophenylglycine,
-o-aminophenylglycine,
-m-aminophenylglycine ,
-p-aminophenylglycine,
-o-chlorophenylglycine, -m-chlorophenylglycine,
-p-chlorophenylglycine,
-o-bromophenylglycine,
-m-bromophenylglycine,
-p-bromophenylglycine, -o-iodophenylglycine,
-m-iodophenylglycine,
-p-iodophenylglycine,
-o-fluorophenylglycine,
-m-fluorophenylglycine, -p-fluorophenylglycine,
-2-amino-adipic acid,
-2-amino-butanoic acid,
-2-amino-3-hydroxybutanoic acid,
-2-amino-4-phenylbutanoic acid, -2-amino-l , 4-butanedioic acid,
-3 , 3 -dimethyl-2 -amino butanoic acid,
-2 -amino-3 -methyl-1, 5-pentanedioic acid,
-3-methyl-2-amino-pentanoic acid,
-2-amino-pentanoic acid, -2-amino-l, 7-heptanedioic acid,
-3 -carboxy-3 -aminopropanesulfonic acid,
-N- tl-carboxy-3- ( tetrazol -5-yl ) propyl] amino, -N- [1-carboxy-7- ( tetrazol-5-yl) heptyl] amino,
-N- [l-carboxy-4-aminobutyl] mino,
-N- [l-carboxy-4- (tert-butoxycarbonyl amino) butyl] amino,
-N- [l-carboxy-4- (phthalimido-1-yl) butyl] amino, -N-{ [l-carboxy-4- (N' -o-carboxybenzoyl ) amino] butyl) amino,
-N- [ 1-carboxy (3-methoxycarbonyl ) propyl] amino,
-N-{2- [tetrazol-5-yl] ethyl) amino,
-N- (3- [tetrazol-5-yl) propyl)amino,
-N- {4- [ tetrazol-5-yl] butyl) mino, -N-{5- [tetrazol-5-yl] pentyl)amino,
-N-{6- [ tetrazol-5-yl]hexyl) amino,
-N- {7- [tetrazol-5-yl] heptyl } amino,
-2-carboxypiperidine,
-3-carboxypiperidine, -4-carboxypiperidine, and
-methionine sulfoxide.
As stated previously, for α-amino acid residue preferred groups the amino acid residue group is bonded to the carbonyl group of Compound III through the α-amino nitrogen.
For other preferred groups, the group is bonded to the carbonyl group of Compound III through the preferred groups terminal nitrogen.
The following are preferred compounds of formula (III) .
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2- yl ] phen-4-ylcarbonyl } alanine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2,3-d]pyrimidin-5-yl)eth-2- yl ] phen-4-ylcarbonyl }arginine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- y1 ] phen-4-ylcarbonyl ) asparagine , N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl }aspartic acid,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl)cysteine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl }cystine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl )glycine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl)histidine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl }hydroxyproline,
N-{ [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] yrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl) isoleucine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2 , 3-d]pyrimidin-5-yl ) eth-2- yl] phen-4 -ylcarbonyl ) 1eucine ,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl) eth-2 - yi] phen-4-ylcarbonyl) lysine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi] phen- -ylcarbonyl }methionine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yi) phen-4-ylcarbonyl)phenylalanine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yl] phen-4-ylcarbonyl }proline, N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 yi] phen-4 -ylcarbonyl } serine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl ) threonine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl } tryptophan,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4 -ylcarbonyl } tyrosine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl}valine,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl Jalanine,
N-{ [ (2-amino-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2 - yl] phen-4 -ylcarbonyl } arginine ,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrιmidin-5-yl) eth-2- yi] phen-4-ylcarbonyl } asparagine ,
N-{ [ (2-amino-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl }aspartic acid,
N-{ [ (2-ami o-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2- yi]:phen-4-ylcarbonyl } cysteine ,
N-{ [ (2-amino-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi]:phen-4-ylcarbonyl) cystine,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3-d] yrimidin-5-yl ) eth-2- yi]:phen-4 -ylcarbonyl } glycine, N- [ (2-amino-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl)histidine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yl phen-4-ylcarbonyl }hydroxyproline,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl) isoleucine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl } leucine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yi phen-4 -ylcarbonyl) lysine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d)pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl }methionine ,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yl phen-4-ylcarbonyl)phenylalanine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yi phen-4 -ylcarbonyl }proline,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi phen-4-ylcarbonyl)serine,
N- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl } threonine ,
N- [ (2-amino-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl } tryptophan,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yl phen-4-ylcarbonyl) tyrosine, N- { [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi ] phen-4-ylcarbonyl)valine,
N- { 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi ] thiophen-5-ylcarbonyl }alanine,
N- { 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi ] thiophen-5-ylcarbonyl }arginine,
N- { 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yi ] thiophen-5-ylcarbonyl)asparagine,
N- { 2- [ ( 2-methyl-4-hydroxypyrrolo [2,3 -d] pyrimidin-5-yl ) eth-2- yi ] thiophen-5-ylcarbonyl)aspartic acid,
N- { 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl) eth-2 - yi ] thiophen-5-ylcarbonyl)cysteine,
N- { 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi ] thiophen-5-ylcarbonyl } cystine ,
N- { 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi ] thiophen-5-ylcarbonyl } glycine ,
N- { 2- [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl ) eth-2- yi ] thiophen-5-ylcarbonyl)histidine,
N- { 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi ] thiophen-5-ylcarbonyl }hydroxyproline,
N- { 2- ( (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi ] thiophen-5-ylcarbonyl)isoleucine,
N- { 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2- yi ] thiophen-5-ylcarbonyl)leucine, N-{ 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi] thiophen-5-ylcarbonyl } lysine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yi] thiophen-5-ylcarbonyl)methionine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl)phenylalanine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl)proline,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl } serine ,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2 - yi] thiophen-5-ylcarbonyl)threonine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-yl) eth-2 - yi] thiophen-5-ylcarbonyl } tryptophan,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl)tyrosine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3 -d]pyrimidin-5-yl ) eth-2 - yi] thiophen-5-ylcarbonyl }valine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yi] thiophen-5-ylcarbonyl } alanine ,
N-{ 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl)arginine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi] thiophen-5-ylcarbonyl }asparagine, N-{2- [ (2-amino-4-hydroxypyrrolo [2, -d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl)aspartic acid,
N-{2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl)cysteine,
N- {2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yl ] thiophen-5-ylcarbonyl } cystine ,
N-{2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yl ] thiophen-5-ylcarbonyl } glycine ,
N- {2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yl] thiophen-5-ylcarbonyl)histidine,
N-{2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl) eth-2 - yl ] thiophen-5-ylcarbonyl }hydroxyproline ,
N-{2- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl) eth-2 - yl] thiophen-5-ylcarbonyl) isoleucine,
N-{2- [ (2-amino-4-hydroxypyrrolo [2 , 3 -d] yrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl }leucine,
N- {2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yl ] thiophen-5-ylcarbonyl } lysine ,
N- {2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yl] thiophen-5-ylcarbonyl)methionine,
N-{2- [ (2-amino-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yl] thiophen-5-ylcarbonyl)phenylalanine,
N-{2- [ (2-amino-4-hydroxypyrrolo[2 , 3 -d]pyrimidin-5-yl) eth-2 - yl] thiophen-5-ylcarbonyl)proline, N-{2- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yi] thiophen-5-ylcarbonyl)serine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi] thiophen-5-ylcarbonyl}threonine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl)tryptophan,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi] thiophen-5-ylcarbonyl) tyrosine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yi] thiophen-5-ylcarbonyl)valine,
N-{ [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yi] phen-4 -ylcarbonyl } alanine ,
N-{ [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2 - yi] phen-4 -ylcarbonyl } arginine ,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl }asparagine,
N-{ [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl)aspartic acid,
N-{ [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl } cysteine,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl }cystine,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yi] phen-4-ylcarbonyl } glycine , N-{ [ (2-methyl-5, 6-dihydropyrrolo [ 2 , 3-d] pyrimidin-5-yl ) eth-2- yi] phen-4 -ylcarbonyl } histidine ,
N-{ [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl }hydroxyproline,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl } isoleucine,
N-{ [ (2-methyl-5 , 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl) leucine,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl } lysine,
N-{ [ (2 -methyl-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yl] phen-4 -ylcarbonyl Jmethionine,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl)phenylalanine,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3 -d) pyrimidin-5-yl ) eth-2- yi] phen-4 -ylcarbonyl }proline ,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl } serine,
N-{ [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yi] phen-4-ylcarbonyl) threonine,
N-{ [ (2 -methyl -5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl } tryptophan,
N-{ [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi ]phen-4-ylcarbonyl }tyrosine, N-{ [ (2-methyl-5, 6-dihydropyrrolo [2, 3-d] pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl }valine ,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi] phen-4-yicarbonyl }alanine,
N-{ [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl) eth-2 - yi] phen-4 -ylcarbonyl } arginine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl }asparagine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4 -ylcarbonyl }aspartic acid,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi] phen-4-ylcarbonyl)cysteine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4 -ylcarbonyl } cystine,
N-{ [ (2-amino-5 , 6-dihydropyrrolo [2 , 3-d] yrimidin-5-yl ) eth-2- yi] phen-4 -ylcarbonyl } glycine,
N-{ [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4 -ylcarbonyl }histidine,
N-{ [ (2-amino-5, 6-dihydropyrrolo [ 2 , 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl }hydroxyproline,
N-{ [ (2-amino- , 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi] phen-4-ylcarbonyl } isoleucine ,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4 -ylcarbonyl } leucine , N-{ [ (2-amino-5, 6-dihydropyrrolo [2 , -d]pyrimidin-5-yl) eth-2 - yl] phen-4-ylcarbonyl) lysine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yl] phen-4-ylcarbonyl)methionine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yl] phen-4-ylcarbonyl }phenylalanine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl }proline,
N-{ [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yl] phen-4 -ylcarbonyl) serine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3 -d]pyrimidin-5-yl ) eth-2- yl] phen-4 -ylcarbonyl } threonine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl) eth-2 - yl] phen-4-ylcarbonyl }tryptophan,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2 - yl ] phen-4-ylcarbonyl } tyrosine,
N-{ [ (2 -amino-5, 6-dihydropyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl }valine,
N-{2- [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2 -yl ] thiophen-5-ylcarbonyl } alanine ,
N-{2- [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth- 2 -yl ] thiophen-5-ylcarbonyl } arginine ,
N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl) eth- 2-yl] thiophen-5-ylcarbonyl)asparagine, N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl}aspartic acid,
N- {2- [ (2 -methyl -5, 6-dihydropyrrolo [2 , 3 -d]pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)cysteine,
N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] hiophen-5-ylcarbonyl) cystine,
N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl) eth- 2-yl ] thiophen-5-ylcarbonyl)glycine,
N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)histidine,
N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl Jhydroxyproline,
N- {2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl } isoleucine,
N-{2- [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl) leucine,
N- {2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)lysine,
N-{2- [ (2-methyl-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl ) eth- 2 -yl ] thiophen-5-ylcarbonyl }methionine ,
N-{2- [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)phenylalanine,
N-{2- [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)proline, N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2 -y1 ] thiophen-5-ylcarbonyl } serine,
N- {2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl) threonine,
N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2, 3 -d]pyrimi in-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl }tryptophan,
N-{2- [ (2 -methyl-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl) tyrosine,
N-{2- [ (2-methyl-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)valine,
N- {2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl}alanine,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth- 2-yl] hiophen-5-ylcarbonyl)arginine,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl ) eth- 2-yl ] thiophen-5-ylcarbonyl }asparagine,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl ) eth- 2-yl] hiophen-5-ylcarbonyl)aspartic acid,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth- 2-yl] thiophen-5-ylcarbonyl)cysteine,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth- 2-yl] thiophen-5-ylcarbonyl }cystine,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth- 2-yl] thiophen-5-ylcarbonyl) glycine, N-{2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth- 2-yl] thiophen-5-ylcarbonyl)histidine,
N-{2- [ (2 -amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)hydroxyproline,
N-{2- [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d]pyrimidin-5-yl) eth- 2-yl ] thiophen-5-ylcarbonyl } isoleucine,
N-{2- [ (2 -amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl) eth- 2 -yl ] thiophen-5-ylcarbonyl } leucine ,
N-{2- [ (2 -amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl) lysine,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2 , 3-d] pyrimidin-5-yl ) eth- 2-yl ] thiophen-5-ylcarbonyl }methionine,
N- {2- [ (2-amino-5, 6-dihydropyrrolo [2, 3 -d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyljphenylalanine,
N-{2- [ (2 -amino-5, 6-dihydropyrrolo [2, 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl }proline,
N- {2- [ (2 -amino-5, 6-dihydropyrrolo [2 , 3-d] yrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl)serine,
N-{2- [ (2 -amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl) eth- 2-yl] thiophen-5-ylcarbonyl) threonine,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl) eth- 2 -yl ] thiophen-5-ylcarbonyl } tryptophan ,
N-{2- [ (2-amino-5, 6-dihydropyrrolo [2, 3-d] pyrimidin-5-yl ) eth- 2-yl] thiophen-5-ylcarbonyl) tyrosine, N-{2- [ (2-amino-5, 6-dihydropyrrolo [2, 3-d]pyrimidin-5-yl) eth- 2-yl] thiophen-5-ylcarbonyl)valine,
N- { [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yl ] phen-4 -ylcarbonyl) -2 -aminoadipic acid,
N- { [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yl] phen-4-ylcarbonyl) -2 -aminoadipic acid,
N-{2- [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl ) eth-2- yl] thiophen-5-ylcarbonyl } -2 -aminoadipic acid,
N-{2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -2-aminoadipic acid,
N-{ [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl) -2-amino-l , 7-hep anedioic acid,
N- { [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl) -2-amino-l, 7-heptanedioic acid,
N- {2- [ (2-methyl-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2- yl) thiophen-5-ylcarbonyl) -2-amino-l , -heptanedioic acid,
N- {2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -2-amino-l , 7-heptanedioic acid,
N- { [ (2-methyl-4-hydroxypyrrolo [2 , -d] pyrimidin-5-yl ) eth-2- yl] phen-4-ylcarbonyl) -2-amino-3-methyl-l , 5-pentanedioic acid,
N-{ [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yl]phen-4-ylcarbonyl) -2-amino-3-methyl-l , 5-pentanedioic acid, N-{2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yl] thiophen-5-ylcarbonyl) -2-amino-3 -methyl-1, 5-pentanedioic acid,
N-{2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] yrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -2 -amino-3 -methyl -1 , 5-pentanedioic acid,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2- yl]phen-4-ylcarbonyl)-2-amino-3-methyl-l, 4-butanedioic acid,
N-{ [ (2-amino-4-hydroxypyrrolo [2, 3 -d]pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl) -2-amino-3-methyl-l, 4-butanedioic acid,
N-{2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2- yl] thiophen-5-ylcarbonyl) -2-amino-3-methyl-l , 4-butanedioic acid,
N-{2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yl] thiophen-5-ylcarbonyl) -2-amino-3-methyl-l , 4-butanedioic acid,
N-{ [ (2-methyl-4-hydroxypyrrolo[2 , 3-d]pyrimidin-5-yl) eth-2 - yl] phen-4-ylcarbonyl) -N- [l-carboxy-3- (tetrazol-5- yl) propyl] amine,
N-{ [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yl]phen-4-ylcarbonyl) -N- [l-carboxy-3- (tetrazol-5- y1 ) propyl ] amine,
N-{2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yl] thiophen-5-ylcarbonyl) -N- [l-carboxy-3- (tetrazol-5- y1 ) propyl ) amine,
N-{2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yl] thiophen-5-ylcarbonyl } -N- [l-carboxy-3- (tetrazol-5- y1 ) propyl ] amine , N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl) -N- [l-carboxy-7- (tetrazol-5- yi heptyl] amine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl) -N- [l-carboxy-7- ( tetrazol-5- yi heptyl] amine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi thiophen-5-ylcarbonyl) -N- [l-carboxy-7- (tetrazol-5- yi heptyl] amine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi thiophen-5-ylcarbonyl) -N- [l-carboxy-7- (tetrazol-5- yi heptyl] amine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi phen-4-ylcarbonyl) -N- [1-carboxy-4-aminobutyl] amine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl) -N- [l-carboxy-4-aminobutyl] amine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi thiophen-5-ylcarbonyl) -N- [l-carboxy-4-aminobutyl ] amine,
N- 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yi thiophen-5-ylcarbonyl) -N- [l-carboxy-4-aminobutyl] amine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yl] phen-4-ylcarbonyl }-N- [l-carboxy-4- ( tert- butoxycarbonylamino) butyl ] amine ,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi phen-4-ylcarbonyl)-N- [l-carboxy-4- (tert- butoxycarbonylamino ) butyl ] amine , N-{2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yl] thiophen-5-ylcarbonyl } -N- [l-carboxy-4- (tert- butoxycarbonylamino) butyl ] amine ,
N-{2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yl] hiophen-5-ylcarbonyl) -N- [l-carboxy-4- (tert- butoxycarbonylamino) butyl] amine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl) -N- [l-carboxy-4- (phthalimido-1- yl) butyl] amine,
N-{ [ (2-amino-4-hydroxypyrrolo[2 , 3 -d] pyrimidin-5-yl) eth-2 - yl]phen-4-ylcarbonyl) -N- [l-carboxy-4- (phthalimido-1- yl ) butyl] amine,
N- (2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl) eth-2- yl] hiophen-5-ylcarbonyl) -N- [l-carboxy-4- (phthalimido-1- yl) butyl] amine,
N-{2- [ (2-amino-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -N- [l-carboxy-4- (phthalimido-1- yl ) butyl ] amine ,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl }-N-{ [l-carboxy-4- (N' -o- carboxybenzoy1 ) amino] butyl ) amine ,
N-{ [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yl]phen-4-ylcarbonyl)-N-{ [l-carboxy-4- (N' -o- carboxybenzoyl) amino] butyl) amine,
N-{2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2- yl] thiophen-5-ylcarbonyl) -N- { [l-carboxy-4- (N' -o_- carboxybenzoy1 ) amino] butyl }amine , N-{2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl) eth-2 - yl] thiophen-5-ylcarbonyl) -N- { [l-carboxy-4- (N ' -o- carboxybenzoyl ) amino) butyl}amine,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl) -N- [1-carboxy- (3- methoxycarbony1 ) propyl ] amine,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yl] phen-4-ylcarbonyl) -N- [1-carboxy- (3- methoxycarbony1 ) propyl ] amine,
N- (2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrιmidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -N- [1-carboxy- (3- methoxycarbonyl) propyl ] amine,
N- {2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] yrimidin-5-yl ) eth-2- yl] thiophen-5-ylcarbonyl)-N- [1-carboxy- (3- methoxycarbonyl ) propyl ] amine ,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yl] phen- -ylcarbonyl) -N- [1-carboxy- (3- benzyloxycarbonyl ) propyl ] amine,
N-{ [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl } -N- [1-carboxy- (3- benzyloxycarbonyl ) propyl ] amine ,
N-{2- [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -N- [1-carboxy- (3- benzyloxycarbonyl ) propyl ] amine,
N-{2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -N- [1-carboxy- ( 3- benzyloxycarbonyl ) propyl ] amine , N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi] phen-4-ylcarbonyl) - ' -methanesulfonylglutamine,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi] phen- -ylcarbonyl) -N' -methanesulfonylglutamine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yi] thiophen-5-ylcarbonyl } - ' -methanesulfonylglutamine ,
N-{ 2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] yrimidin-5-yl) eth-2 - yi] thiophen-5-ylcarbonyl) -N' -methanesulfonylglutamine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl } -N' -triphenylmethylglutamine,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] phen-4-ylcarbonyl) -N ' -triphenylmethylglutamine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl) - ' -triphenylmethylglutamine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-yl ) eth-2 - yi] thiophen-5-ylcarbonyl) -N' -triphenylmethylglutamine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl) -3-methyl-2-aminopentanoic acid,
N-{ [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yi] phen-4-ylcarbonyl) -3-methyl-2-aminopentanoic acid,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl) -3-methyl-2-aminopentanoic acid,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yi] thiophen-5-ylcarbonyl) -3-methyl-2-aminopentanoic acid, N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi phen-4-ylcarbonyl) -3 , 3 -dimethyl-2 -aminobutanoic acid,
N- [ ( 2 -amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2- yi phen-4-ylcarbonyl}-3 , 3 -dimethyl -2 -aminobutanoic acid,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi thiophen-5-ylcarbonyl}-3 , 3 -dimethyl-2-aminobutanoic acid,
N- 2- [ (2-amino-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-y1 ) eth-2 - yi thiophen-5-ylcarbonyl } -3 , 3 -dimethyl-2 -aminobutanoic acid,
N- [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl ) eth-2- yi phen-4-ylcarbonyl }phenylglycine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl }phenylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3 -d] yrimidin-5-y1 ) eth-2- yi thiophen-5-ylcarbonyl }phenylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-y1 ) eth-2- yi thiophen-5-ylcarbonyl)phenylglycine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl) -c--fluorophenylglycine,
N- [ (2-amino-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2- yi phen-4-ylcarbonyl}-o.-fluorophenylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-yl ) eth-2 - yi thiophen-5 -ylcarbonyl }-o-fluorophenylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi thiophen-5-ylcarbonyl)-c,-fluorophenylglycine, N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl } hien-2-ylglycine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yl phen-4 -ylcarbonyl }thien-2-ylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1) eth-2 yl thiophen-5-ylcarbonyl } thien-2 -ylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2- yi hiophen-5-ylcarbonyl) thien-2-ylglycine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4 -ylcarbonyl } -o-carboxyphenylglycine ,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2 - yi phen-4 -ylcarbonyl) -o.-carboxyphenylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yl thiophen-5-ylcarbonyl) -o-carboxyphenylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yi thiophen-5-ylcarbonyl) -o-carboxyphenylglycine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl) -m-carboxyphenylglycine,
N- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl) -m-carboxyphenylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2- yi thiophen-5-ylcarbonyl) -m-carboxyphenylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-yl) eth-2 - yl thiophen-5-ylcarbonyl) -m-carboxyphenylglycine, N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrιmιdm-5-yl ) eth-2 - yi phen-4 -ylcarbonyl) -p_-carboxypheny lglycine,
N- [ (2-ammo-4-hydroxypyrrolo [2 , 3-d] pyπmιdιn-5-yl ) eth-2- yl phen- 4 -ylcarbonyl) -p_ -carboxypheny lglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3 -d] pyrιmιdm-5-yl ) eth-2- yi thιophen-5-ylcarbonyl) -p_-carboxyphenylglycme,
N- 2- [ (2-ammo-4-hydroxypyrrolo [2 , 3-d] pyrιmιdιn-5-yl ) eth-2- yi thιophen-5-ylcarbonyl } -^-carboxypheny lglycine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrιmιdm-5-yl ) eth-2 - yi phen-4 -ylcarbonyl) -o-hydroxyglycme,
N- [ (2-ammo-4-hydroxypyrrolo [2 , 3-d]pynmιdιn-5-yl) eth-2 - yi phen-4 -ylcarbonyl } -o.-hydroxyglycme,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3 -d] pyrιmιdm-5-yl ) eth-2 - yl thιophen-5-ylcarbonyl) -o-hydroxyglycme,
N- 2- [ (2-ammo-4-hydroxypyrrolo [2 , 3-d] pyrιmιdm-5-yl ) eth-2- yi thιophen-5-ylcarbonyl } -o-hydroxyglycme ,
N- [ (2-methyl-4-hydroxypyrrolo [2 , -d] yrimidin- 5 -yl ) eth-2- yi phen-4-ylcarbonyl) -m-hydroxyglycme,
N- [ (2-ammo-4-hydroxypyrrolo [2, 3-d] pyrιmιdm-5-yl ) eth-2 - yi phen-4 -ylcarbonyl) -m-hydroxyglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2, 3 -d] pyrimidin- 5 -y 1 ) eth-2 - yi thιophen-5-ylcarbonyl) -m-hydroxyglycme,
N- 2- [ (2-ammo-4-hydroxypyrrolo[2 , 3-d]pyrιmιdm-5-yl ) eth-2 - yl thiophen- 5 -ylcarbonyl) -m-hydroxyglycme, N- [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl) -r-carboxycyclohexylglycine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5 -yl ) eth-2 - yi phen-4-ylcarbonyl) -p_-carboxyeyelohexylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-y1 ) eth-2- yi thiophen-5-ylcarbonyl) -p_-hydroxyglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl) eth-2 - yi thiophen-5-ylcarbonyl) -j-hydroxyglycine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl) -2 ' -carboxycyclohexylglycine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl) -2 ' -carboxycyclohexylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] yrimidin-5-yl ) eth-2 - yi thiophen-5-ylcarbonyl) -2 ' -carboxycyclohexylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2 - yi thiophen-5-ylcarbonyl) -2 ' -carboxycyclohexylglycine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl }cyclohexylglycine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi phen-4-ylcarbonyl)cyclohexylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi thiophen-5-ylcarbonyl)cyclohexylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2 - yi thiophen-5-ylcarbonyl)cyclohexylglycine, N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi phen-4-ylcarbonyl) -o-chlorophenylalanine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2 - yl phen-4 -ylcarbonyl } -o-chlorophenylalanine ,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2- yi thiophen-5-ylcarbonyl) -o-chlorophenylalanine,
N- 2- [ (2-amino-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5 -yl) eth-2- yi thiophen-5-ylcarbonyl) -o-chlorophenylalanine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl) -N- (2- [tetrazol-5-yl] ethyl) amine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi phen-4-ylcarbonyl}-N- (2- [tetrazol-5-y1] ethyl) amine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yl thiophen-5-ylcarbonyl)-N- (2- [tetrazol-5-yl] ethyl) amine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi thiophen-5-ylcarbonyl)-N- (2- [ tetrazol- 5-yl] ethyl) amine,
N- [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl)-N- (3- [tetrazol-5-y1 ] propyl ) amine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi phen-4-ylcarbonyl }-N- (3- [tetrazol-5-yl ] propyl ) amine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-yl) eth-2- yi thiophen-5-ylcarbonyl)-N- (3- [ tetrazol-5-yl] propyl) amine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-yl) eth-2 - yl thiophen-5-ylcarbonyl } -N- (3- [tetrazol-5-yl]propyl) amine, N- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl) -N- (4- [ te razol-5-yl] butyl) amine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4 -ylcarbonyl }-N- (4- [ tetrazol-5-yl] butyl ) amine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yi thiophen-5-ylcarbonyl) -N- (4- [tetrazol-5-yl] butyl) amine,
ar¬ 2- [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2 - yl thiophen-5-ylcarbonyl) -N- (4- [tetrazol-5-yl] butyl ) amine,
N- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl) -N- (5- [ tetrazol -5-y1 ] pentyl ) amine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yi phen-4 -ylcarbonyl) -N- (5- [ tetrazol-5 -y1 ] penty1 ) amine,
ar2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yl thiophen-5-ylcarbonyl }-N- (5- [ tetrazol-5-y1] pentyl ) amine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2- yi thiophen-5-ylcarbonyl) -N- (5- [ tetrazol -5-y1] entyl ) amine,
N- [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4 -ylcarbonyl }-N- (6- [tetrazol-5-yl] hexyl) amine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl) -N- (6- [ tetrazol-5 -yl] hexyl) amine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] yrimidin-5-y1 ) eth-2 - yi thiophen-5-ylcarbonyl) -N- (6- [tetrazol-5-yl] hexyl) mine,
N- 2- [ (2-amino-4-hydroxypyrrolo[2 , 3-d]pyrimidin-5-yl ) eth-2 - yl thiophen-5-ylcarbonyl)-N- (6- [tetrazol-5-yl] hexyl ) amine, N-{ [ (2-methyl-4-hydroxypyrrolo[2 , 3-d]pyrιmιdm-5-yl) eth-2 - yi] phen-4 -ylcarbonyl) -N- (7- [ tetrazol- 5 -y 1 ] heptyl ) amine,
N-{ [ (2-ammo-4-hydroxypyrrolo [2 , 3-d] pyrimidm- 5-y 1 ) eth-2 - yi] phen-4 -ylcarbonyl) -N- (7- [ tetrazol -5-y 1 ] heptyl ) amme,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo[2, 3 -d] pyrimidm- 5 -yl) eth-2 • yi] thiophen- 5 -ylcarbonyl }-N- (7- [tetrazol-5-yl ] heptyl ) amme,
N-{ 2- [ (2-ammo-4-hydroxypyrrolo [2 , 3-d] pyrimidm- 5-y 1) eth-2 - yi] thiophen- 5 -ylcarbonyl) -N- (7- [ tetrazol -5-y 1 ] heptyl) amme,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrιmιdm-5-yl) eth-2- yi] phen- 4 -ylcarbonyl) -2 -carboxypiperidme,
N-{ [ (2-ammo-4-hydroxypyrrolo[2, 3 -d] pyrimidm- 5 -yl ) eth-2 - yi] phen-4 -ylcarbonyl) -2 -carboxypiperidme,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyπmιdm-5-yl ) eth-2- yi] thιophen-5-ylcarbonyl) -2 -carboxypiperidme,
N-{ 2- [ (2-ammo-4-hydroxypyrrolo [2,3 -d] pyrιmιdm-5-yl ) eth-2- yi] thiophen- 5 -ylcarbonyl) -2 -carboxypiperidme,
N-{ [ (2-methyl-4-hydroxypyrrolo[2 , 3 -d] pyrιmιdιn-5-yl ) eth-2 - yi] phen-4-ylcarbonyl } -3-carboxypιperιdme,
N-{ [ (2-ammo-4-hydroxypyrrolo [2 , 3-d] pyπmιdm-5-yl ) eth-2 - yl] phen-4 -ylcarbonyl } -3 -carboxypiperidme ,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrιmιdm-5-yl) eth-2- yi] thiophen-5 -ylcarbonyl) -3 -carboxypiperidme,
N-{ 2- [ (2-ammo-4-hydroxypyrrolo [2 , 3-d]pyrιmιdιn-5-yl ) eth-2- yi] thιophen-5-ylcarbonyl) -3 -carboxypiperidme, N- { [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2 - yi ] phen-4-ylcarbonyl) -4-carboxypiperidine,
N- { [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi ] phen-4-ylcarbonyl) -4-carboxypiperidine,
N- { 2- [ (2-methyl-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-y1 ) eth-2- yi ] thiophen-5-ylcarbonyl) -4-carboxypiperidine,
N- { 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi ] thiophen-5-ylcarbonyl) -4-carboxypiperidine,
N- { [ (2-methyl-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2 - yi ] phen-4-ylcarbonyl) -2-aminopentanoic acid,
N- { [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2 - yl ] phen-4-ylcarbonyl) -2-aminopentanoic acid,
N- { 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi ] thiophen-5-ylcarbonyl) -2-aminopentanoic acid,
N- { 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi ] thiophen-5-ylcarbonyl) -2-aminopentanoic acid,
N- { [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi ] phen-4-ylcarbonyl) -2 -aminobutanoic acid,
N- { [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi ] phen-4-ylcarbonyl) -2-aminobutanoic acid,
N- { 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d]pyrimidin-5-yl) eth-2 - yi ] thiophen-5-ylcarbonyl) -2 -aminobutanoic acid,
N- { 2- [ (2-amino-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-yl) eth-2 - yi ] thiophen-5-ylcarbonyl) -2 -aminobutanoic acid, N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-y1 ) eth-2 - yl ] phen-4-ylcarbonyl } -2 -amino-3 -hydroxybutanoic acid,
N-{ [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2 - yl] phen-4-ylcarbonyl } -2 -amino-3 -hydroxybutanoic acid,
N-{2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -2-amino-3 -hydroxybutanoic acid,
N-{2- [ (2-amino-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-y1 ) eth-2 - yl] thiophen-5-ylcarbonyl } -2 -amino-3 -hydroxybutanoic acid,
N- { [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yl ] phen-4-ylcarbonyl) -2-amino-4-phenylbutanoic acid,
N- { [ (2-amino-4-hydroxypyrrolo [2, 3-d] pyrimidin-5-y1 ) eth-2 - yl] phen-4-ylcarbonyl } -2-amino-4-phenylbutanoic acid,
N- (2- [ (2-methyl-4-hydroxypyrrolo [2,3 -d] yrimidin-5-y1 ) eth-2 - yl] thiophen-5-ylcarbonyl) -2-amino-4-phenylbutanoic acid,
N-{2- [ (2-amino-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-y1 ) eth-2 - yl] thiophen-5-ylcarbonyl) -2-amino-4-phenylbutanoic acid,
N-{ [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yl] phen-4-ylcarbonyl) -3-carboxy-3-aminopropanesulfonic acid,
N-{ [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2 - yl ] phen-4-ylcarbonyl } -3 -carboxy-3 -aminopropanesulfonic acid,
N-{2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-y1) eth-2 - yl ] thiophen-5-ylcarbonyl } -3 -carboxy-3 -aminopropanesulfonic acid,
N-{2- [ (2-amino-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-ylcarbonyl) -3 -carboxy-3 -aminopropanesulfonic acid, N- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d]pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl)methionine sulfoxide,
N- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-y1 ) eth-2 - yi phen-4-ylcarbonyl)methionine sulfoxide,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl) eth-2- yi thiophen-5-ylcarbonyl}methionine sulfoxide,
N- 2- [ (2-amino-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-y1 ) eth-2 - yi thiophen-5-ylcarbonyl)methionine sulfoxide,
N- [ (2-methyl-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl ) eth-2- yl phen-4-ylcarbonyl) -_-nitrophenylglycine,
N- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi phen-4-ylcarbonyl) -o-nitrophenylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-y1) eth-2- yi thiophen-5-ylcarbonyl } -o_-nitrophenylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl) eth-2- yi thiophen-5-ylcarbonyl) -o-nitrophenylglycine,
N- [ (2-methyl-4-hydroxypyrrolo[2, -d]pyrimidin-5-yl) eth-2 - yi phen-4-ylcarbonyl } -m-nitrophenylglycine,
N- [ (2-amino-4-hydroxypyrrolo[2, 3 -d] pyrimidin-5-yl) eth-2 - yl phen-4-ylcarbonyl) -m-nitrophenylglycine,
N- 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi thiophen-5-ylcarbonyl) -m-nitrophenylglycine,
N- 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yi thiophen-5-ylcarbonyl) -m-nitrophenylglycine, -51-
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] phen- -ylcarbonyl) -jj-nitrophenylglycine,
N-{ [ (2-amino-4-hydroxypyrrolo[2, 3-d]pyrimidin-5-yl) eth-2- yi] phen-4-ylcarbonyl)-p_-nitrophenylglycine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo[2 , 3-d] pyrimidin-5-y1 ) eth-2- yi] thiophen-5 -ylcarbonyl) -p_-nitrophenylglycine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yi] thiophen-5-ylcarbonyl) -jj-nitrophenylglycine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-y1 ) eth-2 - yi] phen-4-ylcarbonyl) -o_-aminophenylglycine,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-yl ) eth-2 - yi] phen-4 -ylcarbonyl) -o_-aminophenylglycine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-yl ) eth-2- yi] thiophen-5 -ylcarbonyl } -o_-aminophenylglycine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo [2 , 3 -d] pyrimidin-5-yl) eth-2- yi] thiophen-5-ylcarbonyl) -p_-aminophenylglycine,
N-{ [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yi] phen-4-ylcarbonyl) -m-aminophenylglycine,
N-{ [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yi] phen-4 -ylcarbonyl) -m-aminophenylglycine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2- yi] thiophen-5-ylcarbonyl) -m-aminophenylglycine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo[2, 3-d] pyrimidin-5-yl) eth-2- yi] thiophen-5-ylcarbonyl } -m-aminophenylglycine, N-{ [ (2 -methyl -4-hydroxypyrrolo [2, 3-d]pyrιmidin-5-yl) eth-2- yi] phen-4-ylcarbonyl) -j-aminopheny lglycine,
N-{ [ (2-ammo-4-hydroxypyrrolo[2, 3-d] pyrimidin -5-y 1) eth-2 - yi] phen-4-ylcarbonyl } - -ammophenylglycine,
N-{ 2- [ (2-methyl-4-hydroxypyrrolo [2 , 3-d] pyπmιdin-5-yl ) eth-2 - yi] thiophen-5-ylcarbonyl) -p_-aminophenylglycine,
N-{ 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidιn-5-yl ) eth-2- yi] th ophen- 5 -ylcarbonyl) -p_-aminopheny lglycine,
N-{ [ (2 -methyl -4-hydroxypyrrolo [2 , 3-d] pyrimidm- 5 -yl) eth-2 - yi] phen-4 -ylcarbonyl) -o-chlorophenylglycme,
N-{ [ (2-ammo-4-hydroxypyrrolo [2 , 3-d] pyrιmιdm-5-yl ) eth-2- yi] phen-4 -ylcarbonyl } -cj-chloropheny lglycine ,
N-{ 2- [ (2 -methyl -4-hydroxypyrrolo [2 , 3-d] pyrimidm- 5 -yl ) eth-2 - yi] thiophen- -ylcarbonyl } -o-chlorophenylglycme,
N-{ 2- [ (2-ammo-4-hydroxypyrrolo [2 , 3 -d] pyrimidm- 5-y 1) eth-2 - yi] thiophen-5-ylcarbonyl } -o-chlorophenylglycme,
N-{ [ (2 -methyl -4-hydroxypyrrolo [2 , 3-d] pyrimidin- 5-y 1 ) eth-2 - yi] phen-4 -ylcarbonyl) -m-chloropheny lglycine,
N-{ [ (2 -amino- 4-hydroxypyrrolo [2, 3-d] pyrimidin- 5-y 1) eth-2 - yi] phen-4 -ylcarbonyl) -m-chlorophenylglycme,
N-{ 2- [ (2 -methyl -4-hydroxypyrrolo [2 , 3 -d] pyrimidm- 5 -y 1 ) eth-2 - yi] thiophen- 5 -ylcarbonyl) -m-chlorophenylglycme,
N-{ 2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d]pyrιmιdm-5-yl) eth-2- yi] thiophen-5-ylcarbonyl } -m-chlorophenylglycme, N-{ [ (2-methyl-4-hydroxypyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yl] phen-4 -ylcarbonyl) -p_-chlorophenylglycine,
N-{ [ (2 -amino-4-hydroxypyrrolo [2, 3-d] pyrimidi -5-y1 ) eth-2 - yl ] phen-4 -ylcarbonyl } -p_-chlorophenylglycine ,
N-{2- [ (2 -methyl-4-hydroxypyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yl] thiophen-5-ylcarbonyl } -p_-chlorophenylglycine, and
N-{2- [ (2-amino-4-hydroxypyrrolo [2 , 3-d] pyrimidin-5-y1 ) eth-2 - yl] thiophen-5-ylcarbonyl) -rj-chlorophenylglycine, and
the pharmaceutically acceptable salts and solvates thereof.
For each of the above-identified compounds, all tautomeric equivalents of each structure are intended to be included. For example N- {[ (2 -methyl-4-hydroxypyrrolo [2 , 3- d]pyrimidin-5-yl) eth-2 -yl ] phen-4-ylcarbonyl } alanine is equivalent to N- { [ (2-methyl-3H-4-oxo-pyrrolo [2 , 3- d]pyrimidin-5-yl) eth-2 -yl] phen-4-ylcarbonyl) alanine .
The compounds of the present invention can be made via a process entitled "Rapid Analogue Process" or RAP. The "rapid" part of the process refers to the relative rapid rate that non-classical antifolates can be synthesized, isolated and purified, when using this process.
The process to make a compound of formula (III) involves reacting an "active ester" of formula (I):
where ©^-^ , L and B are as defined previously, R^O is selected from the group consisting of N-hydroxysuccinimidyl N-hydroxysulphosuccinimidyl and salts thereof, 2- nitrophenyl, 4-nitrophenyl and 2 , 4-dichlorophenyl, with an amine of formula (II) : HNR!R2 ( I I )
1 2 where R and R are as defined previously, in the presence of a silylating agent. Silylating agents are selected from any reagent capable of attaching a silyl group to a target group.
Typical silylating agents include any reagent with a trialkylsilyl group such as trimethylsilyl, triethylsilyl , triisopropylsilyl , dimethylisopropylsilyl , diethylisopropylsilyl, dimethylthexylsilyl, and t- butyldimethylsilyl, any reagent with an alkylarylsilyl group such as tribenzylsilyl , diphenylmethylsilyl , t- butylmethoxyphenylsilyl and tri-p-xylylsilyl , and any reagent with a triarylsilyl group such as triphenylsilyl . The preferred silylating agent is a trimethyl silylating agent. Typical trimethyl silylating agents include N,0- Bis (trimethylsilyl ) acetamide, allyltrimethylsilane, N,0- Bis (trimethylsilyl ) -carbamate, N, - Bis ( trimethylsilyl )methylamine, Bis (trimethylsilyl) sulfate, N, O-Bis (trimethylsilyl) trifluoroacetamide, N,N-
Bis (trimethylsilyl) rea, trimethylsilane, ethyl trimethyl silylacetate, hexamethyldisilane, hexamethyldisilazane, hexamethyldisiloxane, hexamethyldisilylthiane, (isopropenyloxy) trimethyl silane, l-methoxy-2 -methyl-1- trimethyl-siloxy-propene, (methylthio) trimethylsilane, methyl 3-trimethylsiloxy-2-butenoate, N-methyl-N- trimethylsilylacetamide, methyl trimethylsilylacetate, N- methyl-N-trimethylsilylhepta-fluorobutyramide, N-methyl-N- trimethylsilyl-trifluoroacetamide, (phenylthio) trimethylsilane, trimethylbromosilane, trimethylchlorosilane, trimethyliodosilane, 4- trimethylsiloxy-3-penten-2-one, N- (trimethylsilyl ) acetamide, trimethylsilyl acetate, trimethylsilyl azide, trimethylsilyl benzenesulfonate, trimethylsilyl cyanide, N- trimethylsilyldiethylamine, N-trimethylsilyldimethylamine, trimethylsilyl N, -dimethylcarbamate, 1- ( trimethylsilyl) imidazole, trimethylsilyl methanesulfonate, 4- (trimethylsilyl )morpholine, 3-trimethylsilyl-2- oxazolidinone, trimethylsilyl trichloroacetate, trimethylsilyl trifluoroacetate and trimethylsilyl trifluoromethane sulfonate.
A more preferred silylating agent is N,0-bis- ( trimethylsilyl) acetamide. The N,0-Bis (trimethylsilyl ) acetamide acts to protect carboxylic acid groups present, as well as any hydroxy group present, on the active ester and/or the amine of formula II.
An added benefit of using a trimethylsilyl protecting agent is that the trimethylsilyl protected forms of the amine/active ester tend to be more soluble which leads to better yields in the reaction. It is also believed, without intending to be bound thereby, that the silylation of the N atoms activates the amino group towards nucleophilic attack. Protection of the carboxylic acid groups on the active ester of formula (I) and the amine of formula (II) permits the coupling of the active ester and amine to form the compounds of formula (III) .
The reaction takes place at a temperature preferably between about 25 C and about 100 C, more preferably between about 40 C and about 80 C, and most more preferably between about 50 C and about 60 C. The reaction should take place in a solvent. Any non-reactive organic solvent such as dimethylformamide, ethyl acetate, methylene chloride, toluene or acetonitrile is suitable. The preferred solvent is dimethylformamide . It takes between about 5 hours and 70 hours to make a measurable amount of product. Preferably the reaction is run for about 10 hours to about 60 hours and more preferably the reaction is run for about 16 hours to about 48 hours.
In order to maximize the number of compounds made typically one compound of formula (I) is made and then reacted with different compounds of formula (II) to form the antifolate compounds of formula (III). Compounds of formula I can be made by reacting an acid of formula (IV) :
where Θ—^ , L and B are as defined previously, with an alcohol under known conditions. For example when the active ester is a N-hydroxysuccinimide (NHS) ester, a compound of formula (IV) is reacted with N-hydroxysuccinimide (NHS) in a suitable solvent, such as dimethylformamide (DMF), under known conditions (such as room temperature stirring for approximately 24 hours after addition of 1,3-dicyclo- hexylcarbodimide) . The preferred active ester is a N- hydroxysuccinimide ester. Compounds of formula (IV) can be made using known technology in the art of pyrrolo [ 2 , 3-d] pyrimidinyl fused ring system antifolate chemistry. See, for example, U.S. Patent No. 5,106,974 to Akimoto et al . , U.S. Patent No. 4,997,838 to Akimoto et al . , U.S. Patent No. 4,818,819 to Taylor et al . , U.S. Patent No. 5,028,608 to Taylor et al., U.S. Patent No. 5,344,932 to Taylor et al . , U.S. Patent No. 5,254,687 to Taylor et al . , U.S. Patent No. 5,416,211 to Barnett et al . , U.S. Patent No. 5,403,843 to Skimoto et al . , and Synthesis and Antitumor Activity of Pyrrolo [2 , 3-d] Pyrimidine Antifolates with a Bridge Chain Containing a Nitrogen Atom, Aso et al . , Chem. Phar . Bull .. 43(2) 256- 261(1995) which are all incorporated by reference.
Where Θ-'- is the 5, 6-dihydropyrrolo [2, 3- d]pyrimidin-yl fused ring system, compounds of formula (IV) can be made by following the procedures described in, "The Synthesis of N- {2-Amino-4-Substituted [ ( Pyrrolo [2 , 3- d] Pyrimidin-5-yl) Ethyl] Benzoyl } -L-Glutamic Acids as Antineoplastic Agents", Shih and Gossett, Heterocvcles . Vol. 35, No. 2, 1993. Amines of formula (II) can be made by standard techniques known in the art. See for example, Organic Chemistry, pp. 828-843 by Morrison & Boyd, 6th Edition, 1992 by Prentice-Hall, Inc., and Advanced Organic Chemistry, by J. March, 4th Edition, 1992 by John Wiley and Sons, Inc. or they can be obtained through standard reagent supply companies such as Sigma Chemical Company, P.O. Box 14508, St. Louis, MO 63178.
The reaction of compound (I) and compound (II) to make the compound of formula (III) can also take place in the presence of a suitable strong base. Such suitable strong bases include NaOH, KOH, etc. The preferred strong base is NaOH.
After the antifolate compounds of formula (III) are synthesized, they must be worked-up to provide an antifolate compound suitable for testing or use. An advantage of the claimed process is that it includes a rapid work-up procedure wherein the compound of formula (III) is isolated from the reaction mixture by performing the following steps: a) optionally adding a suitable diamine; b) adding a suitable aqueous acid; c) separating the product from its solvent; d) preparing the product physically for collecting, washing and drying; and e) collecting, washing and drying the product. A suitable diamine is any diamine capable of reacting with unreacted active ester to create a product with an amine functionality. This product with an amine functionality can then be washed out of the reaction mixture, along with unreacted HNRIR*-- . One such suitable diamine is ethylene diamine. The addition of the diamine is optional, though preferred.
The suitable acid is a mineral acid selected from the group consisting of HCl, HBr, HI, and HF. The preferred suitable acid is HCl. The most preferred suitable acid is
1 Normal aqueous HCl . Separating the product from its solvent can be done by any technique known in the art . One such method is to strip the solvent from the product by heating the solvent. When the solvent is a high-boiling solvent another solvent, or mixture of solvents, can be added to form a lower-boiling azeotropic mixture which can be boiled off at a lower temperature. Typical solvents used to create a lower boiling azeotropic solvent mixture can be selected from the group consisting of o-xylene, m-xylene, p-xylene, toluene, benzene, and mixtures thereof. The most preferred solvent for this purpose is a mixture of o-xylene, m-xylene and p-xylene.
Preparing the product physically for collecting, washing and drying involves breaking up the clumped product into particles sufficiently small so that the particles may readily be collected by any suitable technique such as by filtration or evaporation. After collection, the product is washed and dried. Any method can be used to break up the product . A preferred method is sonicating the product in the presence of acid.
Collecting, washing, and drying can be accomplished using standard techniques in the art of organic chemistry. For example, the product can be collected by filtering it through a Buchner funnel, then washing it with water and then ether, and then drying it in a vacuum oven. By following this non-conventional workup and purification procedure the time involved is reduced significantly because there is no need for traditional time consuming separation techniques such as chromatography. This invention includes pharmaceutically acceptable salts and solvates of all compounds. The pharmaceutically acceptable salts of the invention are typically formed by reacting a compound of formula (III) which possesses one or more suitable acidic or basic functionalities with an equimolar or slight excess amount of base or acid. The reactants generally are combined in a mutual solvent such as diethyl ether or benzene for acid addition salts, or water or alcohols for base addition salts . The salt usually precipitates out of solution within about 1 hour to about 10 days, and can be isolated by filtration or other conventional means. In addition, some of the compounds of the present invention may form solvates with water or common organic solvents. Such solvates are included as compounds of this invention .
It is also contemplated that the acid portions of these compounds may be modified to form esters, using techniques known in the art. These ester compounds typically contain C1-C4 alkyl moieties in place of the acid hydrogen. These ester intermediates are also considered to be part of the invention. The compounds of the present invention may be administered to any mammal. Of all mammals, it is believed that humans will benefit the most from administration of these compounds .
The compounds of the present invention are antineoplastic agents. An embodiment of the present invention provides a method of treating susceptible neoplasms in mammals, preferably humans, in need of such treatment. The present compounds are useful in inhibiting the growth of neoplasms or "cancers", including, but not limited to, carcinoma, sarcoma, melanoma, colorectal, choriocarcinoma, prostate, leukemia, breast, squamous or small cell lung cancer, non-small cell lung cancer, ovarian, testicular, adenocarcinoma, epidermal, lymphosarcoma, pancreatic, head and neck, kidney, bone and liver cancer. The compounds are tested for their ability to inhibit the growth of certain tumor cell lines and data reported as standard ICso's and Ki inhibition constants.
The compounds of the present invention are also useful in the treatment of psoriasis and arthritis, in mammals, preferably humans.
The compounds of the present invention can be administered orally, parenterally, or by means of insufflation or by insertion of a suppository. The compounds can be administered individually or in combination, preferably parenterally, and usually in the form of a pharmaceutical composition. Parenteral routes of administration include intramuscular, intrathecal, subcutaneous, intravenous, intra-arterial , intraorbital , intracapsular, intraspinal, and intrasternal . Oral dosage forms, including tablets and capsules, contain from 1 to 3000 mg of drug per unit dosage. Isotonic saline solutions containing 1-100 mg/mL can be used for parenteral administration .
Compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Accordingly, the present invention also includes pharmaceutical compositions comprising as active ingredient one or more compounds of formula (III) associated with at least one pharmaceutically acceptable carrier, diluent or excipient .
In making the compositions of the present invention, as well as compositions containing one or more other compounds of formula (III), the active ingredients are usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum arabic, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidinone, cellulose, water, syrup, and methyl cellulose, the formulations can additionally include lubricating agents such as talc, magnesium stearate and mineral oil, wetting agents, emulsifying and suspending agents, preserving agents such as methyl- and propyl - hydroxybenzoates, sweetening agents or flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The compositions are preferably formulated in a unit dosage form with each dosage normally containing from about 0.1 milligrams per square meter of body surface area (mg/M2) to about 3000 mg/M2, more usually about 10 mg/M2 to about 250 mg/M2 of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical excipient.
However, it will be understood that the amount of the compound actually administered, and the frequency of administration, will be determined by a physician or veterinarian in light of the relevant circumstances including the relative severity of a disease state, the choice of compound to be administered, the age, weight, and response of the individual patient, and the chosen route of administration. Therefore, the above dosage ranges are not intended to limit the scope of this invention in any way.
EXAMPLES
The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
The terms "NMR", "IR", "UV" or "MS" following a synthesis protocol indicates that the nuclear magnetic resonance spectrum, infrared spectrum, ultraviolet spectrum or mass spectrometry, respectively, were performed and the data were consistent with the title product. All other terms and abbreviations used in the instant examples have their normal meanings unless otherwise designated. For example " °C" refers to degrees Celsius; "DMF" refers to dimethylformamide, "g" refers to gram or grams; "h" refers to hour or hours; "kPa" refers to kiloPascals ; "L" refers to liter or liters; "mg" refers to milligrams; "ml" refer to milliliter or milliliters ; "mol" refers to moles,; "mmol" refers to millimole or millimoles; "N" refers to normal or normality; "psi" refers to pounds per square inch; and "RT" refers to room temperature.
Preparation 1
Step 1 ; Synthesis of ethyl 4 4-diethoxy-2-cyano-butanoate
A stirred mixture of ethyl cyanoacetate (550 mL, 5.17 mol), bromo diethylacetal (155 mL, 1.03 mol), powdered potassium carbonate (140 g, 1.01 mol), and sodium iodide (20.1 g, 0.13 mol) was heated at 130°C for 4 hours. The mixture was cooled to room temperature, diluted with water (1.2 L) and then extracted with diethyl ether (4 x 1 L) . The combined organics were washed with brine (3 x 250 mL) , dried (MgSθ4), and then concentrated to give a brown oil which was distilled under reduced pressure to give the product as a clear oil (99.10 g, 42%).
b.p. (0.03 torr) : 71-80°C; XH NMR (CDCI3) δ 4.70 (t, J = 5.70 Hz, CH) , 4.27 (q, J = 7.17 Hz, CH2), 3.77 - 3.64 (m, CH, CH2), 3.59 - 3.50 (m, CH2 ) , 2.34 - 2.15 (m, CH ), 1.33 (t, J = 7.17 Hz, CH3 ) , 1.23 (t, J = 6.99 Hz, CH3), 1.21 (t, J = 6.99 Hz, CH3 ) ppm; IR (neat) υ 3528, 3020, 2982, 2932, 2900, 2253, 1746, 1263, 1127, 1060 cm"1; MS (FI) 230 ( [MH]+, 15) .
Step 2; Synthesis of 2-methyl-3H-4-oxo-5-(2,2-diethoxy- ethyl) -6-amino-pyrimidine
Sodium metal (8.10 g, 352 mmol) was added to dry distilled methanol (100 mL) and stirred for 0.5 hours. Methyl acetamidine (11.13 g, 117 mmol) was added and the resulting mixture was refluxed for 0.5 hours and then cooled to room temperature. Neat cyanoester from Step 1 (26.83 g, 117 mmol) was then added and the resulting mixture was refluxed for 1.5 hours. The solvent was removed in vacuo and the resulting residue diluted with water (100 mL) and the pH adjusted to 6 with cone. HCl producing a precipitate which was filtered and dried to give the pyrimidine as a white solid (19.15 g, 68%) .
1H NMR (DMSO-d6) δ 11.42 (s, NH) , 5.99 (s, NH2 ) , 4.54 (t, J = 5.52 Hz, CH) , 3.65-3.55 (m, CH2 ) , 3.45-3.35 (m, CH2), 3.34 - 3.32 (hidden m, CH2) , 2.11 (s, CH3 ) , 1.07 (t, J = 6.99 Hz, 6 H, 2 CH3 ) ppm; IR (KBr) υ 3465, 3314, 3166, 2973, 2928, 2855, 1635, 1606, 1455, 1287, 1062, 809 cm*-1; MS (FD) 241 (M+, 100) .
Step 3 : Synthesis of 2-methyl-3H-4-oxo-pyrrolo[2, 3-d] - pyrimidine
A suspension of the pyrimidine diethylacetal from Step 2 (19 g, 78.80 mmol) in IN aqueous HCl (210 mL) was stirred at room temperature for 4 hours. The reaction mixture was filtered and the solid washed with water (1 L) , diethyl ether (1 L) , and then dried to give the pyrrolopyrimidine as a white solid (11.70 g, 99%).
XH NMR (DMSO-d6) 5 11.67 (s, NH) , 11.62 (s, NH) ,
6.94 (dd, J = 2.57 and 3.31 Hz, Pyr H) , 6.37 (dd, J -- 2.21 and 3.31 Hz, Pyr H) , 2.30 (s, CH3 ) ppm,- IR (KBr) υ 3404, 3170, 3102, 2932, 2847, 1657, 1602, 1370, 1297, 1190, 901, 809 cm-1; UV (EtOH) λmax 213 (ε = 14863), 261 (ε = 9888) nm; MS (FD) 149 (M+, 100); Anal, calcd. for C7H7N3O requires: C, 56.37; H, 4.73; N, 28.17% ; Found: C, 56.09; H, 4.62; N, 27.92%.
Step 4 ; Synthesis of 2-methyl-3H-4-oxo-5-iodo-pyrrolo [2, 3- d]pyrimidine
A stirred solution of 2-methyl-3H-4-oxo-pyrrolo- [2 , 3-d] pyrimidine (250 mg, 1.68 mmol), and N,0- bis (trimethylsilyl) acetamide (3.8 mL, 15.4 mmol), in DMF (! mL) was heated at 40oC under nitrogen for 2 hours. The mixture was then cooled to -8°C in an ice/brine bath and N- iodo-succinimide (1.55 g, 6.88 mmol) was added. The reaction mixture was stirred for 0.75 hours then quenched with water
(5 mL) to produce a precipitate which was filtered, washed with water and dried to provide the iodide as a light yellow solid (1.77 g, 96%) .
*-H NMR (DMSO-d6) δ 11.96 (s, NH) , 11.77 (s, NH) , 7.13 (d, J = 2.21 Hz, Pyr H) , 2.28 (s, CH3 ) ppm; IR (KBr) υ 3160, 3063, 2920, 2823, 1666, 1601 cm"1,- UV (EtOH) λmax 224 (ε = 13228), 272 (ε = 9086) nm; MS (FD) 275 (M+, 100); Anal, calcd. for C7H6 3IO requires: C, 30.57; H, 2.20; N, 15.27% ; Found: C, 30.56; H, 2.26; N, 15.02%.
Step 5 : Synthesis of 2-methyl-3H-4-oxo-5- (trimethylsilylethyne) -pyrrolo[2, 3-d]pyrimidine
A stirred solution of the iodide from Step 4 (21 g, 76.4 mmol), and N, O-bis (trimethyl) acetamide (42 mL, 170.3 mmol), in DMF (120 mL) was heated at 40°C under nitrogen for 2 hours The reaction solution was allowed to cool to room temperature and then trimethylsilylacetylene (16.2 mL, 114.5 mmol), copper (II) iodide (1.45 g, 7.6 mmol) and triethylamine (11.7 mL, 84.1 mmol) added followed by a preformed catalyst mixture of palladium chloride (1.35 g, 7.6 mmol), and triphenyl phosphine (4.0 g, 15.4 mmol) in DMF (11 mL) . The resulting mixture was stirred at room temperature for 18 hours, diluted with acetonitrile (510 mL) and the reaction mixture filtered through a sintered glass funnel. To the rapidly stirring filtrate was added water (15 mL) dropwise causing a solid to precipitate which was filtered, rinsed with fresh acetonitrile (500 mL) and dried to give the product as a light green solid (13.7 g, 73%).
*-H NMR (DMSO-d6) δ 11.76 (s, NH) , 11.56 (s, NH) , 7.12 (d, J = 2.57 Hz, Pyr H) , 2.09 (s, CH3 ) , 0.00 (s, 9 H SiMe3) ppm; IR (KBr) υ 3098, 2960, 2918, 2814, 2163, 1662, 1605, 1302, 1249, 1074, 863, 842 cm"1; UV (EtOH) λmax 235 (ε = 14898), 242 (ε = 14782), 277 (ε = 13534) ran; MS (FD) 245 (M+, 100); Anal, calcd. for Cι Hιs 3θ requires: C, 58.74; H, 6.16; N, 17.13% ; Found: C, 58.46; H, 5.96; N, 17.12%.
Step 6. Synthesis of 2-methyl-3H-4-oxo-5-ethynepyrrolo- [2, 3-d] yrimidine
To a stirred solution of the TMS-pyrrolopyrimidine of Step 5 (11.0 g, 44.9 mmol) in dry DMF (150 mL) was added tetra-n-butylammonium fluoride (12.3 g, 47.2 mmol) at room temperature. The mixture was stirred at room temperature for 4 hours and then glacial acetic acid (3.4 mL) was added followed by water (200 mL) causing a solid to precipitate which was filtered, washed with water (500 mL) and dried to give the acetylene as a tan solid (5.7 g, 73%).
*-H NMR (DMSO-d6) 6 11.95 (s, NH) , 11.83 (s, NH) , 7.30 (d, J = 2.57 Hz, Pyr H) , 3.88 (s, CH) , 2.29 (s, CH3 ) ppm; IR (KBr) υ 3248, 3170, 3093, 2920, 2838, 1656, 1604, 1448, 1294, 1141, 814, 792 cm-1; UV (EtOH) λmaχ 230 (ε = 14648), 271 (ε = 10960) ran; MS (FD) 173 (M+, 100).
Step 7 ; Synthesis of 2-methyl-3H-4-oxo-5-(2-(4- carboxyphenyl ) ethynyl )pyrrolo [2,3-d]pyrimidine
A stirred mixture of pyrrolopyrimidine of Step 6(2.26 g, 13.0 mmol), p-iodobenzoic acid (3.24 g, 13.0 mmol), and N,0-bis (trimethylsilyl) acetamide (11 mL, 44.6 mmol) in dry acetonitrile (65 mL) was heated at 40°C under nitrogen for 4 hours. Triethylamine (3.4 mL, 24.4 mmol) was added and the mixture was deoxygenated with dry nitrogen for 20 minutes. A preformed catalyst mixture containing palladium chloride (119 mg, 0.67 mmol) and triphenylphosphine (347 mg, 1.32 mmol) in acetonitrile (10 mL) was added and the resulting mixture was heated at reflux for 3 hours The reaction mixture was cooled to 0°C and water (1.8 mL) added dropwise causing a solid to precipitate which was filtered, rinsed with acetonitrile and dried to give the coupled product as a gray solid (3.15 g, 82%) .
--H NMR (DMSO-d6) 6 13.03 (broad singlet, COOH), 12.12 (broad singlet, NH) , 11.89 (bs, NH) , 7.96 (d, J = 8.46 Hz, ArH ), 7.58 (d, J = 8.09 Hz, ArH2), 7.46 (d, J = 2.57 Hz, Pyr H) , 2.32 (s, CH3 ) ppm; IR (KBr) υ 2918, 2855, 2209, 1666, 1604, 1462, 1377, 1269, 768 cm"1; UV (EtOH) λ --mmaaχx 264.5 (ε = 5084) , 325 (ε = 5469) rim.
Step 8; Synthesis of 4-{ [2-methyl-3H-4-oxo-pyrrolo[2,3- d]pyrimidin-5-yl]eth-2-yl}benzoic acid (a compound of formula (IV))
A mixture of the acetylene of Step 7 (3.1 g, 10.58 mmol) and 5% Pd/C (1.5 g) in dimethylformamide (150 mL) was stirred under 60 psi (414 kPa) H at 50°C for 24 hours The mixture was filtered through Ceiite® 521 filter agent to remove the catalyst, and the filtrate concentrated to -1/5 of its original volume. Methanol (25 mL) was added to precipitate a solid which was filtered, washed with methanol (25 mL) and dried to give the product as a gray solid (1.45 g, 46%) .
1H NMR (DMS0-d6) δ 12.70 (broad singlet, COOH), 11.59 (broad singlet, NH) , 11.28 (broad singlet, NH) , 7.84 (d, J = 8.09 Hz, ArH2), 7.32 (d, J = 8.09 Hz, ArH2 ) , 6.64 (d, J = 1.84 Hz, Pyr H) , 3.06 - 2.92 (m, CH2CH2 ) , 2.29 (s, CH3) ppm; IR (KBr) υ 3275, 2928, 2855, 1658, 1610, 1273, 1176, 1071 cm-1; UV (EtOH) λmax 223 (ε = 18330), 266.5 (ε = 10650) ran; MS (FAB) 298 (M+, 15).
Step 9 : Synthesis of 4-{ [2-methyl-4-oxo-3H-pyrrolo[2, 3- d]pyrimidin-5-yl]eth-2-yl}benzoic acid (N-succinimide ester) "Active Ester" (compound of formula (I))
To a stirred solution of the carboxylic acid of Step 8 (1.3 g, 4.4 mmol) and N-Hydroxysuccinimide (756 mg, 6.6 mmol) in dimethylformamide (50 mL) at room temperature was added 1, 3-dicyclohexylcarbodiimide (1.4 g, 6.7 mmol) under nitrogen. The reaction mixture was stirred for 24 hours and then filtered to remove dicyclohexylurea . The filtrate was concentrated in vacuo and the resulting residue sonicated in 20% methanol/ethyl acetate (50 mL) to produce a solid which was filtered, washed with ethyl acetate (75 mL) and dried to give the active ester as a gray solid (1.2 g, 69%) .
1H NMR (DMSO-d6) δ 11.61 (broad singlet, NH) , 11.27 (broad singlet, NH) , 7.99 (d, J = 8.46 Hz, ArH2) , 7.46 (d, J = 8.46 Hz, ArH ), 6.63 (d, J = 1.84 Hz, Pyr H) , 3.10 (t, J = 6.80 Hz, CH2) , 2.98 (t, J -- 6.80 Hz, CH ), 2.89 (bs, CH CH ), 2.29 (s, CH3) ppm; IR (KBr) υ 3115, 3070, 3001, 2935, 2855, 1771, 1741, 1653, 1609, 1235, 1207, 1069, 917 cm"1; UV (EtOH) λmax 204 (ε = 28116), 225 (ε = 29641), 283 (ε = 7500) nm; MS (FD) 394 (M+, 100).
Preparation 2
Step 1; Synthesis of 1- [2-methyl-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl] -2- [2-carboxythien-5-yl]ethyne
A mixture of 2-methyl-3H-4-oxo-5-ethynepyrrolo- [2, 3-d] yrimidine made from steps 1-6 of Preparation 1 (2.25 g, 13.0 mmol), 2-bromothiophene-5-carboxylic acid (2.71 g, 13.0 mmol), and N, O-bis (trimethylsilyl) acetamide (11 mL, 44.6 mmol) in acetonitrile (65 mL) was heated at 40°C under nitrogen for 4 hours Triethylamine (3.4 mL, 24.4 mmol) was added and the mixture was deoxygenated with nitrogen for 20 minutes . A preformed catalyst mixture containing palladium chloride (119 mg, 0.67 mmol), and triphenylphosphine (347 mg, 1.32 mmol) in acetonitrile (10 mL) was added and the resulting mixture was heated at reflux for 3 hours The reaction mixture was then cooled to 0°C and water (1.8 mL) added dropwise causing a precipitate to form which was filtered, washed with acetonitrile, and dried to give the product as a gray solid (3.57 g, 92%).
--H NMR (DMSO-dδ) δ 13.32 (broad singlet, COOH), 12.18 (broad singlet, NH) , 11.92 (broad singlet, NH) , 7.67 (d, J = 3.68 Hz, ThH) , 7.51 (d, J = 2.57 Hz, Pyr H) , 7.31 (d,-J = 3.68 Hz, ThH), 2.32 (s, CH3 ) ppm; IR (KBr) υ 3125, 2207, 1673, 1420, 1369, 1293, 816, 749 cm-1; UV (EtOH) λmax 271 (ε =376), 321 (ε = 164), 326 (ε = 157) n ; MS (FD) 299 (M+, 60) .
Step 2; Synthesis of {2- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl)eth-2-yl] thiophen-5-yl)carboxylic acid
A mixture of the acetylene from Preparation 2, step 1 (3.4 g, 11.26 mmol) and 5% Pd /C (3.4 g) in dimethylformamide (75 mL) was stirred under 60 psi (414 kPa) H2 at 50°C for 24 hours. The mixture was filtered through Celite® 521 filter agent to remove catalyst, and the filtrate concentrated to -1/5 of its original volume. Methanol (25 mL) was added to precipitate a solid which was filtered, washed with methanol (25 mL) and dried to give the product as a gray solid (1.26 g, 37%) .
*-H NMR (DMSO-dε) δ 12.73 (broad singlet, COOH), 11.62 (broad singlet, NH) , 11.33 (broad singlet, NH) , 7.53 (d, J = 3.68 Hz, ThH), 6.89 (d, J = 3.68 Hz, ThH), 6.70 (d, J = 2.21 Hz, Pyr H) , 3.23 (t, J = 7.35 Hz, CH2), 2.98 (t, J= 7.54 Hz, CH2), 2.29 (s, CH3 ) ppm; IR (KBr) υ 3113, 2928, 2854, 1657, 1537, 1459, 1268, 1098, 814, 755 cm*-1; UV (EtOH) λma 218.5 (ε = 15236), 278.5 (ε = 15258), 361.5 (ε = 2525) nm; MS (FAB) 304 (M+, 60) .
Step 3 : Synthesis of {2- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl)eth-2-yl]thiophen-5-yl}carboxylic acid (N- succinimide ester) "Active Ester" (compound of formula I)
To a stirred solution of the carboxylic acid from Preparation 2 , step 2 (1.2 g, 3.8 mmol) and N- hydroxysuccinimide (661 mg, 5.8 mmol) in N,N- dimethyl formamide (40 mL) was added 1,3- dicyclohexylcarbodiimide (1.2 g, 5.8 mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 24 hours and then filtered to remove dicyclohexylurea. The filtrate was concentrated in vacuo and the resulting residue sonicated in 20% methanol/ethyl acetate (50 mL) to produce a solid which was filtered, washed with ethyl acetate (75 mL) and dried to give the active ester as a gray solid (950 mg, 59%) .
λH NMR (DMSO-dδ) δ 11.64 (broad singlet, NH) , 11.34 (broad singlet, NH) , 7.94 (d, J = 4.04 Hz, ThH), 7.08 (d, J = 4.04 Hz, ThH), 6.72 (d, J = 2.21 Hz, Pyr H) , 3.38 - 3.30 (m,-CH2), 3.06 - 3.00 (m, CH2 ) , 2.86 (broad singlet , CH2CH2 ) , 2.29 (s, CH3 ) ppm; IR (KBr) υ 3112, 3073,
2931, 2854, 1740, 1653, 1447, 1366, 1204, 1066, 814 cm"1; UV (EtOH) λmax 217.5 (ε = 15722), 262.0 (ε = 14769), 286.5 (ε = 18291) nm; MS (FD) 400 (M+, 100).
Preparation 3
Preparation of {2-fluoro-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl) -eth-2-yl] }benzoic acid (N-succinimide ester) Step 1; Synthesis of 2-amino-3H-4-oxo-pyrrolo[2, 3- d]pyrimidine
To a suspension of 2, 4-diamino-6-hydroxypyrimidine (40 g, 317 mmol) in H20 (400 mL) was added NaHC03 (66.61 g,
793 mmol) and the mixture was heated to 50°C. Chloroacetaldehyde (50% in H20, 28.6 g, 46 mL, 365 mmol) was added dropwise over 40 min, and the reaction was stirred for 1 hour. The mixture was cooled to 5-10°C and the product filtered. The filtered product was washed with H20, reslurried with H2O (130 mL) , filtered and dried to give 36.24 g product (76%) as a brown solid.
lH NMR (DMSO-dg) δ 10.95 (s, NH) , 10.21 (s, NH) , 6.59 (s, PyrH) , 6.16 (s, PyrH) , 6.03 (s, NH2 ) ppm; IR (KBr) υmaχ 3448, 3361, 3224, 3119, 2924, 1658, 1622, 1427, 1376, 1356, 823 cm-1; UV (MeOH) λmaχ 214.75 (ε = 16432) , 258.25 (ε = 9687) nm; MS (FD) m/z 150 (M+, 100) ;
Step 2 : Synthesis of 2-t-butylacetamidyl-3H-4-oxo- pyrrolo [2 , 3-d] pyrimidine
A mixture of 2-amino-3H-4-oxo-pyrrolo [2 , 3- d] pyrimidine (33.5 g, 223 mmol), pivalic anhydride (166.2 g, 180 L, 893 mmol), and 4-dimethylaminopyridine (1.36 g, 11.1 mmol) was heated to 120°C and stirred for 2 hours The reaction was cooled to 40°C, and added to Et 0 (400 mL) with stirring. The precipitated product was filtered, washed with Et20, reslurried in Et20 (300 mL) , filtered and dried to give 36.72 g product (70%) as a tan solid.
XH NMR (DMSO-dg) δ 11.83 (s, NH) , 11.58 (s, NH) , 10.80 (s, NH) , 6.94 (t, J = 2.7 Hz, PyrH), 6.40 (d, J = 2.04 Hz, PyrH), 1.26 (s, 3CH3) ppm; IR (KBr) υ-nax 3300, 3219, 2968, 1655, 1569, 1430, 1242, 1170, 802 cm"-1; UV (MeOH) λmaχ 217.75 (ε = 13121), 272.75 (ε = 11683) nm; MS (FD) m/z 234 (M+, 100) ;
Step 3 : Synthesis of 2-t-butylacetamidyl-3H-4-oxo-5- (trimethylsilylethyne) -pyrrolo [2, 3-d]pyrimidine
To a suspension of 2-t-butylacetamidyl-3H-4-oxo- pyrrolo [2, 3-d] yrimidine (32.9 g, 140 mmol) in DMF (125 mL) was added N, O-bis (trimethylsilyl ) acetamide (62.8 g, 76 mL, 309 mmol) and the reaction was stirred at 40°C for 1.5 hours The reaction was then cooled to 0°C and N-iodosuccinimide (37.9 g, 168 mmol) was added. The resulting mixture was stirred for 2 hr while gradually warming to RT. In a separate flask, a mixture of palladiu (II) chloride (2.49 g, 14.0 mmol) and triphenylphosphine (7.37 g, 28.1 mmol) in DMF (25 mL) was stirred at RT for 30 minutes. Copper (I) iodide (2.67 g, 14.0 mmol), triethylamine (17.0 g, 23.5 mL, 168 mmol) and (trimethylsilyl) acetylene (25.0 g, 254 mmol) were added to the pyrrolopyrimidine reaction, followed by the triphenylphosphine-palladium chloride mixture. The resulting mixture was stirred at RT for 18 hr, then diluted with CH3CN (1000 mL) and filtered to remove any insoluble material. Water (31 mL) was then added with stirring, and the resulting solid was filtered, washed with CH3CN and dried in vacuo to give 23.84 g product (51%) as a brown solid.
*H NMR (DMSO-de) δ 11.92 (s, NH) , 11.84 (s, NH) , 10.88 (s, NH) , 7.31 (d, J = 1.93 Hz, PyrH), 1.23 (s, 3CH3), 0.19 (s, 3CH3) ppm; IR (KBr) \_max 3228, 2154, 1677, 1660, 1619, 1582, 1434, 1244, 861, 793 cm"1; UV (MeOH) λmaχ 248.5 (ε = 13287), 284.75 (ε = 13539) nm; MS (FD) m/z 330 (M\ 100);
Step 4 ; Synthesis of 2-t-butylacetamidyl-3H-4-oxo-5- ethyne-pyrrolo [2 , 3-d]pyrimidine
To a solution of the 2-t-butylacetamidyl-3H-4-oxo- 5- (trimethylsilylethyne) -pyrrolo [2 , 3-d] pyrimidine (19.55 g, 59.2 mmol) in DMF (150 mL) was added tetra-n-butylammonium fluoride (15.47g, 59.2 mmol) and the reaction was stirred at RT for 1.5 hours Acetic acid (4.4 mL) was added, followed by H0 (200 mL) . The resulting solid is filtered, washed with H0 and dried in vacuo to give 12.94 g product (85%) as a brown solid.
--H NMR (DMSO-d6) δ 11.88 (s, NH) , 11.85 (s, NH) , 10.86 (s, NH) , 7.31 (s, PyrH), 3.92 (s, CH) , 1.22 (s, 3CH3) ppm; IR (KBr) υmax 3233, 2113, 1683, 1649, 1617, 1580, 1432, 1240, 791 cm"1; UV (MeOH) λmax 234.75 (ε = 14417), 280.25 (ε = 14019) nm; MS (FD) m/z 258 (M\ 100); Step 5 : Synthesis of 1- (2-t-butylaσetamidyl-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-y1) -2- (3-fluoro-4- carbonylmethoxyphenyl ) ethyne
A mixture of 2-t-butylacetamidyl-3H-4-oxo-5- ethyne-pyrrolo [2 , 3-d] pyrimidine (10.0 g, 38.75 mmol), methyl 2-fluoro-4-iodobenzoate (11.9 g, 42.63 mmol), and bis- trimethylsilylacetamide (21 mL, 85.13 mmol) in acetonitrile (200 mL) was heated at 40°C under nitrogen for 2.5 hours. Tri-ethylamine (10 mL, 71.70 mmol) was added and the mixture was de-gassed for 20 minutes. Next a catalyst mixture containing palladium chloride (343 mg, 1.93 mmol), and tri- phenylphosphine (1.02 g, 3.87 mmol) in acetonitrile (35 mL) was added and the resulting mixture was refluxed for 2.5 hours After cooling to room temperature the reaction mixture was filtered and water (5.0 mL) was added dropwise causing a precipitate to form which was collected, rinsed with acetonitrile (125 mL) and dried to give the product as a tan solid (11.92 g, 75%)
-H NMR (DMSO-dis) δ 12.13 (s, NH) , 11.93 (s, NH) , 10.95 (s, NH) , 7.94 (t, J = 8.01 Hz, ArH) , 7.51 (s, ArH) , 7.42 (s, ArH), 7.39 (s, ArH), 6.61 (s, PyrH), 3.87 (s, OCH3 ) , 1.25 (s, 3CH3) ppm; IR (KBr) υmaχ 3217, 1733, 1657, 1615, 1581, 1435, 1293, 1247, 1142, 1090, 791 cm"1; MS (FD) m/z 410 (M+, 100). Anal. Calcd. for C2ιHιc,N404F requires: C, 64.54; H, 4.92; N, 10.26; F, 4.64%. Found: C, 60.76; H, 4.71; N, 13.43; F, 6.35%. Step 6: Synthesis of {2-fluoro-4- [(2-t-butylacetamidyl-3H-4- oxo-pyrrolo [2, 3-d]pyrimidin-5-yl) -eth-2-yl] }benzoic acid methyl ester
A mixture of the acetylene from Preparation 3, Step 5 (11.9 g, 29.0 mmol) and 5% Pd/C (6.0 g) in DMF (140 mL) was stirred under 60 psi (414 kPa) H at room temperature for 24 hours The mixture was passed through Celite® 521 to remove catalyst, the filtrate was concentrated to a small volume and methanol (50 mL) was added. The product was filtered, rinsed with methanol (75 mL) and dried to give a tan solid (7.1 g, 59%) .
XH NMR (DMSO-d6) δ 11.77 (s, NH) , 11.24 (s, NH) , 10.77 (s, NH) , 7.77 (t, J = 8.01 Hz, ArH) , 7.2-7.1 (m, ArH? ) , 6.63 (s, PyrH) , 3.81 (s, OCH3) , 3.1-2.8 ( , CH2CH2) , 1.23 (s, 3 CH3 ) ppm; IR (KBr) υmax 3290, 3228, 1739, 1721, 1653, 1615, 1588, 1533, 1438, 1304, 1240, 790 cm"1; UV (EtOH) λmaχ 229.5 (ε = 23424) , 284.5 (ε = 14936) nm; MS (FAB) m/z 415 (M+ , 100) . Anal. Calcd. for C2ιH23N404F requires: C, 60.86; H, 5.59; N, 13.52; F, 4.58%. Found: C, 60.93; H, 5.66; N, 13.74; F, 4.52%.
Step 7 ; Synthesis of {2-fluoro-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) -eth-2-yl] }benzoic acid:
The protected amino acid from Preparation 3, Step 6 (7.0 g, 16.9 mmol) was combined with p-toluenesulfonic acid (7.1 g, 37.2 mmol) in ethanol (235 mL) and refluxed overnight (18 h) . After cooling to room temperature the solid was collected and rinsed with fresh ethanol. Without drying the solid was taken up in aqueous. NaOH (100 mL, IN) and stirred at 45°C for 2 hours After cooling to room temperature the solution was adjusted to pH = 3 with aqueous. HCl (IN). The resulting solid was collected by suction filtration, rinsed with water then dried to give the product as a tan solid (4.96 g, 94%).
--H NMR (DMSO-dg) δ 13.02 (br s, COOH) , 10.62 (s, NH) , 10.15 (s, NH) , 7.74 (t, J = 7.87 Hz, ArH) , 7.10 (d, J = 9.84 Hz, ArH) , 6.31 (s, PyrH) , 6.00 (s, NH2 ) , 3.02-2.90 (m, CH2 ) , 2.88-2.80 ( , CH2 ) ppm; IR (KBr) υmax 3614, 3475, 3210, 2925, 1669, 1536, 1421, 1305, 1231, 1162, 1082 c -; UV (EtOH) λmaχ 202.5 (ε = 28206) , 225 (ε =- 24803) , 263.5 (ε = 12113) n ; and MS (FAB) m/z 317 (M+, 85) .
Anal. Calcd. for Ci5H13N403F requires: C, 56.96; H, 4.14; N, 17.71; F, 6.01%. Found: C, 53.06; H, 4.14; N, 16.65; F, 5.20%.
Step 8 ; Synthesis of {2-f luoro-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d] pyrimidin- 5 -yl) -eth-2 -yl] }benzoic acid (N- succinimide ester) :
A mixture of the acid from Preparation 7, Step 3 (4.80 g, 15.2 mmol), N-hydroxysuccinimide (2.10 g, 18.3 mmol), and l-ethyl-3- (3-dimethylaminopropyl) carbodiimide (3.50 g, 18.3 mmol) in DMF (80 mL) was stirred at room temperature under nitrogen for 24 hours The reaction mixture was concentrated and the residue was sonicated in aqueous. HCl (100 mL, IN). The solid was filtered, rinsed with water (150 mL) and dried to give the ester as a yellow solid (5.83 g, 92%) .
lE NMR (DMSO-de) δ 10.64 (s, NH) , 10.17 (s, NH) , 7.93 (t, J = 7.68 Hz, ArH), 7.31 (d, J -- 12.34 Hz, ArH), 7.25 (d, J = 7.79 Hz, ArH), 6.31 (s, PyrH), 6.07 (s, NH2 ) , 3.15-3.00 (m, CH ), 2.99-2.79 (m, CH2CH2 , ArCH2 ) ppm; IR (KBr) υmaχ 3367, 3216, 1773, 1733, 1633, 1540, 1427, 1206, 1068, 993 cm**1; UV (EtOH) λmax 222 (ε = 20758), 246 (ε = 21424) nm; and MS (FAB) m/z 414 (M<, 100). Anal. Calcd. for Cι9Hι6N5θ5F requires: C, 55.21; H, 3.90; N, 16.94%. Found: C, 52.14; H, 4.01; N, 15.94%.
Preparation 4
Preparation of 4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl) -eth-2-yl]benzoic acid (N-succinimide ester)
Step 1: Synthesis of 4- [ (2-t-butylacetamidyl-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) -ethyn-2-yl] benzoic acid:
To a solution of the acetylene from Preparation 3, Step 4 (258 mg, 1.0 mmol) and 4-iodobenzoιc acid (248 mg, 1.0 mmol) in CHCN (4 mL) was added N-O- bis (trimethylsilyl) acetamide (671 mg, 0.82 mL, 3.3 mmol) and the reaction was stirred at 40°C for 2 hours In a separate flask, a mixture of palladium(II) chloride (9 mg, 0.05 mmol) and triphenylphosphine (26 mg, 0.1 mmol) in DMF (1 mL) was stirred at RT for 90 minutes. Triethylamine (182 mg, 0.25 mL, 1.8 mmol) was added to acetylene mixture followed by the triphenylphosphine-palladium chloride mixture. The reaction was then refluxed for 2 hr, cooled and H;0 was added (1 mL containing 6-8 drops of IN HCl) . The resulting solid was filtered, washed with CH3CN and dried m vacuo. The crude product was purified by flash chromatography on silica gel (0.25% AcOH/10% MeOH/CH2Cl2) to give 111 mg product (29%) as a tan solid.
*H NMR (DMSO-de) δ 12.08 (s, NH) , 11.92 (s, NH) , 10.92 (s, NH) , 7.93 (d, J = 8.13 Hz, ArH2 ) , 7.52 (d, J = 8.1 Hz, ArH2), 7.46 (s, PyrH), 1.24 (s, 3CHj) ppm; IR (KBr) umax 3221, 2974, 2213, 1658, 1605, 1580, 1435, 1409, 1308, 1287, 1169, 788 cm"1; UV (MeOH) λmax 269 (ε = 19512), 322 (ε = 23843) nm; MS (FAB) m/z 379 (M+J , 26).
Step 2: Synthesis of 4- [ (2-t-butylacetamidyl-3H-4-oxo- pyrrolo [2,3-d] yrimidin-5-yl ) -eth-2-yl]benzoic acid:
To a solution of acetylene from Preparation 4, Step 1 (497 mg, 1.31 mmol) in methanol (15 mL) was added 5% Pd/C (250 mg) and the mixture was stirred under 60 psi (414 kPa) H at 50°C for 24 hours The reaction was filtered, concentrated in vacuo and triturated with methanol . The resulting solid was filtered and dried to give 232 mg product (46%) as off-white solid.
-H NMR (DMSO-d6) δ 11.76 (s, NH) , 11.24 (s, NH) , 10.77 (s, NH) , 7.83 (d, J = 8.01 Hz, ArH2 ) , 7.31 (d, J = 8.08 Hz, ArH2), 6.64 (s, PyrH), 3.01-2.87 (m, CH2CH2 ) , 1.23 (s, 3CH3) ppm; IR (KBr) υmaχ 3286, 3228, 2967, 1652, 1614, 1436, 1420, 1240, 1176, 789 cm-1; UV (MeOH) λm χ 228.25 (ε = 20859), 295.25 (ε = 12430) nm; MS (FAB) m/z 383 (M+1, 55).
Step 3 : Synthesis of 4- [ <2-amino-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl) -eth-2-yl] benzoic acid:
To a solution of protected amine from Preparation
4, Step 2 (5.76 g, 15.1 mmol) in EtOH (200 mL) was added p- toluenesulfonic acid monohydrate (6.30 g, 33.1 mmol) and the mixture was stirred at reflux for 16 hours The reaction was cooled and the resulting precipitate was filtered, washed with EtOH and dried in vacuo to give 5.22 g product as tosic acid salt (74%) . A sample was dissolved in aqueous LiOH and the solution was acidified to pH 3 with IN HCl, the solid was filtered, washed with H0 and dried in vacuo to give product as a tan solid.
*-H NMR (DMSO-ds) δ 10.61 (s, NH) , 10.14 (s, NH) , 7.82 (d, J = 7.99 Hz, ArH2), 7.30 (d, J = 7.99 Hz, ArH2 ) , 6.30 (s,
PyrH), 5.99 (s, NH2 ) , 3.00 - 2.81 (m, CH2CH2) ppm; IR (KBr) Umax 3475, 3209, 2923, 1665, 1389, 1289 cm-1; UV (MeOH) λ ■max 223.75 (ε = 24465) nm; MS (FAB) m/z 299 (M-1, 8).
Step 4: Synthesis of 4- [ (2-amino-3H-4-oxo-pyrrolo[2,3- d]pyrimidin-5-yl) -eth-2-yl]benzoic acid (N-succinimide ester) :
To a solution of acid from Preparation 4, Step 4 (10.0 g, 33.5 mmol) and N-hydroxysuccinimide (4.24 g, 36.9 mmol) in DMF (150 mL) was added 1 , 3-dicyclohexylcarbodiimide (7.61 g, 36.9 mmol) and the reaction was stirred at RT overnight. After 20 hr, the mixture was filtered and the clear solution concentrated in vacuo. The crude product was triturated with 20% iPrOH/EtOAc and filtered, then triturated again and dried in vacuo to give 10.36 g product (76%) as off-white solid. --H NMR (DMSO-de) δ 10.61 (s, NH) , 10.18 (s, NH) , 7.97 (d, J = 8.06 Hz, ArH2), 7.44 (d, J = 8.07 Hz, ArH2 ) , 6.29 (s, PyrH), 6.02 (s, NH2 ) , 3.10-3.03 (m, CH2 ) , 2.92-2.84 (m, CH2), 2.88 (s, 2CH2) ppm; IR (KBr) umax 3367, 1773, 1735, 1661, 1633, 1378, 1211, 1072, 979 cm"-1; UV (MeOH) λmaχ 222.5 (ε = 20997), 249.75 (ε = 25447) nm; MS (FD) m/z 395 (M+, 100); Anal. Calcd. for Ci9Hι7N5θ5 requires: C, 57.72; H, 4.33; N, 17.71%. Found: C, 57.54; H, 4.43; N, 17.42%.
Preparation 5
NOTE: In all of Preparation 5, "active ester" refers to succinimide ester made by the preparation described in any of Preparation 1, 2, 3 or 4 ; and the term amine refers to an amine of Formula II (namely: HNR---R2, where R1 and R*-- are as described previously) .
5A. Rapid Analogue Process (RAP) General Procedure A
A mixture of active ester (0.126 mmol), amine
(0.38 mmol), and N, O-bis (trimethylsilyl ) acetamide (0.2 mL, 0.81 mmol) in dry dimethylformamide (3 mL) is heated at 55°C under nitrogen for 18-48 hours. The reaction is quenched with IN aqueous HCl (0.05 mL) then the solvent is removed in vacuo to give a residue which is azeotroped with xylenes (6 mL) and dried under high vacuum to remove any remaining traces of solvent. The residue is sonicated with IN aqueous HCl (15 mL) for -0.5 hours and the resulting solid is filtered, washed with water (5 mL) , diethyl ether (5 mL) and dried to give the desired product as a solid.
5B. Rapid Analogue Process (RAP) General Procedure B
A mixture of active ester (0.126 mmol), amine (0.38 mmol), and N, O-bis (trimethylsilyl ) acetamide (0.2 mL,
0.81 mmol) in dry dimethylformamide (3 mL) is heated at 55°C under nitrogen for 18 hours. Ethylenediamine (-20 equivalents) is added and the solution stirred at 55°C for a further 0.5 hours The reaction is then quenched with IN aqueous HCl (0.05 mL) then the solvent is removed in vacuo to give a residue which is azeotroped with xylenes (6 L) and dried under high vacuum to remove any remaining traces of solvent. The residue is sonicated with IN aqueous HCl (15 mL) for -0.5 hours and the resulting solid is filtered, washed with water (5 mL) , diethyl ether (5 mL) and dried to give the desired product as a solid.
5C. Rapid Analogue Process (RAP) General Procedure C
To a solution of active ester (0.126 mmol) in dimethylformamide (3 L) is added a solution of amino acid (0.634 mmol) in IN aqueous NaOH (0.634 mmol) and the solution heated at 55°C under nitrogen for 18 hours The reaction is then quenched with IN aqueous HCl (2 mL) . Then the solvent is removed in vacuo to give a residue which is azeotroped with xylenes (6 mL) and dried under high vacuum to remove any remaining traces of solvent . The residue is sonicated with IN aqueous HCl (15 L) for -0.5 hours and the resulting solid is filtered, washed with water (5 mL) , diethyl ether (5 mL) and dried to give the desired product as a solid.
Preparation 6
Preparation of starting material for L-glutamic acid that is used in Preparation 7: Sulfonamide Coupling General Procedure D
Active ester made using Preparation 4 (7.59 g, 19.2 mmol) and L-glutamic acid-α-t-butyl ester (5.85 g, 28.8 mmol) were reacted according to General Procedure 5A for 16 hours to give the α-t-butyl-N-4- [ (2-amino-3H-4-oxo-pyrrolo [2 , 3- d] pyrimid-5-yl ) -eth-2-yl] benzoyl-L-glutamic acid product as a green solid (9.1 g, 98%).
XH NMR (DMSO-de) δ 10.59 (br s, NH) , 10.38 (br s, NH) , 7.78 (d, J = 8.15 Hz, ArH2), 7.26 (d, J = 8.03 Hz, ArH2 ) , 6.29 (s, PyrH), 6.12 (br s, NH2 ) , 4.27-4.21 (m, CH) , 2.99-2.80 (m, CH2CH2), 2.24 (t, J = 6.34 Hz, CH: ) , 2.05-1.89 (m, CH2 ) , 1.39 (s, 3CH3) ppm; IR (KBr) υmax 3345, 1639, 1539, 1369, 1155 cm"1; UV (EtOH) λmax 224 (ε = 22632) nm; MS (FAB) m/z 483 (M+, 15) .
Preparation 7
Sulfonamide Coupling General Procedure D
A mixture of L-glutamic acid (1 equ) made using Preparation 6, sulfonamide (3 equ) and N,N- dimethylaminopyri ine (1 equ) in dimethylformamide is treated with dicyclohexylcarbodiimide (1.5 equ) and stirred at RT overnight. The reaction is filtered, and the solvent was removed in vacuo. The resulting crude product is purified by flash chromatography (MeOH/CH2Cl2 mixtures with 0.5% AcOH) on silica gel to give the desired product as a solid. Example 1
Synthesis of N-α-4- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl) -eth-2-yl] -benzoyl-N-Δ-BOC-L-ornithine
Active ester from Preparation 1, Step 9 (50 mg, 0.13 mmol) and L-Boc-ornithine (88 mg, 0.38 mmol) were reacted according to General Procedure 5A to give the product as a gray solid (40 mg, 61%) .
--H NMR (DMSO-dδ) δ 12.52 (broad singlet, COOH),
11.59 (broad singlet, NH) , 11.27 (broad singlet, NH) , 8.48 (d, J = 7.35 Hz, NH) , 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.29 (d, J = 8.46 Hz, ArH ), 6.79 (t, J = 5.15 Hz, NH) , 6.62 (s, Pyr H) , 4.38 - 4.29 (m, CH) , 3.03-2.89 ( , CH CH2, CH N) , 2.29 (s, CH3), 1.88-1.63 ( , CH2) , 1.56 - 1.41 (m, CH2), 1.37 (s, 9 H Boc) ppm; IR (KBr) υ 3318, 2932, 2859, 1685, 1529, 1505, 1448, 1366, 1290, 1251, 1168 cm"1; MS (FAB) 512 (M+, 25).
Example 2
Synthesis of N-4- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3- d] yrimidin-5-yl) -eth-2-yl] -benzoyl-L-valine:
Active ester from Preparation 1, Step 9 (50 mg, 0.13 mmol) and L-valine (74 mg, 0.63 mmol) were reacted according to General Procedure 5A to give the product as a gray solid (28 mg, 55%) .
*-H NMR (DMSO-dδ) δ 12.55 (broad singlet, COOH), 11.58 (broad singlet, NH) , 11.26 (broad singlet, NH) , 8.30 (d, J = 8.09 Hz, NH) , 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.29 (d, J = 8.09 Hz, ArH2), 6.63 (d, J = 1.84 Hz, Pyr H) , 4.27 (t, J = 7.36 Hz, CH), 3.03 - 2.93 (m, CH2CH2 ) , 2.28 (s, CH3 ) , 2.23 - 2.15 (m, CH), 0.96 (t, J = 6.07 Hz, 2 CH3 ) ppm; IR (KBr) υ 3140, 2965, 2932, 2857, 1653, 1610, 1528, 1500, 1447, 1296, 812 cm"1; MS (FAB) 397 (M+, 70) .
Example 3
Synthesis of N-4- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl-eth-2-yl] -benzoylglycine
2H
Active ester from Preparation 1, Step 9 (50 mg, 0.13 mmol) and glycine (48 mg, 0.64 mmol) were reacted according to General Procedure 5A to give the product as a tan solid (34 mg, 75%) .
--H NMR (DMSO-dβ) δ 11.64 (s, NH), 11.30 (s, NH), 8.76 (t, J = 5.88 Hz, NH), 7.78 (d, J = 8.09 Hz, Ar 2 H), 7.30 (d, J = 8.09 Hz, Ar 2 H) , 6.63 (d, J = 2.21 Hz, Pyr H) , 3.91 (d, J = 5.88 Hz, NCH2) , 3.04 - 2.92 ( , CH2CH2), 2.29 (s, CH3) ppm; IR (KBr) υ 3291, 3152, 2926, 2365, 1668, 1642, 1542, 1505, 1410, 1232, 1110, 913 cm"1; MS (FAB) 355 (M+, 60) .
Example 4
Synthesis of N-{2- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3-d] - pyrimidin-5-yl) eth-2-yl] thiophen-5-yl}carbonyl-α-amino adipic acid
Active ester from Preparation 2, Step 3 (50 mg, 0.13 mmol) and α-aminoadipic acid (40 mg, 0.25 mmol) were reacted according to General Procedure 5A to give product as a yellow solid (13 mg, 23%) .
■-H NMR (DMSO-d6) δ 11.61 (broad singlet, NH) ,
11.31 (broad singlet, NH) , 8.46 (d, J = 7.81 Hz, NH) , 7.66 (d, J = 3.65 Hz, Th H) , 6.82 (d, J = 3.57 Hz, Th H) , 6.67 (s, Pyr H), 4.29-4.26 (m, CH) , 3.22-2.86 (m, CH2CH2), 2.27 (s, CH3), 1.82-1.63 (m, CH2) , 1.63-1.45 ( , CH2 ) , 1.25-0.93
(m, CH2) ppm; IR (KBr) υ 3114, 2932, 2856, 1654, 1452, 1294, 1234, 1072 cm-1; MS (FAB) 447 (M+, 25) .
Exampla __
Synthesis of N-{2- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl) eth-2-yl] thiophen-5-yl} -carbonyl-2-amino-4■ phosphonobutyric acid:
Active ester from Preparation 2, Step 3 (50 mg, 0.13 mmol) and DL-2-amino-4-phosphonobutyric acid (68 mg, 0.38 mmol) were reacted according to General Procedure 5A to give product as a gray solid (22 mg, 38%) .
--H NMR (DMSO-dδ) δ 11.61 (broad singlet, NH) , 11.31 (broad singlet, NH) , 8.72 (d, J = 7.47 Hz, NH) , 7.68 (d, J = 3.57 Hz, Th H) , 6.83 (d, J = 3.51 Hz, Th H) , 6.68 (s, Pyr H), 4.34-4.29 (m, CH) , 3.21-3.13 (m, CH2 ) , 2.99-2.91 (m, CH2), 2.27 (s, CH3), 2.03-1.87 ( , CH2 ) , 1.66-1.53 (m, CH2) ppm; IR (KBr) υ 3148, 2931, 1699, 1661, 1549, 1520, 1451, 1234, 1043 cm"1; UV (EtOH) λmax 219.5 (ε - 16423), 280.5 (ε = 19355) nm; MS (FAB) 469 (M+, 20).
Example 6
Synthesis of N-{2- [ (2-methyl-3H-4-oxo-pyrrolo[2, 3-d] - pyrimidin-5-yl)eth-2-yl] -thiophen-5-yl} -carbonyl-trans-4- (aminomethyl)cyclohexanecarboxylic acid
Active ester from Preparation 2, Step 3 (50 mg, 0.13 mmol) and trans-4- (aminomethyl) cyclohexane carboxylic acid (40 mg, 0.25 mmol) were reacted according to General Procedure 5A to give the product as a gray solid (13 mg, 23%) .
-H NMR (DMSO-dδ) δ 11.63 (broad singlet, NH) , 11.34 (broad singlet, NH) , 8.30 (t, J = 5.88 Hz, NH) , 7.55 (d, J -= 3.68 Hz, ThH), 6.82 (d, J = 3.68 Hz, ThH), 6.68 (s, Pyr H), 3.22-3.13 (m, CH ) , 3.08-2.93 (m, CHCH2), 2.29 (s, CH3), 2.19-2.07 (m, CH) , 1.94-1.85 (m, CH2) , 1.79-1.70 (m, CH2), 1.51-1.40 (m, CH) , 1.33-1.17 (m, CH2), 1.01-0.85 (m, CH2) ppm; IR (KBr) υ 3114, 2929, 2855, 1692, 1644, 1546, 1521, 1439, 1275, 1234, 1094 cm"1; UV (EtOH) λmaχ 220.5 (ε = 13379), 279.5 (ε = 15680) nm; MS (FAB) 443 (M+, 85).
Example 7
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl) eth-2-yl] -benzoyl-L-aspartic acid
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-aspartic acid (50 mg, 0.38 mmol), were reacted according to General Procedure 5A to give the product as a pink solid (43 mg, 83%) .
XH NMR (DMSO-dff) δ 10.87 (broad smglet, NH) , 10.67 (broad smglet, NH) , 8.65 (d, J = 7.72, NH) , 7.75 (d, J = 8.46, Ar H2), 7.28 (d, J = 8.09, ArH2 ) , 6.38 (s, PyrH), 4.79-4.70 (m, CH) , 3.01-2.93 (m, CH2 ) , 2.90-2.80 ( , CH2 ) , 2.75-2.65 ( , CH2CO2H) ppm; IR (KBr) υna< 3155, 2925, 1690, 1611, 1535, 1384, 1337, 1226, 1082 cm ; UV (EtOH) λmaχ 203.5 (ε = 33841), 224.5 (ε = 23301), 242.5 (ε = 17789) n ; MS (FAB) /z 414 (M+1, 13) .
Example 8
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3-d]pyrimidin- 5-yl) th-2-yl] -benzoyl-L-alanine
A mixture of the active ester Preparation 4, Step
4 (50 mg, 0.13 mmol) and L-alanme (34 mg, 0.38 mmol) were reacted according to General Procedure 5A to give the product as a light pink solid (43 mg, 91%) .
*-H NMR (DMSO-d6) δ 11.18 (broad singlet, NH, NH) , 8.56 (d, J = 7.35, NH) , 7.79 (d, J = 8.09, ArH2), 7.28 (d, J = 8.46, ArH2), 6.44 (s, PyrH), 4.46-4.36 (m, CH) , 3.00-2.84 (m, CH2CH2), 1.39 (d, J = 7.35, CH3 ) ppm; IR (KBr) υmax 3151, 2618, 1671, 1534, 1502, 1423, 1305, 1132 cm"1; UV (EtOH) λmax 202.5 (ε = 34951), 224.5 (ε = 23174) nm; MS (FAB) m/z 370 (M+1, 100); Anal. Calcd. for C18H1Q 5O4 requires: C, 58.53; H, 5.18; N, 18.96%. Found: C, 50.26; H, 4.99; N, 16.57%.
Example 9
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl) eth-2-yl] -benzoyl- -phenylalanine :
A mixture of the active ester Preparation 4, Step
4 (50 mg, 0.13 mmol) and L-phenylalanine (63 mg, 0.38 mmol) were reacted according to General Procedure 5A to give the product as an off-white solid (46 mg, 82%) .
--H NMR (DMSO-de) δ 10.67 (s, NH) , 10.28 (broad singlet, NH) , 8.59 (d, J = 7.72, NH), 7.70 (d, J = 8.09, ArH2), 7.34-7.15 (m, ArH2 , ArHB), 6.32 (s, PyrH), 4.64-4.56 (m, CH) , 3.22-2.73 (m, CH2CH2 , CH2Ph) ppm; IR (KBr) υmax 3321, 2929, 1638, 1531, 1498, 1437, 1229, 1077 cm"1; UV (EtOH) λmax 202.5 (ε = 47012), 223 (ε = 26496) nm; MS (FAB) m/z 446 (M+1, 45); Anal. Calcd. for C24H? r,04 requires: C, 64.71; H, 5.20; N, 15.72%. Found: C, 60.72; H, 5.28; N, 14.82%.
Example 10
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl)eth-2-yl] -benzoyl-L-serine:
A mixture of the active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-serine (40 mg, 0.38 mmol) were reacted according to General Procedure 5A to give the product as a pink solid (40 mg, 82%) .
*-H NMR (DMSO-d6) δ 10.98 (broad singlet, NH) , 10.85 (broad singlet, NH) , 8.31 (d, J = 8.09, NH) , 7.80 (d, J = 8.09, ArH2) , 7.29 (d, J = 8.09, ArH2 ) , 6.40 (s, PyrH) , 4.49-4.43 (m, CH) , 3.79 (d, J = 5.15, CH2C02H) , 3.00-2.84 (m, CH2CH2) ppm; IR (KBr) υpaχ 3150, 2621, 1671, 1503, 1427, 1305, 1224, 1131, 1078 cm-1; UV (EtOH) λmax 202.5 (ε = 31105) , 224.5 (ε = 21031) nm; MS (FAB) m/z 386 (M+1, 26) ; Anal. Calcd. for Cι8Hι9N5θ5 requires: C, 56.10; H, 4.97; N, 18.17%. Found: C, 50.04; H, 4.70; N, 16.34%.
Example 11
Synthesis of α-amino-N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl)eth-2-yl] -benzoylthiopheneacetic acid:
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and DL-α-amino-2-thiopheneacetic acid (60 mg, 0.38 mmol) were reacted according to General Procedure 5C to give the product as a light brown solid (49 mg, 89%) .
*-H NMR (DMSO-dfs) δ 10.73 (broad singlet, NH) , 10.38 (broad singlet, NH) , 9.13 (d, J = 7.72, NH) , 7.84 (d, J = 8.09 ArH2), 7.50 (d, J = 5.15, ThiH), 7.29 (d, J = 8.09, ArH2), 7.18 (d, J = 3.31, ThiH), 7.03 (dd, J = 5.15, 3.68, ThiH), 6.35 (s, PyrH), 5.83 (d, J = 7.35, CH) , 3.02-2.81 (m, CH2CH2) ppm; IR (KBr) υmaχ 3328, 1687, 1527, 1496, 1380, 1230, 1078 cm-1; UV (EtOH) λmax 226.5 (ε = 26890) nm; MS (FAB) m/z 438 (M+1, 4) .
Example 12
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3-d]pyrimidi - 5-yl) eth-2-yl] -benzoyl-L-proline :
A mixture of the active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-proline (44 mg, 0.38 mmol) were reacted according to General Procedure 5A to give the product as an off-white solid (25 mg, 50%) .
--H NMR (DMSO-ds) δ 10.98 (broad singlet s, NH) , 10.83 (broad singlet, NK) , 7.44 (d, J = 8.09, ArH2) , 7.28 (d, J = 7.35, ArH2) , 6.42 (s, PyrH) , 4.42-4.35 (m, CH) , 3.61-3.43 (m, CH2) , 2.99-2.82 (m, CH2CH2 ) , 2.55-2.45 (m, CHH) , 2.30-2.20 (m, CHH) , 1.93-1.79 (m, CH2 ) ppm; IR (KBr) υmax 3235, 2766, 1674, 1602, 1438, 1226, 1079 cm"-1; UV (EtOH) λmax 202.5 (ε = 30942) , 223.0 (ε = 24450) , 251.5 (ε = 12966) nm; MS (FAB) m/z 396 (M+1, 28) .
Example 13
Synthesis of N-isopropyl-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl) eth-2-yl]benzamide:
A mixture of the active ester from Preparation 4,
Step 4 (75 mg, 0.19 mmol) and isopropyl amine (50 μL, 0.57 mmol) in CHCl /MeOH was stirred at room temperature under nitrogen for 2.5 hours. The reaction was concentrated in vacuo, and the crude product was sonicated in aqueous HCl and filtered. The solid was sonicated in H0, the solid was filtered and dried to give the product as an off-white solid (42 mg, 66%) .
*-H NMR (DMSO-d6) δ 10.60 (s, NH) , 10.16 (s, NH) , 8.09 (d, J = 8.09, NH) , 7.73 (d, J = 8.09, ArH2 ) , 7.25 (d, J = 8.46, ArH2), 6.30 (s, PyrH), 6.01 (s, NH2 ) , 4.14-4.03 (m, CH) , 2.99-2.93 (m, CH2 ) , 2.88-2.81 (m, CH2 ) , 1.15 (d, J = 6.62, 2CH3) ppm; IR (KBr) υmax 3373, 3231, 2973, 2931, 1633, 1531, 1437, 1366, 1352 cm"1; UV (EtOH) λmaχ 203 (ε = 35708) , 224.5 (ε-= 24191) nm; MS (FAB) m/z 340 (M+1, 52) .
Example 14
Synthesis of N-benzyl-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl ) eth-2-yl]benzamide
A mixture of the active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and benzyl amine (41 mg, 40 μL, 0.38 mmol) was reacted according to General Procedure 5A to give the product as a gray solid (43 mg, 88%) .
lH NMR (DMSO-d6) δ 10.88 (broad singlet, NH) , 10.67 (broad singlet, NH) , 8.96 (t, J = 5.88, NH) , 7.80 (d, J = 8.09, ArH2), 7.36-7.22, m, ArH2 , ArH-,), 6.39 (s, PyrH), 4.47 (d, J = 4.04, CH2Ph) , 3.01-2.82 (m, CH2CH2 ) ppm; IR (KBr) Umax 3126, 2922, 1672, 1638, 1539, 1427, 1308, 1079 cm"1; UV (EtOH) λmax 203.5 (ε = 38228), 224 (ε = 23645) nm; MS (FAB) m/z 388 (M+1, 28) .
Example 15
Synthesis of γ-tetrazole-N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl)eth-2-yl] -benzoyl-L-glutamic acid:
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-glutamic acid γ-tetrazole hydrate (72 mg, 0.38 mmol) were reacted according to General Procedure 5C for 18 hours to give the product as an off white solid (52 mg, 91%) .
*-H NMR (DMSO-dg) δ 10.90 (s, NH) , 10.69 (br s, NH) , 8.65 (d, J = 7.72 Hz, NH) , 7.81 (d, J = 8.09 Hz, ArH2 ) , 7.30 (d, J = 8.46 Hz, ArH2), 6.39 (s, PyrH), 4.48-4.39 (m, CH) , 3.04-2.83 (m, 3CH2), 2.38-2.14 (m, CH2 ) ppm; IR (KBr) υmaχ 3142, 1687, 1634, 1547, 1509, 1341, 1216, 1079 cm"-1; UV (EtOH) λraaχ 224.5 (ε = 23605) nm; MS (FAB) /z 452 (M+1, 22).
Example 16
Synthesis of γ-tetrazole-N- {2-f luoro-4- [ ( 2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] -benzoyl-L-glutamic acid:
The active ester from Preparation 3, Step 4 (50 mg, 0.13 mmol), and L-glutamic acid-γ-tetrazole (69 mg, 0.36 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a brown solid (43 mg, 76%) .
*-H NMR (DMSO-d6) δ 11.18 (s, 2 NH) , 8.55 (dd, J = 7.17, 5.51 Hz, NH) , 7.54 (t, J = 7.60 Hz, ArH), 7.51-6.98 (br s, NH2), 7.18-7.05 (m, ArH2), 6.46 (s, PyrH), 4.49-4.38 (m, CH) , 3.02-2.78 (m, CH2CH2 ) , 2.43-2.12 (m, CH2CH2) ppm; IR (KBr) Umax 3154, 1673, 1643, 1625, 1538, 1421, 1221, 1081, 764 cm"1; MS (FAB) m/z 470 (M+1, 60).
Example 17
Synthesis of γ-4-carboxyphenylsulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2-yl]benzoyl-L-glutamic acid
Step 1; Synthesis of γ-t-butyl-γ-4- carboxymethylphenylsulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-y1) eth-2-y1]benzoylglutamate :
Carboxylic acid from Preparation 6 (500 mg, 1.03 mmol) and methyl 4- (aminosulfonyl)benzoate (668 mg, 3.10 mmol) were reacted according to the Sulfonamide Coupling
Procedure of Preparation 7 for 16 hours to give the product as a white solid (326 mg, 46%) .
*-H NMR (DMSO-dg) δ 10.60 (s, NH) , 10.13 (s, NH) , 8.65-8.58 (m, NH) , 8.04 (d, J = 8.36 Hz, ArH2 ) , 7.94 (d, J = 8.14 Hz, ArH2) , 7.72 (d, J =8.08 Hz, ArH2 ) , 7.24 (d, J = 8.18 Hz, ArH2) , 6.30 (s, PyrH), 5.99 (br s, NH2 ) , 4.18-4.08 (m, CH) , 3.86 (s, CH3) , 2.99-2.78 (m, CH2CH2 ) , 2.30-2.21 (m, CH2 ) , 1.93-1.78 (m, CH2), 1.36 (s, 3CH3) ppm; IR (KBr) υmaχ 3362, 1730, 1661, 1634, 1538, 1437, 1369, 1282, 1154, 1086 cm"1; UV (MeOH) λmax 225 (ε = 33811) nm; MS (FAB) m/z 681 (M+1, 23)
Step 2 ; Synthesis of γ-t -butyl -γ-4-carboxyphenylsulfonamyl- N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d] pyrimidin- 5 -yl) eth-2 - yl] benzoyl -L-glutamic acid:
A solution of methyl ester from Example 17, Step 1 (304 mg, 0.45 mmol) and IN aqueous LiOH (1.11 mL, 1.11 mmol) in dioxane/H20 (15 mL) was stirred at 100°C for 5 hours The reaction was cooled, concentrated to small volume, acidified to pH 2 and the resulting solid was filtered. The crude product was purified by flash chromatography (0.5% AcOH/15% MeOH/CH2Cl2) to give the product as a white solid (173 mg, 58%) .
*-H NMR (DMSO-dg) δ 10.61 (s, NH) , 10.18 (s, NH) , 8.86 (d, J = 6.17 Hz, NH) , 7.94 (d, J = 8.18 Hz, ArH2 ) , 7.81 (d, J = 8.22 Hz, ArH2), 7.73 (d, J = 8.02 Hz, ArH2 ) , 7.24 (d, J =
8.05 Hz, ArH2) , 6.31 (s, PyrH) , 6.01 (br s, NH2) , 4.18-4.09 (m, CH) , 2.99-2.84 (m, CH2CH2) , 2.15 (t, J = 6.96 Hz, CH2 ) , 1.95-1.81 (m, CH2), 1.38 (s, 3CH3) ppm; IR (KBr) υmax 3359, 2931, 1636, 1543, 1404, 1369, 1253, 1153, 1085 cm*-1; UV (MeOH) λroax 226.25 (ε = 30379) nm; MS (FAB) /z 667 (M+1, 2) . Step 3 ; Synthesis of γ-4-carboxyphenylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo[2,3-d]pyrimidin-5-yl)eth-2- yl]benzoyl-L-glutamic acid:
Tert-butyl ester from Example 17, Step 2 (149 mg, 0.22 mmol) and trifluoroacetic acid (5 mL) were stirred for 1 hours at RT. The reaction was concentrated in vacuo, and the crude product was purified by column chromatography (5% H20/5% AcOH/CH3CN to 10% H20/5% AcOH/CH3CN) to give the product as an off-white solid (132 mg, 97%) .
1H NMR (DMSO-d6) δ 10.62 (s, NH) , 10.17 (s, NH) , 8.45 (d, J = 7.52 Hz, NH) , 8.13 (d, J = 8.3 Hz, ArH2 ) , 8.01 (d, J = 8.42 Hz, ArH2), 7.76 (d, J = 8.22 Hz, ArH2), 7.28 (d, J = 7.99 Hz, ArH2), 6.31 (s, PyrH), 6.03 (br s, NH ) , 4.30-4.22 (m, CH) , 3.00-2.82 ( , CH2CH2 ) , 2.40 (t, J = 6.6 Hz, CH2 ) , 2.04-1.97 (m, CHH), 1.87-1.80 (m, CHH) ppm; IR (KBr) Umax 3370, 1696, 1640, 1536, 1179, 1085 cm-1; UV (EtOH) λmax 228.0 (ε = 32834) n ; MS (FAB) m/z 611 (M+1, 5) .
Example 18
Synthesis of γ-3-carboxyphenylsulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2-yl]benzoyl-L-glutamic acid Step 1 : Synthesis of γ-t-butyl-γ-3- carboxymethylphenylsulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2,3-d]pyri idin-5-yl) eth-2-yl]benzoyl glutamate :
Carboxylic acid from Preparation 6 (500 mg, 1.03 mmol) and methyl 3- (aminosulfonyl ) benzoate (668 mg, 3.10 mmol) were reacted according to the Sulfonamide Coupling Procedure of Preparation 7 for 18 hours to give the product as a white solid (273 mg, 39%) .
*-H NMR (DMSO-d,5) δ 10.61 (s, NH) , 10.14 (s, NH), 8.46-8.39 (m, NH, ArH), 8.22 (d, J = 7.68 Hz, ArH), 8.14 (d, J = 7.43 Hz, ArH) , 7.79-7.68 ( , ArH3 ) , 7.26 (d, J = 7.93 Hz, ArH2 ) , 6.30 (s, PyrH) , 5.99 (s, NH2 ) , 4.18-4.11 (m, CH) , 3.90 (s, CH3) , 2.99-2.79 (m, CH2CH2) , 2.36 (t, J = 7.26 Hz, CH2 ) , 1.94-1.71 ( , CH2 ) , 1.36 (s, 3CH3) ppm; IR (KBr) υmax 3366, 1728, 1662, 1635, 1534, 1439, 1301, 1271, 1154 cm"1; UV (EtOH) λmaχ 222 (ε = 37876) nm; MS (FD) m/z 680 (M\ 88) .
Step 2: Synthesis of γ-t-butyl-γ-3-carboxyphenylsulfonamyl- N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3 -d] pyrimidin- 5 -yl) eth-2 - yl] benzoyl -L-glutamic acid:
A solution of methyl ester (241 mg, 0.354 mmol) and IN aqueous LiOH (0.88 mL, 0.88 mmol) in dioxane/H20 (15 mL) was stirred at 100°C for 4 hours The reaction was cooled, concentrated to small volume, acidified to pH 2 and the resulting solid was filtered. The crude product was purified by flash chromatography (0.5% AcOH/15% MeOH/CH2Cl2) to give the product as a white solid (111 mg, 47%) .
XH NMR (DMSO-dg) δ 10.61 (s, NH) , 10.20 (br s, NH) , 8.89 (d, J = 5.66 Hz, NH) , 8.34 (s, ArH), 7.96 (d, J = 7.57 Hz, ArH), 7.89 (d, J = 7.62 Hz, ArH), 7.73 (d, J = 8.05 Hz, ArH2 ) , 7.44 (t, J = 7.75 Hz, ArH), 7.23 (d, J = 8.04 Hz, ArH2 ) , 6.31 (s, PyrH), 6.03 (br s, NH2), 4.11-4.05 (m, CH) , 2.98- 2.78 (m, CH2CH2), 2.13-2.05 (m, CH2 ) , 1.92-1.79 (m, CH2 ) , 1.37 (s, 3CH3) ppm; IR (KBr) υmax 3358, 1636, 1546, 1437, 1394, 1370, 1155 cm"1; UV (MeOH) λπ,aχ 221.5 (ε = 32377) nm; MS (FAB) m/z 667 (M+1, 7);
Step 3 ; Synthesis of γ-3-carboxyphenylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl) eth-2- yl]benzoyl-L-glutamic acid:
Tert-butyl ester from Example 18, Step 1 (78 mg, 0.12 mmol) and trifluoroacetic acid (3 mL) were stirred for 1 hour at RT. The reaction was concentrated in vacuo, and the crude product was sonicated in AcOH/CHCN, centrifuged and dried to give the product as a green solid (65 mg, 91%) .
XH NMR (DMSO-d6) δ 10.61 (s, NH) , 10.15 (s, NH) , 8.46 (d, J = 8.05 Hz, NH) , 8.42 (s, ArH) , 8.21 (d, J = 8.23 Hz, ArH) , 8.12 (d, J = 7.52 Hz, ArH) , 7.80-7.72 ( , ArH3 ) , 7.27 (d, J = 8.01 Hz, ArH2) , 6.30 (s, PyrH) , 6.00 (s, NH2 ) , 4.29-4.23 (m, CH) , 3.00-2.82 (m, CH2CH2), 2.43-2.35 (m, CH2 ) , 2.03- 1.80 (m, CH2) ppm; IR (KBr) υmax 3355, 1693, 1639, 1536, 1502, 1441, 1345, 1180 cm"1; UV (MeOH) λmax 222.75 (ε = 30604) nm; MS (FAB) m/z 611 (M+1, 5) .
Example 19
Active ester (100 mg, 0.25 mmol) and dimethyl DL- 3-carboxycyclohexylglycinate (116 mg, 0.51 mmol) in dimethylformamide (2 mL) were stirred for 17 hours at 50°C. The reaction was concentrated and purified by flash chromatography (10% MeOH/CH2Cl2) to give the desired intermediate product as a white solid (61 mg, 47%); MS (FD) m/z 509 (M+, 100) .
The resulting dimethyl ester precursor of the above-depicted compound (61 mg, 0.12 mmol) was reacted with IN aqueous NaOH (0.36 mL, 0.36 mmol) in dioxane (3 mL) and H0 (2 mL) at 50°C for 4 hours The reaction was concentrated and the crude product was sonicated with IN aqueous HCl and the resulting solid was filtered, washed with H0, Et 0 and dried to give the product as a green solid (43 mg, 74%) .
*-H NMR (DMSO-df?) δ 11.08 (br s, NH) , 11.02 (br s, NH) , 8.39- 8.32 (m, NH) , 7.78 (d, J = 7.77 Hz, ArH2 ) , 7.27 (d, J = 8.09 Hz, ArH2), 6.41 (s, PyrH), 4.31-4.25 (m, CH) , 2.96-2.83 (m, CH2CH2), 2.22-2.13 (m, CH) , 1.93-1.01 ( , 4CH2 , CH) ppm; IR (KBr) υmax 3390, 2930, 1685, 1536, 1503, 1216 cm"1; UV (EtOH) λma 203.5 (ε = 33617), 224.5 (ε = 24060) nm; MS (FAB) /z 482 (M+1, 22) .
Example 20
Synthesis of γ-tetrazole-N-{2- [2-methyl-3H-4-oxo- pyrrolo [2 , 3-d] -pyrimidin-5-yl) eth-2-yl] thiophen-5-yl)- carbonyl-L-glutamic acid
The active ester from Preparation 2, Step 3 (50 mg, 0.124 mmol) and L- (γ-tetrazole) glutamic acid (118 mg, 0.623 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a white solid (18 mg, 30%) .
*-H NMR (DMSO-dg) δ 10.62 (s, NH) , 10.14 (s, NH) , 8.60 (d, J = 7.79 Hz, NH) , 7.63 (d, J = 3.50 Hz, ArH), 6.81 (d, J = 3.52 Hz, ArH), 6.33 (s, PyrH), 5.98 (s, NH2 ) , 4.36-4.30 (m, CH) , 3.20-3.05 (m, CH2 ) , 2.95-2.85 (m, CH2 ) , 2.80-2.70 (m,
CH2), 2.30-2.09 (m, CH2 ) ppm; IR (KBr) υmax 3336, 3220, 2928 1631, 1544, 1523, 1457 cm"1; UV (EtOH) λmaχ 221.75 (ε = 22246), 279.50 (ε = 21947) nm; MS (FAB) m/z 458 (M+1, 95).
Example 21
Synthesis of N- {2-Fluoro-4 - [ ( 2-amino-3H-4 -oxo-pyrrolo [2 , 3 - d ] pyrimidin- 5 -yl) eth-2 -yl] benzoyl } - -tert-leucine :
The active ester from Preparation 3, Step 4 (50 mg, 0.13 mmol), and L-tert-leucine (95 mg, 0.73 mmol) were reacted according to General Procedure 5B for 20 hours to give the product as a tan solid (38 mg, 49%) .
*-H NMR (DMSO-d<-) δ 10.86 (s, NH) , 10.59 (s, NH) , 8.09 (dd, J = 8.66, 4.38 Hz, NH) , 7.52 (t, J = 7.68 Hz, ArH), 7.20-7.05 (m, ArH2), 6.62-6.30 (br s, NH ) , 6.40 (s, PyrH), 4.31 (d, J = 8.68 Hz, CH) , 3.05-2.85 (m, CH2CH2 ) , 1.02 (s, 3 CH3 ) ppm; IR (KBr) Umax 3340, 3335, 3240, 2965, 2872, 1670, 1624, 1529, 1495, 1422, 1226 cπr1; MS (FAB) m/z 430 (M+1, 55).
Example 22
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl)eth-2-yl] -benzoyl-L-tert-leucine:
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-tert-leucine (50 mg, 0.38 mmol) were reacted according to General Procedure 5C for 16 hours to give the product as a blue solid (46 mg, 88%) .
*-H NMR (DMSO-dg) δ 11.23 (br s, 2NH) , 8.03 (d, J = 8.78 Hz, NH) , 7.76 (d, J = 7.92 Hz, ArH2 ) , 7.26 (d, J = 8.00 Hz, ArH2), 6.45 (s, PyrH), 4.33 (d, J = 8.73 Hz, CH) , 2.95-2.82 (m, CH2CH2), 1.02 (s, 3CH3) ppm; IR (KBr) Umax 3242, 2968, 2765, 1697, 1672, 1525, 1502, 1375, 1225, 1077 cm"1; UV (EtOH) λmaχ 203 (ε = 33542), 224.5 (ε = 22407), 246.5 (ε = 17576) nm; MS (FAB) m/z 412 (M+1, 27) .
Example 23
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidi - 5-yl)eth-2-yl]-benzoyl-L-valine:
Active ester from Preparation 4, Step 4 (200 mg, 0.51 mmol) and L-valine (178 mg, 1.52 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a light green solid (120 mg, 60%) .
lH NMR (DMSO-de) 6 10.83 (br s, NH) , 8.30 (d, J = 8.46 Hz, NH), 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.28 (d, J = 8.09 Hz, ArH2), 6.38 (s, PyrH), 4.30-4.24 ( , CH) , 3.00-2.83 (m,
CH2CH2) , 2.28-2.15 (m, CH) , 0.97 (d, J = 6.62 Hz, CH3 ) , 0.95 (d, J = 5.15 Hz, CH3) ppm; IR (KBr) υmax 3244, 2760, 1675, 1528, 1501, 1413, 1225, 1192, 1072 cm"1; UV (MeOH) λmax 202.5 (ε = 33724) , 224.5 (ε = 23094) nm; MS (FAB) /z 398 (M+*, 85) .
Example 24
Synthesis of γ-methylsulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2,3-d]pyrimidin-5-yl) eth-2-yl]benzoyl-L-glutamic acid:
Step 1 : Synthesis of γ-t-butyl-γ-methylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl ) eth-2- yl]bβnzoyl-glutamate:
Carboxylic acid from Preparation 6 (3.0 g, 6.20 mmol) and methanesulfonamide (1.77 g, 18.6 mmol) were reacted according to the Sulfonamide Coupling Procedure of Preparation 7 for 14 hours to give the product as a white solid (1.33 g, 38%) .
--H NMR (DMSO-dg) δ 10.60 (br s, NH) , 10.14 (s, NH) , 8.53 (d, J = 7.49 Hz, NH) , 7.77 (d, J = 8.06 Hz, ArH2 ) , 7.28 (d, J = 8.26 Hz, ArH2), 6.29 (s, PyrH), 5.99 (br s, NH2 ) , 4.31-4.24 (m, CH) , 3.17 (s, CH3 ) , 3.01-2.81 (m, CH2CH2), 2.40 (t, J = 7.38 Hz, CH2), 2.09-1.86 (m, CH2 ) , 1.40 (s, 3CH3) ppm.
Step 2 : Synthesis of γ-methylsulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl]benzoyl-L-glutamic acid:
Tert-butyl ester from Example 24, Step 1 (150 mg, 0.40 mmol) and trifluoroacetic acid (3 mL) were stirred for 3 hours at RT. The reaction was concentrated in vacuo, and the crude product was sonicated in IN HCl, filtered, washed with H20 and Et20 and dried to give the product as an off- white solid (28 mg, 14%) .
*-H NMR (DMS0-d6-) δ 11.68 (s, NH) , 11.17 (br s, NH) , 8.51 (d, J =■ 7.69 Hz, NH) , 7.78 (d, J = 7.81 Hz, ArH2 ) , 7.28 (d, J = 8.13 Hz, ArH2), 6.43 (s, PyrH), 4.40-4.33 (m, CH) , 3.20 (s, CH3), 2.96-2.80 (m, CH2CH2), 2.41 (t, J = 7.13 Hz, CH2 ) , 2.18-1.91 (m, CH2) ppm; IR (KBr) \jma x 3391, 2705, 1697, 1670, 1505, 1436, 1326, 1132, 1092 cm"1; MS (FAB) m/z 505 (M+1, 6)
Example 25
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidi - 5-yl) eth-2-yl] -benzoyl L-ornithine
To a solution of phthalimide-protected amine (see Example 44 supra ) (65 mg, 0.12 mmol) in dimethylsulfoxide (1 mL) was added 2.5 N aqueous NaOH (0.2 mL) dropwise over 1 minute. The reaction was stirred at RT for 5 min, diluted with H20, acidified to pH 2 with IN HCl and the resulting solid was filtered, washed with H20 and Et20 and dried to give the product as a white solid (49 mg, 73%) .
*-H NMR (DMSO-d-s) δ 10.60 (s, NH) , 10.13 (s, NH) , 8.49 (d, J = 7.51 Hz, NH) , 8.28 (t, J = 5.85 Hz, NH) , 7.78 (d, J -- 8.08 Hz, ArH2), 7.74 (d, J = 7.31 Hz, ArH), 7.57-7.45 (m, ArH2 ) , 7.39 (d, J = 7.18 Hz, ArH), 7.27 (d, J = 8.03 Hz, ArH2),
6.30 (s, PyrH), 5.99 (s, NH2 ) , 4.38-4.32 (m, CH) , 3.23-3.14 (m, CH2), 2.99-2.80 (m, CH2CH2 ) , 1.90-1.54 ( , 2CH2) ppm; IR (KBr) υma 3318, 2933, 1689, 1638, 1539, 1503, 1440, 1307, 1233 cm"1; UV (EtOH) λmax 224 (ε = 33377) nm; MS (FAB) m/z 561 (M+1, 7) .
Example 26
Active ester (100 mg, 0.25 mmol) and dimethyl DL-
4-carboxycyclohexylglycinate (117 mg, 0.51 mmol) in dimethylformamide (2 mL) were stirred for 20 hours at 75°C. The reaction was concentrated and purified by flash chromatography (10% MeOH/CH2Cl2) to give the dimethyl ester of the above depicted compound as an off white solid (33 mg, 25%). MS (FD) m/z 509 (M+, 100).
The resulting dimethyl ester (130 mg, 0..25 mmol) was reacted with 2.5N aqueous NaOH (0.4 mL) in dimethyl sulfoxide (2 mL) at RT for 1 hours The reaction was acidified and the resulting solid was filtered, washed with H20, Et 0 and dried to give the compound drawn above as a white solid (93.5 mg, 76%).
*H NMR (DMSO-ds) δ 10.60 (s, NH) , 10.14 (s, NH) , 8.39 (d, J = 8.12 Hz, 0.5 NH) , 8.33 (d, J = 7.94 Hz, 0.5 NH) , 7.77 (dd, J = 2.71, 8.13 Hz, ArH2), 7.26 (d, J = 8.07 Hz, ArH2 ) , 6.30 (s, PyrH), 6.00 (s, NH2), 4.31 (t, J = 8.16 Hz, 0.5 CH) , 4.23 (t, J = 7.43 Hz, 0.5 CH) , 2.98-2.81 (m, CH2CH ) , 1.93- 1.10 (m, 4CH2, 2CH) ppm; IR (KBr) υMχ 3335, 2934, 2861, 1638, 1533, 1502, 1343, 1227 cm"1; UV (EtOH) λmaχ 224 (ε = 22605) nm; MS (FAB) m/z 482 (M+1, 35) . -Ill-
Example 27
The active ester (50 mg, 0.13 mmol), and methyl sulfonamide (150 mg, 0.67 mmol) were reacted according to General Procedure 5B for 20 hours to give the product as a brown solid (35 mg, 55%) .
XH NMR (DMSO-de) δ 11.72 (s, NH) , 11.09 (s, NH) , 10.99 (br s, NH) , 8.40 (dd, J = 7.39, 5.31 Hz, NH) , 7.60-7.52 (m, ArH), 7.35-6.75 (br s, NH) , 7.16-7.00 (m, ArH2 ) , 6.44 (s, PyrH), 4.42-4.30 (m, CH) , 3.22 (s, CH ) , 3.00-2.76 (m, CH2CH2), 2.40-2.32 (m, CH2 ) , 2.25-1.86 (m, CH2 ) ppm; IR (KBr) υmax 3385, 2714, 1705, 1667, 1508, 1422, 1332, 1145, 1088 cm"1; MS (FAB) m/z 523 (M+1, 68).
Example 28
Synthesis of γ-amino-N-{2-Fluoro-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] } -benzoyl-2-thiophene- acetic acid
The active ester from Preparation 3, Step 4 (75 mg, 0.18 mmol), and DL-α-amino-2-thiopheneacetic acid (114 mg, 0.73 mmol) were reacted according to General Procedure 5B for 20 hours to give the product as a brown solid (40 mg, 61%) .
*-H NMR (DMSO-d6) δ 10.92 (s, NH) , 10.69 (s, NH) , 8.92 (dd, J = 6.82, 3.55 Hz, NH) , 7.57 (t, J = 7.78 Hz, ArH), 7.51 (d, J = 4.63 Hz, ArH), 7.30-7.00 (m, ArH4 ) , 6.41 (s, PyrH), 5.78 (d, J = 7.26 Hz, CH) , 3.00-2.80 (m, CH2CH2 ) ppm; IR (KBr) Umax 3160, 2925, 1692, 1668, 1622, 1517, 1491, 1421, 1380, 1227 c -1; MS (FAB) m/z 456 (M+1, 85) .
Example 29
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl) eth-2-yl] -benzoyl-4-carboxyphenylglycine
Step 1; Synthesis of dimethyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] -benzoyl-4- carboxyphenylglycinate
Active ester from Preparation 4, Step 4 (100 mg,
0.25 mmol) and dimethyl DL-4-carboxyphenyl glycinate (135 mg, 0.60 mmol) in dimethylformamide (2 mL) were stirred for 16 hours at 50°C, then 20 hours at 75°C. The reaction was concentrated and purified by flash chromatography (5% MeOH/CH2Cl2, changing to 15% MeOH) to give the product as an off white solid (97 mg, 76%). [--H NMR (DMSO-d6) δ 10.60 (br s, NH) , 10.13 (br s, NH) , 9.21 (d, J = 7.33 Hz, NH) , 7.96 (d, J - 8.22 Hz, ArH2), 7.81 (d, J = 8.11 Hz, ArH2 ) , 7.62 (d, J = 8.33 Hz, ArH ), 7.28 (d, J = 8.12 Hz, ArH2 ) , 6.29 (s, PyrH), 5.99 (br s, NH2 ) , 5.79 (d, J = 7.3 Hz, CH) , 3.85 (s, CH3), 3.66 (s, CH3), 3.00-2.83 (m, CH2CH2 ) ppm; MS (FD) /z 504 (M\ 100) ]
Step 2 : Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3- d]pyrimidin-5-yl) eth-2-yl] -benzoyl-4-carboxyphenylglycine
The dimethyl ester from Example 29, Step 1 (95 mg, 0.19 mmol) was reacted with IN aqueous NaOH (0.57 mL, 0.57 mmol) in dioxane (3 mL) and H0 (2 mL) at RT for 3 hours The reaction was concentrated and the crude product was sonicated with IN aqueous HCl and the resulting solid was filtered, washed with H 0, Et20 and dried to give the product as a green solid (69 mg, 77%) .
*-H NMR (DMSO-de) δ 10.78 (br s, NH) , 10.51 (br s, NH) , 9.03 (d, J = 7.46 Hz, NH) , 7.92 (d, J = 8.03 Hz, ArH2 ) , 7.81 (d, J = 7.92 Hz, ArH2), 7.60 (d, J = 8.05 Hz, ArH2 ) , 7.27 (d, J = 8.01 Hz, ArH2), 6.34 (s, PyrH), 5.68 (d, J -= 7.36 Hz, CH) , 2.98-2.79 (m, CH2CH2 ) ppm; IR (KBr) υma , 3330, 1690, 1528, 1497, 1378, 1262, 1183, 1116, 1078, 1019 cm'1; UV (EtOH) λmax 202.5 (ε = 52514), 227 (ε = 29683), 243.5 (ε = 30754) nm; MS (FAB) m/z 476 (M+1, 8) . Example 30
Synthesis of γ-ethanesulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d] -pyrimidin-5-yl) eth-2-yl]benzoyl-glutamic acid:
Step 1: Synthesis of γ-t-butyl-γ-ethanesulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo[2,3-d] -pyrimidin-5-yl) eth-2- yl] benzoyl-gluta te :
Carboxylic acid from Preparation 6 (400 mg, 0.83 mmol) and ethanesulfonamide (271 mg, 2.48 mmol) were reacted according to the Sulfonamide Coupling Procedure of Preparation 7 for 18 hours to give the product as a white solid (198 mg, 42%) .
-H NMR (DMSO-d,s) δ 11.58 (br s, NH) , 10.61 (br s, NH) , 10.13 (s, NH) , 8.51 (d, J = 7.41 Hz, NH) , 7.77 (d, J = 8.03 Hz,
ArH2), 7.28 (d, J = 8.06 Hz, ArH2 ) , 6.30 (s, PyrH), 5.99 (br s, NH2), 4.31-4.26 (m, CH) , 3.34-3.27 (m, CH2 ) , 3.01-2.81 (m, CH2CH2), 2.42 (t, J = 7.25 Hz, CH2 ) , 2.09-1.89 (m, CH2 ) , 2.09-1.89 (m, CH2), 1.40 (s, 3CH3), 1.17 (t, J = 7.32 Hz, CH2) ppm.
Step 2 : Synthesis of γ-ethanesulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2,3-d] -pyrimidin-5-yl ) eth-2-yl]benzoyl- - glutamic acid:
Tert -butyl ester from Example 30, Step 1 (175 mg, 0.30 mmol) and trifluoroacetic acid (5 mL) were stirred for 1 hour at RT. The reaction was concentrated in vacuo, and the crude product was purified by column chromatography (5% AcOH/ 5% H20/ CH3CN) to give the product as an off-white solid (81 mg, 51%) .
*H NMR (DMSO-d6) δ 10.60 (s, NH), 10.20 (s, NH) , 8.61-8.55 (m, NH) , 7.77 (d, J = 7.95 Hz, ArH2 ) , 7.26 (d, J = 8.0 Hz, ArH2), 6.29 (s, PyrH), 6.03 (s, NH2 ) , 4.25-4.20 (m, CH) , 3.07-2.81 (m, 3CH2), 2.21 (t, J = 6.90 Hz, CH2 ) , 2.04-1.88 (m, CH2), 1.07 (t, J = 7.35 Hz, CH3 ) ppm; IR (KBr) υmax 3354, 1636, 1540, 1502, 1438, 1410, 1337, 1134 cm"1; UV (MeOH) λmax 223.0 (ε = 22697) nm; MS (FAB) m/z 519 (M+1, 3).
Example 31 Synthesis of γ-n-butylsulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo[2,3-d] -pyrimidin-5-yl)eth-2-yl]benzoyl-L-glutamic acid
Step 1: Synthesis of γ-t-butyl-γ-n-butylsulfonamyl-N-4- [ (2- amino-3H-4-oxo-pyrrolo[2,3-d] -pyrimidin-5-yl)eth-2- yl]benzoyl glutamate:
Carboxylic acid (400 mg, 0.83 mmol) and n- butylsulfonamide (340 mg, 2.48 mmol) were reacted according to the Sulfonamide Coupling Procedure of Preparation 7 for 16 hours to give the product as a white solid (199 mg, 40%) .
*-H NMR (DMSO-de) δ 11.60 (br s, NH) , 10.61 (br s, NH) , 10.13 (br s, NH) , 8.50 (d, J = 7.43 Hz, NH) , 7.77 (d, J = 7.81 Hz, ArH2), 7.28 (d, J -= 7.93 Hz, ArH2 ) , 6.30 (s, PyrH), 5.99 (br s, NH2), 4.32-4.25 (m, CH) , 3.31-3.24 ( , CH2 ) , 2.97-2.79 ( , CH2CH2), 2.45-2.37 (m, CH2 ) , 2.08-1.87 (m, CH2 ) , 1.64- 1.52 (m, CH2), 1.40 (s, 3CH3), 1.37-1.27 (m, CH2), 0.85 (t, J = 7.17 Hz, CH3) ppm; IR (KBr) υmax 3361, 2962, 2934, 1664, 1635, 1533, 1453, 1369, 1338, 1155 cm"1; UV (EtOH) λma x 223 (ε = 25094) nm; MS (FD) m/z 602 (M' , 64).
Step 2 : Synthesis of γ-n-b tylsulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2, 3-d] -pyrimidin-5-yl) eth-2-yl]benzoyl-L- glutamic acid:
Tert-butyl ester from Example 31, Step 1 (161 mg, 0.27 mmol) and trifluoroacetic acid (5 mL) were stirred for 1 hour at RT. The reaction was concentrated in vacuo, and the crude product was sonicated in AcOH/CH3CN, centrifuged and dried to give the product as a green solid (133 mg, 91%) .
*-H NMR (DMSO-dg) δ 11.58 (s, NH) , 10.73 (s, NH) , 10.40 (br s, NH) , 8.46 (d, J = 7.79 Hz, NH) , 7.78 (d, J -- 8.0 Hz, ArH2), 7.28 (d, J = 8.0 Hz, ArH2 ) , 6.34 (s, PyrH), 4.40-4.25 (m, CH) , 3.32 (dd, J = 6.18, 8.99 Hz, CH: ) , 2.99-2.79 (m, CH2CH2), 2.43 (t, J = 7.12 Hz, CH? ) , 2.15-2.06 (m, CHH), 1.95-1.86 (m, CHH), 1.64-1.52 (m, CH: ) , 1.39-1.29 (m, CH2 ) , 0.85 (t, J = 7.27 Hz, CH3 ) ppm; IR (KBr) υmaχ 3360, 2961, 2935, 1636, 1539, 1502, 1450, 1336, 1133 cm*1; UV (MeOH) λmay. 223.0 (ε = 25015) nm; MS (FAB) m/z 547 (M**1, 100).
Example 32
Synthesis of N-{2-Fluoro-4- [ (2-amino-3H-4-oxo-pyrrolo [2 , 3- d]pyrimidin-5-yl) -eth-2-yl] )-benzoyl-L-valine:
The active ester from Preparation 3, Step 4 (50 mg, 0.13 mmol), and L-valine (59 mg, 0.50 mmol) were reacted according to General Procedure 5B for 20 hours to give the product as a tan solid (39 mg, 77%) .
XE NMR (DMSO-drs) δ 11.28 (br s, 2 NH) , 8.23 (dd, J = 7.40,
2.22 Hz, ArH), 7.51 (t, J -- 7.50 Hz, ArH), 7.60-7.00 (br s, NH2), 7.18-7.00 (m, ArH2 ) , 6.49 (s, PyrH), 4.31 (t, J = 6.33 Hz, CH) , 3.05-2.76 (m, CH2CH2 ) , 2.32-2.01 (m, CH) , 0.94 (d, J = 5.39 Hz, 2 CH3) ppm; IR (KBr) υmax 3457, 3244, 1736, 1699, 1674, 1623, 1525, 1202 cm"1; MS (FAB) /z 416 (M+1, 79) .
Example 33
Synthesis of allo-N-4- [ ( 2-amino-3H-4-oxo-pyrrolo [2 , 3 - d] pyrimidin- 5 -yl ) eth- 2-yl ] -benzoyl-L-isoleucine :
The active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol), and L-allo-isoleucine (83 mg, 0.63 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a light blue solid (41 mg, 79%) .
*-H NMR (DMSO-dfj) δ 11.04 (s, NH) , 10.96 (s, NH), 8.19 (d, J = 8.46 Hz, NH) , 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.29 (d, J = 8.09 Hz, ArH2), 6.43 (s, PyrH), 4.54-4.50 (m, CH) , 3.00-2.84 (m, CH2CH2), 2.05-1.93 (m, CH) , 1.49-1.37 (m, CH) , 1.27-1.13 (m, CH) , 0.95 (d, J = 6.62 Hz, CH3 ) , 0.89 (t, J = 7.35 Hz, CH3) ppm; IR (KBr) υmax 3407, 3070, 2967, 1688, 1626, 1596, 1542, 1507, 1335, 1223 cm"1; MS (FAB) m/z 412 (M+1, 45) .
Example 34
Synthesis of 4-isopropylsulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] benzoyl-L-glutamic acid Step 1: Synthesis of γ-t-butyl-γ-4-isopropylsulfonamyl-N-4- [ (2-amino-3H-4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl) eth-2- yl] benzoyl-glutamate :
Carboxylic acid from Preparation 6 (400 mg, 0.83 mmol) and i-propylsulfonamide (306 mg, 2.48 mmol) were reacted according to the Sulfonamide Coupling Procedure of Preparation 7 for 18 hours to give the product as a white solid (233 mg, 48%) .
λE NMR (DMSO-dg) δ 10.60 (s, NH) , 10.13 (s, NH) , 8.56 (d, J = 7.01 Hz, NH) , 7.77 (d, J = 7.99 Hz, ArH2 ) , 7.27 (d, J =
8.02 Hz, ArH2), 6.30 (s, PyrH), 5.99 (br s, NH2 ) , 4.27-4.21 (m, CH) , 3.58-3.50 (m, CH) , 2.99-2.79 ( , CH2CH2 ) , 2.38 (t, J = 7.05 Hz, CH2), 2.07-1.85 (m, CH2 ) , 1.40 (s, 3CH3 ) , 1.21 (d, J = 6.81 Hz, 2CH3) ppm; IR (KBr) υ-nax 3357, 3234, 1663, 1635, 1533, 1501, 1437, 1336, 1233, 1155 cm"1; UV (EtOH) λmaχ 223.25 (ε = 27341) nm; MS (FAB) /z 589 (M+1, 18).
Step 2: Synthesis of 4-isopropylsulfonamyl-N-4- [ (2-amino-3H- 4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl ) eth-2-yl]benzoyl- - glutamic acid:
Tert-butyl ester from Example 34, Step 1 (80 mg, 0.14 mmol) and trifluoroacetic acid (2 mL) were stirred for 1 hour at RT. The reaction was concentrated in vacuo, and the crude product was sonicated in 1:1 CH3CN/Et20, filtered, and dried to give the product as a green solid (63 mg, 87%) .
*-H NMR (DMSO-de) δ 11.50 (s, NH), 11.26 (br s,NH), 8.50 (d, J = 7.73 Hz, NH) , 7.78 (d, J = 8.14 Hz, ArH2 ) , 7.28 (d, J = 8.09 Hz, ArH2), 6.44 (s, PyrH), 4.37-4.30 (m, CH) , 3.60-3.52 (m, CH) , 2.96-2.81 (m, CH2CH2 ) , 2.44 (t, J = 7.33 Hz, CH2 ) , 2.13-2.03 (m, CHH), 1.93-1.83 (m, CHH), 1.23 (d, J = 6.83 Hz, 2CH3) ppm; IR (KBr) υ-nax 3286, 1675, 1612, 1540, 1440, 1326, 1129 cm"1; UV (MeOH) λmax 224.0 (ε = 24160) nm; MS (FAB) m/z 533 (M+1, 37) .
Example 35
Synthesis of α, γ-bis-tetrazole-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] -benzoyl-glutamate
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and DL-glutamic acid, α,γ-bistetrazole (74 mg, 0.38 mmol) were reacted according to General Procedure 5C for 80 hours to give the product as a light green solid (47 mg, 78%) .
--H NMR (DMSO-de) δ 11.20 (br s, 2NH) , 9.06 (d, J = 7.77 Hz, NH) , 7.82 (d, J = 7.84 Hz, ArH2 ) , 7.30 (d, J = 7.92 Hz, ArH2), 6.44 (s, PyrH), 5.48-5.42 (m, CH) , 3.06-2.83 (m, 3CH2), 2.58-2.42 (CH2) ppm; IR (KBr) υmaχ 3162, 2702, 2620, 1671, 1524, 1499 cm"1; UV (EtOH) λmdX 224 (ε = 25153) nm; MS (FAB) m/z 476 (M+1, 4) .
Example 36
Synthesis of β-methyl-N- {2-fluoro-4- [(2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] } -benzoyl-L-glutamic acid
The active ester from Preparation 3, Step 4 (50 mg, 0.13 mmol), and DL-methyl glutamic acid (117 mg, 0.73 mmol) were reacted according to General Procedure 5B for 20 hours to give the product as a blue solid (21 mg, 38%) . Mixture of two diastereomers , 3:2 ratio (isomer 1: isomer 2) .
*-H NMR (DMSO-d6) δ 10.59 (s, NH) , 10.12 (s, NH) , 8.24-8.13 (m, NH) , 7.52-7.44 (m, ArH), 7.07 (d, J = 9.68 Hz, ArH2 ) , 6.29 (s, PyrH), 5.97 (s, NH2), 4.58-4.50 (m, CH isomer 1), 4.46-4.34 (m, CH isomer 2), 3.02-2.78 (m, CH2CH2 ) , 2.42-2.31 (m, CH2), 2.35-2.18 (m, CH2), 0.89 (dd, J = 6.70, 5.97 Hz, CH3) ppm; IR (KBr) υmaχ 3340, 3225, 2965, 2935, 1646, 1625, 1529, 1495, 1422, 1230 cm"1; MS (FAB) m/z 460 (M+1, 55).
Example 37
Synthesis of α-phenyl-N- {2-fluoro-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2-yl] } -benzoyl-glycine
The active ester from Preparation 3, Step 4 (75 mg, 0.18 mmol), and s-phenyl glycine (110 mg, 0.73 mmol) were reacted according to General Procedure 5B for 20 hours to give the product as a tan solid (69 mg, 85%) .
*-H NMR (DMSO-dg) δ 13.00 (br s, C02H), 10.59 (s, NH) , 10.12 (s, NH) , 8.73 (dd, J = 4.70, 0.96 Hz, NH) , 7.53-7.26 (m,
ArH6), 7.15-7.00 (m, ArH2 ) , 6.28 (s, PyrH), 5.98 (s, NH2) , 5.49 (d, J = 7.15 Hz, CH) , 2.98-2.70 ( , CH2CH2 ) ppm; IR (KBr) υmax 3377, 3213, 2926, 1623, 1521, 1491, 1453, 1421, 1372, 1229 cm-1; MS (FAB) m/z 450 (M+1, 80) .
Example 38
Synthesis of γ- ( -toluenesulfonamyl) -N-4- [ (2-amino-3H-4-oxo- pyrrolo[2, 3-d]pyrimidin-5-yl]eth-2-yl] -benzoyl-L-glutamic acid: Step 1: Synthesis of α-t-butyl-γ- (α-toluenesulfonamyl) -N-4- [ (2-amino-3H-4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl] eth-2-yl] - benzoyl glutamate :
Carboxylic acid from Preparation 6 (400 mg, 0.83 mmol) and α-toluenesulfonamide (425 mg, 2.48 mmol) were reacted according to the Sulfonamide Coupling Procedure of Preparation 7 for 20 hours to give the product as a white solid (236 mg, 45%) .
*-H NMR (DMSO-dg) δ 11.56 (br s, NH) , 10.61 (br s, NH) , 10.14 (s, NH) , 8.53 (d, J = 7.60 Hz, NH) , 7.78 (d, J = 8.0 Hz, ArH2), 7.37-7.29 (m, ArH7 ) , 6.30 (s, PyrH), 3.99 (br s, NH2), 4.65 (s, CH2), 4.39-4.30 (m, CH) , 3.02-2.84 ( , CH2CH2), 2.37 (t, J = 7.2 Hz, CH2 ) . 2.18-1.90 (m, CH2 ) , 1.41 (s, 3CH ) ppm.
Step 2 : Synthesis of γ- (α-toluenesulfonamyl) -N-4- [ (2-amino- 3H-4-oxo-pyrrolo[2,3-d]pyrimidin-5-yl]eth-2-yl]benzoyl-L- glutamic acid:
Tert-butyl ester from Example 38, Step 1 (211 mg, 0.33 mmol) and trifluoroacetic acid (5 mL) were stirred for 1 hour at RT. The reaction was concentrated in vacuo, and the crude product was sonicated in AcOH/CH3CN, centrifuged and dried to give the product as a light blue solid (207 mg) . A small sample (50 mg) was further purified by reverse-phase prep HPLC (H0) to give product as a white solid (14 mg, 28%) .
*-H NMR (DMSO-dg) δ 11.53 (s, NH) , 10.81 (s, NH) , 10.59 (br s, NH), 8.52 (d, J = 7.81 Hz, NH) , 7.79 (d, J = 8.06 Hz, ArH2), 7.37-7.27 (m, ArH7), 6.36 (s, PyrH), 4.66 (s, CH2 ) . 4.44-4.37 ( , CH) , 3.03-2.81 ( , CH2CH2 ) , 2.38 (t, J = 7.23 Hz, CH2), 2.24-1.91 (m, CH2 ) ppm; IR (KBr) υ„,aχ 3362, 1636, 1539, 1499, 1456, 1339, 1131 cm *•; MS (FAB) m/z 581 (M+1, 35) .
Example 39
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3-d]pyrimidin- 5-yl)eth-2-yl] -benzoyl-2-amino-L-adipic acid
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and 2-amino-L-adipic acid (61 mg, 0.38 mmol) were reacted according to General Procedure 5A for 18 hours to give the product as a light gray solid (32 mg, 57%) .
*-H NMR (DMSO-dg) δ 10.90 (s, NH), 10.73 (br s, NH) , 8.50 (d, J = 7.72 Hz, NH) , 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.28 (d, J = 8.46 Hz, ArH ), 6.39 (s, PyrH), 4.40-4.31 (m, CH) , 3.00-2.82 (m, CH2CH2), 2.24 (t, J = 7.35 Hz, CH; ) , 1.88-1.72 (m, CH2 ) , 1.66-1.54 ( , CH2 ) ppm; IR (KBr) υmaχ 3388, 1686, 1548, 1508, 1342, 1212, 1082 cm*-1; UV (MeOH) λmax 203 (ε = 34599), 224.5 (ε = 23321) nm; MS (FAB) m/z 442 (M+:, 15).
Example 40
Synthesis of γ-4-benzenesulfonamyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo[2, 3-d]pyrimidin-5-yl)eth-2-yl]benzoyl-L-glutamic acid:
Step 1: Synthesis of α-t-butyl-γ-4-benzenesulfonamyl-N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2- yl] benzoyl-glutamate :
Carboxylic acid from Preparation 6 (400 mg, 0.83 mmol) and benzenesulfonamide (390 mg, 2.48 mmol) were reacted according to the Sulfonamide Coupling Procedure of Preparation 7 for 20 hours to give the product as a white solid (200 mg, 39%) .
*-H NMR (DMSO-dg) δ 10.61 (s, NH) , 10.14 (s, NH) , 8.48 (d, J = 7.25 Hz, NH) , 7.88 (d, J = 7.44 Hz, ArH2 ) , 7.74 (d, J = 7.99 Hz, ArH2), 7.69-7.56 (m, ArH3 ) , 7.26 (d, J = 8.01 Hz, ArH2), 6.30 (s, PyrH), 5.99 (br s, NH; ) , 4.25-4.15 ( , CH) , 3.01-2.82 (m, CH2CH2), 2.35 (t, J = 7.26 Hz, CH2 ) , 1.96-1.81 (m, CH2), 1.36 (s, 3CH3 ) ppm.
Step 2 : Synthesis of γ-4-benzenesulfonamyl-N-4- [ (2-amino-3H- 4-oxo-pyrrolo [2,3-d]pyrimidin-5-yl) eth-2-yl] benzoyl-L- glutamic acid:
Tert-butyl ester from Example 40, Step 1 (175 mg, 0.28 mmol) and trifluoroacetic acid (4 mL) were stirred for 1 hour at RT. The reaction was concentrated in vacuo, and the crude product was purified by column chromatography (5% H20/ 5% AcOH/ CH3CN) to give the product as a light green solid (70 mg, 44%) .
--H NMR (DMSO-dg) δ 10.61 (s, NH) , 10.16 (s, NH) , 8.61 (d, J = 6.86 Hz, NH) , 7.84 (d, J = 7.34 Hz, ArH2 ) , 7.75 (d, J = 8.0 Hz, ArH2) , 7.58-7.48 (m, ArH3 ) , 7.26 (d, J = 8.07 Hz, ArH2), 6.30 (s, PyrH) , 6.01 (br s, NH2 ) , 4.29-4.19 (m, CH) , 3.00-2.82 ( , CH2CH2), 2.28 (t, J = 6.9 Hz, CH2 ) , 1.99-1.82 ( , CH2) ppm; IR (KBr) υmaχ 3365, 3231, 1635, 1534, 1501,
1448, 1339, 1087 cm"1; UV (MeOH) λmax 222.25 (ε = 35461) nm; MS (FAB) m/z 567 (M+1, 51) .
Example 41
Synthesis of β-methyl-N-4- [ (2 -amino- 3H- -oxo-pyrrolo [2, 3- d]pyrimidinyl-5-yl) -eth-2-yl] -benzoyl-L-glutamic acid
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and DL-β-methylglutamic acid (61 mg, 0.38 mmol) were reacted according to General Procedure 5C for 18 hours to give the product as a gray solid (40 mg, 71%) .
λE NMR (DMSO-de) δ 11.25 (br s, 2NH) , 8.40 (d, J = 7.99 Hz, 0.5 NH) , 8.31 (d, J = 8.33 Hz, 0.5NH), 7.78 (d, J = 8.06 Hz, ArH2), 7.27 (d, J = 8.13 Hz, ArH2), 6.45 (s, PyrH), 4.58- 4.51 (m, 0.5 CH) , 4.40-4.32 (m, 0.5 CH) , 2.95-2.83 (m,
CH2CH2) , 2.52-2.33 (m, CH2) , 2.26-2.03 (m, CH) , 0.96 (d, J = 6.71 Hz, CH3) ppm; IR (KBr) υraax 3155, 1685, 1539, 1507, 1328 , 1219 , 1131 , 1082 cm"- 1 ; UV ( EtOH ) λma 202 . 5 (ε = 37800 ) , 224 . 5 (ε = 24099 ) nm; MS ( FAB ) m/z 442 (M+ 1 , 14 ) .
Example 42
Synthesis of γ-2-carboxyphenylsulfonamyl-N-4- [ (2-amino-3H-4- oxo-pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2-yl] benzoyl-L-glutamic acid
Carboxylic acid (500 mg, 1.03 mmol) and methyl 2- (aminosulfonyl) benzoate (668 mg, 3.10 mmol) were reacted according to Sulfonamide Coupling Procedure for 18 hours to give the methyl benzoate ester/pivaloate ester of the above- depicted compound as a white solid (363 mg, 51%) .
*-H NMR (DMSO-de) δ 12.13 (br s, NH) , 10.61 (br s, NH) , 10.14 (br s, NH), 8.48-8.42 (m, NH) , 8.07 (d, J = 7.88 Hz, ArH), 7.76-7.61 (m, ArH5 ) , 7.27 (d, J = 7.87 Hz, ArH2 ) , 6.30 (s, PyrH), 5.99 (br s, NH2 ) , 4.22-4.13 (m, CH) , 3.82 (s, CH3 ) , 2.99-2.78 ( , CH2CH2 ) , 2.43-2.35 (m, CH2 ) , 1.99-1.74 ( , CH2), 1.37 (s, 3CH3) ppm; IR (KBr) υmax 3359, 1731, 1662, 1636, 1533, 1436, 1348, 1297, 1152, 1059 cm"1; UV (MeOH) λma:. 222 (ε = 31266) n ; MS (FD) m/z 681 (M+1, 100);
The resulting diester (50 mg, 0.08 mmol) and NaOH (2.5 N, 0.2 mL) in dimethylsulfoxide (1 mL) were stirred at RT for 45 minutes. The reaction was diluted with H2θ, acidified with IN HCl (pH 2-3) and the solid was filtered and dried to give the depicted product as a tan solid (29 mg, 59%) .
:H NMR (DMSO-dfs) δ 10.61 (s, NH) , 10.15 (s, NH) , 8.47 (d, J = 7.66 Hz, NH) , 8.05 (d, J = 6.97 Hz, ArH) , 7.80-7.64 ( , ArH5) , 7.28 (d, J = 8.14 Hz, ArH2 ) , 6.31 (s, PyrH) , 6.01 (br s, NH2) , 4.34-4.28 (m, CH) , 3.01-2.82 (m, CH2CH2 ) , 2.40 (t, J = 7.0 Hz, CH2) , 2.05-1.83 ( , CH2 ) ppm; IR (KBr) υmaχ 3354, 1691, 1642, 1536, 1441, 1343 cm-1; UV (EtOH) λraaχ 223.0 (ε = 34935) nm; MS (FAB) m/z 611 (M+1, 8) .
Example 43
Synthesis of N- (3-nitrobenzyl) -4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2-yl]benzamide
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and 3- (aminomethyl ) nitrobenzene (57 mg, 0.38 mmol) were reacted according to General Procedure 5A (except no N, O-bis (trimethylsilyl) acetamide was used) for 16 hours to give the product as an off white solid (57 mg) .
*H NMR (DMSO-d6) δ 11.15-11.08 ( , 2NH) , 9.16-9.09 (m, NH) , 8.16 (s, ArH), 8.10 (d, J = 8.05 Hz, ArH), 7.80-7.73 (m, ArH3), 7.62 (t, J = 7.86 Hz, ArH), 7.29 (d, J = 8.07 Hz, ArH2), 6.44 (s, PyrH), 4.57 (d, J = 5.57 Hz, CH2 ) , 2.96-2.81 (m, CH2CH2) ppm; IR (KBr) υraaχ 3123, 1696, 1670, 1634, 1535, 1503, 1346 cm"1; UV (EtOH) λmaχ 221 (ε = 28924), 247 (ε = 23124) n ; MS (FAB) m/z 433 (M+1, 14). Example 44
Synthesis of N-α-4- [ (2 -amino- 3H- 4 -oxo-pyrrolo [2, 3- d] pyrimidin-5 -yl) eth-2 -yl] benzoyl -N-δ-phthalimido-L- omithine
Active ester from Preparation 4, Step 4 (50 mg,
0.13 mmol) and N-δ-phthalimido-L-ornithine hydrochloride (113 mg, 0.38 mmol) were reacted according to General Procedure 5C for 16 hours to give the product as a yellow solid (54 mg, 78%) .
*-H NMR (DMSO-d6) δ 11.02 (br s, NH) , 10.92 (br s, NH) , 8.48 (d, J = 7.7 Hz, NH) , 7.88-7.77 (m, ArH5 ) , 7.74 (d, J = 8.05 Hz, ArH2) , 7.25 (d, J = 8.03 Hz, ArH2 ) , 6.40 (s, PyrH) , 4.40-4.29 (m, CH) , 3.62-3.55 ( , CH2 ) , 2.97-2.80 (m, CH2CH2) . 1.84-1.63 (m, 2CH2) ppm; IR (KBr) Uma 1707, 1687, 1632, 1612, 1540, 1505, 1400 cm"1; UV (EtOH) λmax 220 (ε = 31873) nm; MS (FAB) m/z 543 (M+1, 42) .
Example 45
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3-d]pyrimidin- 5-yl)eth-2-yl] -benzoyl-3-carboxyphenylςrlyeine-
Step 1 : Synthesis of dimethyl-N-4- [ (2-amino-3H-4-oxo- pyrrolo [2, 3-d]pyrimidin-5-yl)eth-2-yl] -benzoyl-3- carboxyphenylglycinate :
Active ester from Preparation 4, Step 4 (100 mg,
0.25 mmol) and dimethyl DL-3-carboxyphenylglycinate (113 mg, 0.51 mmol) in dimethylformamide (2 mL) were stirred for 18 hours at 50°C. The reaction was concentrated and purified by flash chromatography (10% MeOH/CH2Cl2) to give the product as a white solid (108 mg, 85%) .
[XH NMR (DMSO-de) δ 10.60 (s, NH) , 10.12 (s, NH) , 9.22 (d, J = 7.23 Hz, NH) , 8.07 (s, ArH), 7.92 (d, J = 7.65 Hz, ArH), 7.80 (d, J = 8.12 Hz, ArH2 ) , 7.74 (d, J = 7.64 Hz, ArH), 7.54 (t, J = 7.76 Hz, ArH), 7.27 (d, J = 8.11 Hz, ArH2 ) , 6.29 (s, PyrH), 5.98 (br s, NH2 ) , 5.77 (d, J = 7.13 Hz, CH) , 3.85 (s, CH3), 3.65 (s, CH3), 2.96-2.80 (m, CH2CH2) ppm]
Step 2 ; Synthesis of N-4- [ ( 2 -amino -3H- 4 -oxo -pyrrolo [2 , 3- d] pyrimidin-5 -yl ) eth-2 -yl ] -benzoyl - 3 -carboxyphenylglycine :
Dimethyl ester from Example 45, Step 1 (105 mg, 0.21 mmol) was reacted with IN aqueous NaOH (0.62 mL, 0.62 mmol) in dioxane (3 mL) and H20 (1 mL) at RT for 3 hours The reaction was concentrated and the crude product was sonicated with IN aqueous HCl and the resulting solid was filtered, washed with H20, Et 0 and dried to give the product as a light yellow solid (89 mg, 90%) .
*-H NMR (DMS0-d6) δ 10.92 (br s, NH) , 10.75 (br s, NH) , 9.06 (d, J - 7.47 Hz, NH) , 8.05 (s, ArH), 7.88 (d, J = 7.65 Hz, ArH), 7.80 (d, J = 8.04 Hz, ArH), 7.71 (d, J = 7.53 Hz, ArH2), 7.49 (t, J = 7.7 Hz, ArH), 7.26 (d, J = 8.14 Hz, ArH2), 6.37 (s, PyrH), 5.66 (d, J = 7.43 Hz, CH) , 2.96-2.78 (m, CH2CH2) ppm; IR (KBr) Umax 3324, 1688, 1530, 1498, 1380, 1231, 1188, 1078, 1020 cm**1; UV (EtOH) λmax 203 (ε = 61583), 225.5 (ε = 34282) nm; MS (FAB) m/z 476 (M+i, 20).
Example 46
Synthesis of N-4- [ ( 2 -amino-3H-4 -oxo-pyrrolo [2 , 3-d]pyrimidin- 5-yl ) eth-2 -yl] -benzoylpheny lglycine
The active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol), and L-phenyl glycine (96 mg, 0.63 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as an off white solid (43 mg, 78%) .
--H NMR (DMSO-d6) δ 11.05 (s, NH) , 10.96 (s, NH) , 8.95 (d, J = 7.45 Hz, NH) , 7.84 (d, J = 8.12 Hz, ArH2 ) , 7.50 (d, J = 6.77 Hz, ArH2), 7.44-7.21 (m, ArH5 ) , 7.21-6.63 (Br s, NH2 ) , 6.42 (s, PyrH), 5.60 (d, J - 7.48 Hz, CH) , 3.12-2.87 (m, CH2CH2) ppm; IR (KBr) υmaχ 3142, 1682, 1528, 1495, 1377, 1074 cm-1; MS (FAB) m/z 432 (M+1, 67). Example 47
Synthesis of N-4 - [ ( 2 -amino-3H-4-oxo-pyrrolo [2 , 3-d] pyrimidin- 5-yl ] benzoyl -L-isoleucine
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-isoleucine (50 mg, 0.38 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a pale green solid (50 mg, 96%) .
*-H NMR (DMSO-dg) δ 10.89 (br s, NH) , 10.70 (br s, NH) , 8.31 (d, J = 8.09 Hz, NH) , 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.28 (d, J = 8.09 Hz, ArH2), 6.39 (s, PyrH), 4.34-4.29 (m, CH) , 3.01- 2.81 ( , CH2CH2), 1.99-1.89 (m, CH), 1.58-1.45 (m, CHH), 1.36-1.22 (m, CHH), 0.93 (d, J = 6.99 Hz, CH3 ) , 0.87 (t, J = 7.35 Hz, CH3) ppm; IR (KBr) υmaχ 3222, 2966, 1687, 1534, 1503, 1382, 1225, 1079 cm-1; UV (MeOH) λmax 202.5 (ε =
36302), 225 (ε = 23707) nm; MS (FAB) m/z 412 (M+1, 100).
Example 48
Synthesis of N-{2- [ (2-methyl-3H-4-oxo-pyrrolo[2,3- d]pyrimidin-5-yl ) eth-2-yl] thiophen-5-yl } -carbonyl-L-glutamic acid
A mixture of active ester from Preparation 2, Step 3 (33 mg, 0.082 mmol) and L-glutamic acid di-t-butyl ester (127 mg, 0.49 mmol) in DMF (1 mL) was reacted according to General Procedure 5A (except no N,0- bis (trimethylsilyl) acetamide was used) for 18 hours The solvent was removed in vacuo and the crude product was dissolved in a mixture of THF (6 mL) and IN HCl (2 mL) then refluxed for 2 hours Added 5 N HCl (2 L) and refluxed an additional 3 hours, then stirred at RT overnight. The solvent was removed in vacuo and the crude product was sonicated with H20, filtered, washed with H20 and dried to give the desired product as a dark yellow solid (12 mg, 34%) .
*-H NMR (DMSO-de) δ 11.61 (br s, NH) , 11.31 (br s, NH) , 8.47 (d, J = 8.12 Hz, NH) , 7.65 (d, J = 3.67 Hz, ArH), 6.84 (d, J
= 3.27 Hz, ArH), 6.69 (s, PyrH), 4.37-4.28 (m, CH) , 3.26- 3.14 (m, CH2), 3.02-2.93 (m, CH? ) , 2.37-2.26 ( , CH2 ) , 2.28 (s, CH3), 2.13-2.01 (m, CHH), 1.99-1.85 (m, CHH) ppm; IR (KBr) υ-na 3323, 2929, 2855, 1682, 1544, 1518, 1453, 1234,
1080, 815 cm-1; MS (FAB) m/z 433 (M+i, 15).
Example 49
Synthesis of α-bβnzoyl-N-4- [ (2-amino-3H-4-oxo-pyrrolo[2,3- d]pyrimidin-5-yl)eth-2-yl]benzoylglutamate
The active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol), and L-glutamic acid-α-benzylester (120 mg, 0.51 mmol! were reacted according to General Procedure 5A for 16 hours to give the product as a white solid (59 mg, 90%) .
--H NMR (DMSO-dg) δ 10.89 (s, NH) , 10.70 (s, NH) , 8.70 (d, J = 7.72 Hz, NH) , 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.36 (s,ArH5) , 7.30 (d, J = 8.09 Hz, ArH2), 6.39 (s, PyrH) , 5.15 (s, OCH2 ) , 4.53-4.46 (m, CH) , 3.01-2.84 ( , CH2CH2) , 2.37 (t, J = 7.17 Hz, CH2) . 2.14-1.95 (m, CH2 ) ppm; IR (KBr) υmaχ 3234, 2756, 1701, 1669, 1537, 1500, 1358, 1224, 1077 cm"1; MS (FAB) m/z 518 (M***1, 90) .
Example 50
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl)eth-2-yl]benzoyl-L-gluta_nic acid γ-benzyl ester
The active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol), and L-glutamic acid -γ- benzyl ester (120 mg, 0.51 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a white solid (65 mg, 99%) .
*-H NMR (DMSO-d6) δ 10.89 (s, NH) , 10.69 (s, NH), 8.55 (d, J = 7.35 Hz, NH), 7.79 (d, J = 8.09 Hz, ArH2 ) , 7.35 (s, ArHς) , 7.29 (d, J = 8.09 Hz, ArH2 ) , 6.39 (s, PyrH, 1H) , 5.09 (s, OCH2) , 4.45-4.38 (m, CH) , 3.00-2.84 (m, CH2CH ) , 2.22-1.94 (m, CH) ppm; IR (KBr) \>max 3412, 3288, 3126, 2932, 2625, 1727, 1695, 1671 cm"1; MS (FAB) m/z 518 (M+1, 80) .
Example 51
Synthesis of α-L-valine-N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl ) eth-2-yl] benzoyl-L-glutamate
C02H
The active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol), and L-glu-α-L-val (100 mg, 0.41 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a tan solid (64 mg, 96%) .
2H NMR (DMSO-de) δ 10.88 (s, NH) , 10.69 (s, NH) , 8.39 (d, J = 7.72 Hz, NH) , 7.98 (d, J = 8.09 Hz, NH) , 7.79 (d, J = 8.09 Hz, ArH2), 7.29 (d, J = 7.72 Hz, ArH2 ) , 6.39 (s, PyrH), 4.56-4.49 (m, CH) , 4.17-4.12 (m, CH) , 2.99-2.84 (m, CH2CH2 ) , 2.34 (t, J = 7.54 Hz, CH) , 2.10-1.91 (m, CH2) , 0.89 (dd, J = 2.57, 2.57 Hz, 2 CH3 ) ppm; IR (KBr) υmax 3236, 2747, 1723, 1700, 1667, 1540, 1373, 1224 crrr1; MS (FAB) m/z 527 (M+1, 60) .
Example 52
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo [2 , 3-d]pyrimidin- 5-yl ) eth-2 -yl] benzoyl -4 -chlorophenylalanine
The active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol), and DL-4-chlorophenylalanιne (101 mg, 0.51 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a tan solid (38 mg, 63%) .
*H NMR (DMSO-dg) δ 10.89 (s, NH) , 10.70 (s, NH) , 8.64 (d, J = 8.46 Hz, NH) , 7.71 (d, J = 8.46 Hz, ArH.-.), 7.33 (s, ArH4 ) , 7.27 (d, J = 8.09 Hz, ArH2 ) , 6.64 (br s, NH2 ) , 6.39 (s, PyrH), 4.64-4.55 (m, CH) , 3.21-3.01 (m, CH2 ) , 2.98-2.83 (m, CH2CH2) ppm; IR (KBr) υmax 3162, 2928, 1671, 1534, 1493, 1439, 1227, 1091, 1015 cm"1; MS (FAB) m/z 480 (M+1, 85).
Example 53
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin- 5-yl) eth-2-yl]benzoyl-trans-4-(aminomethyl )cyclohexane- carboxylic acid
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and trans-4- (aminomethyl ) cyclohexane-carboxylic acid (60 mg, 0.38 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a dark red solid (53 mg, 96%) .
*-H NMR (DMSO-d6) 5 11.02 (s, NH) , 10.90 (br s, NH) , 8.38- 8.31 (m, NH) , 7.75 (d, J = 8.09 Hz, ArH2 ) , 7.27 (d, J = 8.46 Hz, ArH2), 6.42 (s, PyrH), 3.13-3.05 (m, CH2 ) , 2.99-2.82 (m, CH2CH2), 2.19-2.06 (m, CH) , 1.95-1.85 ( , CH2 ) , 1.84-1.71 (m, CH2), 1.57-1.42 ( , CH) , 1.33-1.16 ( , CH2 ) , 1.03-0.87 (m, CH2) ppm; IR (KBr) Omax 3128, 2924, 1672, 1628, 1533, 1503, 1423, 1310, 1133, 1079 cm1,- UV (EtOH) λmax 225 (ε = 7767) nm; MS (FAB) m/z 438 (M**1, 10).
Example 54
Synthesis of N-{2- [ (2-methyl-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl ) eth-2-yl] thiophen-5-yl}carbonyl-L-melphalan
The active ester from Preparation 2, Step 3 (50 mg, 0.124 mmol), and L-melphalan (116 mg, 0.499 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a white solid (70 mg, 97%) .
*H NMR (DMSO-ds) δ 10.68 (br s, NH) , 10.25 (br s, NH) , 8.54 (s, NH) , 7.63 (d, ArH), 7.18 (d, ArH2 ) , 6.75 (d, ArH), 6.62 (d, ArH2), 6.43 (s, PyrH), 6.04 (br s, NH2 ) , 4.51-4.37 ( , CH) , 3.68-2.75 (m, 7 CH2 ) ppm; IR (KBr) υmaχ 3341, 2928, 1617, 1545, 1520, 1443, 1391, 1351, 1181, 1078, 813 cm"1; MS (FAB) m/z 591 (M-1, 85) .
Example 55
Synthesis of N-4- [ (2-amino-3H-4-oxo-pyrrolo [2 , 3-d]pyrimidin- 5-yl ) eth-2 -yl]benzoyl-L-isoglutamate
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-isoglutamine (55 mg, 0.38 mmol) were reacted according to General Procedure 5C for 24 hours to give the product as a green solid (52 mg, 96%) .
--H NMR (DMSO-dg) δ 10.66 (s, NH) , 10.30 (s, NH) , 8.29 (d, J = 7.85 Hz, NH), 7.79 (d, J = 7.92 Hz, ArH2 ) , 7.39 (s, NHH), 7.26 (d, J = 7.88 Hz, ArH2 ) , 7.04 (s, NHH), 6.30 (s, PyrH), 6.19 (br s, NH2), 4.35-4.25 ( , CH) , 2.98-2.78 (m, CH2CH2), 2.28 (t, J = 7.44 Hz, CH2 ) , 2.04-1.84 (m, CH2 ) ppm; IR (KBr) Umax 3379, 2929, 1674, 1532, 1503, 1075 cm"-1; UV (EtOH) λmaχ 224.5 (ε = 4690), 241.5 (ε = 3636) nm; MS (FAB) m/z 427 (M+1, 8) .
Example 56
Synthesis of α-amino-N-4- [ (2-amino-3H-4-oxo-pyrrolo [2, 3- d]pyrimidin-5-yl)eth-2-yl]benzoyl-cyclohexanepropionic acid
The active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol), and (s ) - ( - ) -α-aminocyclohexane propionic acid (87 mg, 0.51 mmol) were reacted according to General Procedure 5A for 16 hours to give the product as a light blue solid (34 mg, 60%) .
*-H NMR (DMSO-d6) δ 10.95 (s, NH) , 10.79 (s, NH) , 8.49 (d, J = 7.72 Hz, NH) , 7.80 (d, J = 8.09 Hz, ArH2 ) , 7.29 (d, J = 8.09 Hz, ArH2), 6.75 (br s, NH2), 6.40 (s, PyrH), 4.49-4.41 (m, CH) , 2.99-2.85 (m, CH2CH2), 1.78-1.57 ( , 3CH2,CH), 1.45-1.31 (m, CH) , 1.25-1.05 (m, CH2,CH), 1.04-0.80 (m, CH2 ) ppm; IR (KBr) υmaχ 3228, 2924, 2852, 1686, 1539, 1503, 1449, 1223, 1078 cm"1; MS (FAB) m/z 452 (M+1, 88).
Example 57
Synthesis of 4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d]pyrimidin-5* yl)eth-2-yl]-benzoyl-I_-leucine
Active ester from Preparation 4, Step 4 (50 mg, 0.13 mmol) and L-leucine (50 mg, 0.38 mmol) were reacted according to General Procedure 5A for 18 hours to give the product as a very light green solid (39.5 mg, 76%) .
XH NMR (DMSO-d,j) δ 10.97 (s, NH) , 10.83 (br s, NH) , 8.48 (d, J = 7.72 Hz, NH) , 7.79 (d, J = 8.46 Hz, ArH2 ) , 7.28 (d, J = 8.09 Hz, ArH2) , 6.40 (s, PyrH), 4.48-4.39 (m, CH) , 3.00-2.92 (m, CH2) , 2.92-2.82 ( , CH2 ) , 1.83-1.52 (m, CH, CH2 ) , 0.92 (d, J = 6.25 Hz, CH3) , 0.88 (d, J = 6.25 Hz, CH3) ppm; IR (KBr) υmax 3180, 2958, 1687, 1538, 1504, 1438, 1226, 1079 cm"1; UV (MeOH) λmax 202.5 (ε = 35563) , 224.5 (ε = 23046) nm; MS (FAB) m/z 412 (M+1, 40) .
Example 58
Synthesis of 4- [ (2-amino-3H-4-oxo-pyrrolo[2,3-d]pyrimidin-5- yl ) eth-2 -yl ] -benzoyl -L-tryptophan
Active ester from Preparation 4, Step 4 (50 mg,
0.13 mmol) and L-tryptophan (77 mg, 0.38 mmol) were reacted according to General Procedure 5A for 18 hours to give the product as a light brown solid (48 mg, 79%) .
XE NMR (DMSO-dg) δ 10.80 (s, NH) , 10.71 (s, NH) , 10.37 (br s, NH) , 8.52 (d, J = 7.72 Hz, NH) , 7.72 (d, J = 8.09 Hz, ArH2) , 7.59 (d, J = 7.72 Hz, ArH) , 7.32 (d, J = 7.72 Hz, ArH) , 7.25 (d, J = 8.46 Hz, ArH2 ) , 7.20 (s, PyrH) , 7.09-6.96 (m, ArH2) , 6.33 (s, PyrH), 4.68-4.60 (m, CH) , 3.33-3.14 (m, CH2) , 2.98-2.91 (m, CH2 ) , 2.89-2.81 (m, CH2 ) ppm; IR (KBr) Umax 3321, 2929, 1684, 1645, 1535, 1500, 1436, 1341, 1232 cm-1; UV (MeOH) λmax 202.5 (ε = 52411) , 222 (ε = 52188) nm; MS (FAB) /z 485 (M+1, 15) .
BIOLOGICAL TEST DATA
Example # IC5£_ (uσ/mL. GC3* I Ki hTS (nM**)
1 >20 >500
2 >20 264
3 >20 >500
4 >20 >500
5 >20 >500
6 >20 >500
7 >20 >500
8 >20 >500
9 >20 >500
10 >20 >500
11 >20 46
12 >20 >500
13 >20 >500
14 12.5 >500
15 >20 8
16 >20 25
17 1.00 29
18 2.96 30
19 >20 40
20 19.2 41 21 >20 45
22 >20 46
23 >20 48
24 3.42 48
25 >20 48
26 1.90 49
27 1.50 51
28 >20 52
29 >20 53
30 2.49 55
31 NT 61
32 >20 61
33 >20 63
34 10.51 65
35 >20 68
36 3.50 69
37 6.90 73 38 NT 75
39 15.70 76
40 >20 80
41 1.00 81
42 12.66 89
43 NT 91
44 >20 102
45 >20 107
46 >20 109
47 >20 118
48 0.24 455
49 0.20 455
50 0.30 145
51 1.30 455
52 2.70 455
53 0.80 455
54 4.00 455
55 4.70 455
56 >20 454 57 >20 401
58 >20 454
*Cell Cytotoxicity for Human colon carcinoma GC3 cell lines as determined by using a MTT Colorimetric Assay. The IC50 was determined as the concentration of drug required to inhibit cell growth by 50%. See "Role of Membrane- Associated Folate Binding Protein in the Cytotoxicity of Antifolates in KB, IGROVl, and L1210A Cells", Schultz, et al., Oncology Research, Vol. 7, No. 2, pp 97-102, 1995, for test protocol .
**Ki is the inhibition constant for human thymidylate synthase in nanomolar(s) (nM) . Test procedure for the determination of inhibition constants for thymidylate synthase as follows : Recombinant human thymidylate synthase (HTS) expressed in E. Coli, was obtained in purified form from Dr. Daniel Santi at the University of California at San Francisco, [6R]-5,10 methylenetetrahydrofolate was obtained from Eprova AG, Switzerland. The ENZFITTER microcomputer package was purchased from Biosoft, Ferguson, MO. All additional chemicals were obtained from Sigma Chemical Company, St. Louis, MO.
The initial reaction rates, in the presence and absence of inhibitor, were determined by monitoring the increase in absorbance at 340nm resulting from formation of the product, 7, 8-dihydrofolate, using a Beckman™ DU640 spectrophotometer . Assays were performed in 50 mM TES, 25 mM MgCl2, 6.5 mM HCHO, 1 mM EDTA, 75 mM 2-mercaptoethanol , pH 7.4. All compounds were dissolved in DMSO to 10 mM and subsequently diluted into the assay buffer. The final DMSO concentration never exceeded 0.5% and vehicle controls confirmed that there was no effect of DMSO at this concentration. The concentrations of dUMP, [6R]-5,10 methylenetetrahydrofolate and HTS were 100 μM, 30 μM, and 30 nM respectively. An initial screen of each compound was run at 100 nM, 1 μM and 5 μM to determine inhibitory activity. If an IC50 of < lμM was obtained for any compound, inhibition was assessed over a wide range of concentrations and Kiapp values were determined by a nonlinear fit of the data to the Morrison equation using the program ENZFITTER. Ki values were derived using the equation: Kiapp = id + [S]/Km), where [S] is equal to 30 μM and Km is equal to 8 μM. The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way. "Active ingredient" means a compound of Formula III or a pharmaceutically acceptable salt or solvate thereof.
Formulation 1
Hard gelatin capsules are prepared using the following ingredients:
Quantity (mα/capsule)
Active ingredient 250
Starch, dried 200 Magnesium stearate JL0.
Total 460 mg
Formulation 2
A tablet is prepared using the ingredients below: Quantity
(mσ/caosule)
Active ingredient 250 Cellulose, micro crystalline 400 Silicon dioxide, fumed 10 Stearic acid _5 Total 665 mg
The components are blended and compressed to form tablets each weighing 665 mg .
Formulation 3
Tablets, each containing 60 g of active ingredient, are made as follows:
Quantity (mα/tablet)
Active ingredient 60
Starch 45
Micro crystalline cellulose 35 Polyvinylpyrrolidone
(as 10% solution in water) 4
Sodium carboxymethyl starch 4.5
Magnesium stearate 0.5
Talc 1
Total 150
The active ingredient, starch and cellulose are passed through a No . 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No . 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation 4
Capsules, each containing 80 mg of active ingredient, are made as follows:
Quantity (mo/capsule) Active ingredient 80
Starch 59
Micro crystalline cellulose 59
Magnesium stearate 2.
Total 200
The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No . 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
Formulation 5
Suppositories, each containing 225 mg of active ingredient, are made as follows:
Quantity (mα/unit )
Active ingredient 225
Saturated fatty acid glycerides 2 , 000
Total 2,225
The active ingredient is passed through a No . 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of normal 2 g capacity and allowed to cool.
Formulation 6
Suspensions, each containing 50 mg of active ingredient per 5 mL dose, are made as follows:
Quantity (mσ/unit) Active ingredient (s) 50 mg
Sodium carboxymethyl 50 mg cellulose
Syrup 1.25 mL
Benzoic acid solution 0.10 mL
Flavor q.v.
Color q.v.
Purified water to total 5 mL
Formulation 7
An intravenous formulation may be prepared as follows :
Quantity Active ingredient 100 mg
Isotonic saline 1,000 mL

Claims

We Claim :
1. A compound of formula (III) :
where
W and G are independently -H, optionally substituted C1-C6 alkyl, optionally substituted aryl,
-NR3R4, -SR5, -OR6 or halo,
R3 and R"* are independently -H, optionally substituted Cχ-C6 alkyl, or a suitable amino protecting group, or together N, R-- and R4 are a phthalimido group, R5 is -H, optionally substituted Ci-Cβ alkyl or a suitable thiol protecting group, and
R6 is -H, optionally substituted C1-C6 alkyl or a suitable hydroxy protecting group;
L is -R7-Q(a)-< where R7 is selected from the group consisting of -CH2~,
-CH2CH2-, -CH2CH2CH2-, -CH=CH-, -C≡C-, -CH=CHCH2-, -CH2CH2=CH-, -CH2C≡C- and -C≡CCH2-, and when R7 is not -C≡C-, R7 may be substituted with C1-C2 alkyl, C1-C2 hydroxyalkyl, or C1-C2 hydroxyalkyl wherein the H on the hydroxy moiety has been replaced with a hydroxy protecting group,
Q is -0-, -S- or -NR8, a is zero or 1,
R8 is -H, optionally substituted C1-C3 alkyl, alkoxycarbonyl or phenoxycarbonyl ; B is selected from the group consisting of: optionally substituted 1,2-, 1,3-, or 1,4- phenylene, optionally substituted 2,3-, 2,4-, or 2,5- thienediyl , optionally substituted 2,3-, 2,4-, or 2,5- furanediyl, optionally substituted 1,2-, 1,3-, or 1,4- cyclohexanediyl, and optionally substituted -CH2CH2-, -CH2CH2CH2-, or -CH2CH2CH2CH2-;
R1 ■N
\
R' IS
A) an α-amino acid residue, selected from the group consisting of -alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine and -valine, OR
where c is zero or 1, d is zero, 1, 2, 3, 4, 5 or 6, R9 are each independently -H or a suitable carboxylic acid protecting group, and R11 is i) -COOR10, where R10 is -H, optionally substituted alkyl or a suitable carboxylic acid protecting group, or ii) -H, -OH, 1-carboxyeth-l-yl, optionally substituted C1-C6 alkyl, optionally substituted cycloalkyl, carboxycycloalkyl, optionally substituted aryl, carboxyaryl, optionally substituted heteroaryl, optionally substituted alkyl (aryl), optionally substituted Ci-Cβ alkoxy, optionally substituted polycyclic, optionally substituted 5-tetrazolyl, or ii) -(CH2)e-U where: e is 0, 1, 2, 3 or 4,
U is -0-CH2-C00H, -S-CH2-COOH or -NR1 R25,
R---2 is -H or a suitable amino protecting group,
R25 is benzoyl or carboxybenzoyl , or iv) -(CH2)e-T, where e is as above, T is phthalimido, -CO2R-1-0, -SO(g)X, -NR13R14, -CONR13R14, CONHS02R15, -PO3H2 or -CO-α-amino acid residue,
R1*-- is as above, g is zero, 1, 2 or 3 , providing that when g is zero, 1 or 2 , X is optionally substituted C1-C6 alkyl, and when g is 3, X is -H,
R13 is -H,
R14 is -H, optionally substituted C±-Cs alkyl,
O
II optionally substituted C5-C7 aryl, -CHR16NR15R16, c aryl ( or a suitable amino protecting group,
R15 is optionally substituted alkyl, optionally substituted aryl, benzyl or carboxyaryl, and each R16 is independently -H or optionally substituted alkyl, and each α-amino acid residue is as above ; providing that all of R---- is so configured such that is not D- or L-glutamic acid,
-alanine, -arginine, -asparagine, -aspartic acid, -cysteine, -cystine, -glutamine, -glycine, -histidine, -hydroxyproline, -isoleucine, -leucine, -lysine, -methionine, -phenylalanine, -proline, -serine, -threonine, -tryptophan, -tyrosine or -valine;
OR
where s1, b' and c' are independently zero or 1, d' is zero, 1, 2, 3, 4, 5 or 6, each R? ' is independently -H or a suitable carboxylic acid protecting group, Rll' is i) -COOR10', where R10' is -H, optionally substituted alkyl or a suitable carboxylic acid protecting group, ii) -H, -OH, 1-carboxyeth-l-yl, optionally substituted C1-C6 alkyl, optionally substituted cycloalkyl, carboxycycloalkyl, optionally substituted aryl, carboxy aryl, optionally substituted heteroaryl, optionally substituted aryl (alkyl), optionally substituted alkoxy, optionally substituted polycyclic, optionally substituted 5-tetrazolyl, or iii) -(CH2)e'-U*. where: e' is zero, 1, 2, 3 or 4,
IT is -0-CH2-COOH, -S-CH2-COOH or -NR12'R25',
R-^ ' is -H or a suitable amino protecting group, R25' is benzoyl or carboxybenzoyl, iv) - ( CH2 ) e ' -T ' , where e' is as above,
T' is phthalimido, -CO2R10 ' , -SO(g')X', -NR13'R14', -CONR13 'R14' , -CONHSO2R15 ' , -PO3H2 or -CO- α-amino acid residue, where RlO ' is as above, g' is zero, 2 or 3 , providing that when g' is zero or 2 , X" is optionally substituted Cχ-C6 alkyl, and when g' is 3, X' is -H, R13 ' is -H,
R-*-4 ' is -H, optionally substituted C1-C6 alkyl,
optionally substituted C5-C7 aryl, -CHR16 ' NR15 ' R16 ' , O
H
_C aryl ^ or a suitable amino protecting group, R-*-5' is optionally substituted alkyl, optionally substituted aryl, benzyl or carboxyaryl, and each R---6' is independently -H or optionally substituted alkyl; OR D) R1 is optionally substituted C3-C20 cycloalkyl or C3-C20 carboxycycloalkyl, and R2 is -H;
OR
E) R- 1S
where J is optionally substituted 5-tetrazolyl or optionally substituted C1-C6 alkyl, y is zero or 1 , y' is zero, 1, 2, 3, 4, 5 or 6 and R-*--1- is as above, and R2 is -H; OR where j is zero, or an integer from 1 to 10, k is zero, or an integer from 1 to 10, R-1-7 and R--- are independently -H or a suitable carboxylic acid protecting group; OR G) R1 and R2 are both - (CH2 ) n-COOR17 , where n is zero, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, and
R17 is as defined above;
OR
where m is zero, 1 or 2 , R17 is as above, and
Y is selected from the group consisting of halo, nitro, amino and optionally substituted alkyl; or a pharmaceutically acceptable salt or solvate thereof .
2. A compound of Claim 1 having the formula
wherein B" is optionally substituted phenylene or thiophenediyl or a pharmaceutically acceptable salt or solvate thereof.
3. The compound of Claim 2 which is γ-4- carboxyphenylsulfonamyl -N-4- [ (2-amino-3H-4-oxo-pyrrolo [2,3- d]pyrimidin-5-yl) eth-2-yl] benzoyl-L-glutamic acid or a pharmaceutically acceptable salt or solvate thereof.
4. The compound of Claim 2 which is γ-3- carboxyphenylsulfonamyl-N-4- [ (2-amino-3H-4-oxo-pyrrolo [2 , 3- d]pyrimidin-5-yl)eth-2-yl] benzoyl-L-glutamic acid or a pharmaceutically acceptable salt or solvate thereof.
5. The compound of Claim 2 which is γ- methylsulfonamyl -N-4- [ (2-amino-3H-4-oxo-pyrrolo [2,3- d]pyrimidin-5-yl) eth-2-yl] benzoyl-L-glutamic acid or a pharmaceutically acceptable salt or solvate thereof.
6. The compound of Claim 2 which is β-methyl-N-
4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-d] pyrimidinyl-5-yl) -eth-2- yl] -benzoyl-L-glutamic acid or a pharmaceutically acceptable salt or solvate thereof.
7. The compound of Claim 2 which is N-{2-[(2- methyl-3H-4-oxo-pyrrolo [2, 3 -d] pyrimidin-5-yl) eth-2 - yl] thiophen-5-yl} -carbonyl-L-glutamic acid or a pharmaceutically acceptable salt or solvate thereof.
8. The compound of Claim 2 which is α-benzoyl-N- 4- [ (2-amino-3H-4-oxo-pyrrolo[2, 3-dJpyrimidin-5-yl) eth-2 - yl]benzoylglutamate or a pharmaceutically acceptable salt or solvate thereof.
9. The compound of Claim 2 which is N-4-[(2- amino-3H-4-oxo-pyrrolo [2 , 3-d]pyrimidin-5-yl ) eth-2- yl] benzoyl-L-glutamic acid γ-benzyl ester or a pharmaceutically acceptable salt or solvate thereof.
10. The compound of Claim 2 which is α-L-valine- N-4- [ (2 -amino-3H-4-oxo-pyrrolo [2, 3-d]pyrimidin-5-yl) eth-2 - yl]benzoyl-L-glutamate or a pharmaceutically acceptable salt or solvate thereof.
11. The compound of Claim 2 which is N-4-[(2- amino-3H-4 -oxo-pyrrolo [2 , 3-d] yrimidin-5-yl ) eth-2 - yl] benzoyl-4-chlorophenylalanine or a pharmaceutically acceptable salt or solvate thereof.
12. The compound of Claim 2 which is N-{2-[(2- methyl-3H-4-oxo-pyrrolo [2, 3 -d] pyrimidin-5-yl ) eth-2 - yl] thiophen-5-yl}carbonyl-L-melphalin or a pharmaceutically acceptable salt or solvate thereof.
13. The compound of Claim 2 which is N-4- [(2- amino-3H-4-oxo-pyrrolo [2 , 3-d]pyrimidin-5-yl) eth-2- yl]benzoyl-L-isoglutamate or a pharmaceutically acceptable salt or solvate thereof.
14 . An active ester intermediate of formula ( I ) :
where v- , L and B have the same definitions as in Claim 1, and R61-- is selected from the group consisting of N-hydroxysuccinimidyl, N-hydroxysulphosuccinimidyl and salts thereof, 2-nitrophenyl, 4-nitrophenyl and 2,4- dichlorophenyl .
15. The compound of Claim 14 wherein B is optionally substituted phenylene or thiophenediyl .
16. A process to make the compounds of formula
(III), or pharmaceutically acceptable salts or solvates thereof, by reacting an active ester of formula (I):
where Θ^-^- , L and B are as defined in Claim 1, R60 is selected from the group consisting of N-hydroxysuccinimidyl,
N-hydroxysulphosuccinimidyl and salts thereof, 2- nitrophenyl, 4-nitrophenyl and 2 , 4-dichlorophenyl , with an amine of formula (II) : HNR-l-R2 (II), where R 1 and R2 are as defined in Claim 1, in the presence of either a silylating agent or a suitable base.
17. The process of Claim 16 further comprising a rapid work-up procedure wherein a compound or salt of formula (III) is isolated and purified by the following procedure: a) optionally adding a suitable diamine; b) adding a suitable aqueous acid; c) separating the product from its solvent; d) preparing the precipitated product physically for collecting, washing and drying; and e) collecting, washing and drying the product.
18. A pharmaceutical composition comprising a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier, diluent or excipient.
19. A method of treating susceptible neoplasms in a mammal in need of such treatment comprising administering a neoplasm growth inhibiting amount of a compound Claim 1, or a pharmaceutically acceptable salt or solvate thereof, to a mammal .
20. A method of treating arthritis in a mammal comprising administering an arthritis inhibiting amount of a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, to a mammal.
21. A method of treating psoriasis in a mammal comprising administering an psoriasis inhibiting amount of a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, to a mammal.
EP97939567A 1996-08-30 1997-08-27 Nonclassical pyrrolo 2,3-d]pyrimidine antifolates Withdrawn EP0923287A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2496496P 1996-08-30 1996-08-30
US24964P 1996-08-30
PCT/US1997/015017 WO1998008382A1 (en) 1996-08-30 1997-08-27 Nonclassical pyrrolo[2,3-d]pyrimidine antifolates

Publications (2)

Publication Number Publication Date
EP0923287A1 true EP0923287A1 (en) 1999-06-23
EP0923287A4 EP0923287A4 (en) 2001-08-01

Family

ID=21823289

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97939567A Withdrawn EP0923287A4 (en) 1996-08-30 1997-08-27 Nonclassical pyrrolo 2,3-d]pyrimidine antifolates

Country Status (5)

Country Link
EP (1) EP0923287A4 (en)
JP (1) JP2000516961A (en)
AU (1) AU4163197A (en)
CA (1) CA2263907A1 (en)
WO (1) WO1998008382A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002232181B2 (en) * 2001-02-15 2004-03-04 Rheon Automatic Machinery Co., Ltd. Food dough rolling apparatus

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
MXPA02008242A (en) * 2000-02-25 2002-11-29 Lilly Co Eli A novel crystalline form of n-[4-[2- (2-amino-4, 7-dihydro- 4-oxo -3h-pyrrolo [2, 3-d] pyrimidin -5-yl) ethyl]benzoyl] -l-glutamic acid and process therefor.
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DK1450811T3 (en) 2001-11-30 2010-02-15 Osi Pharm Inc Compounds specific for adenosine A1 and A3 receptors and uses thereof
DE60236458D1 (en) 2001-12-20 2010-07-01 Osi Pharm Inc PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONISTIC COMPOUNDS, THEIR SYNTHESIS AND USE
CN1620294A (en) 2001-12-20 2005-05-25 Osi药物公司 Pyrimidine A2b selective antagonist compounds, their synthesis and use
KR100714519B1 (en) 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 Bicyclic pyridine and pyrimidine p38 kinase inhibitors
EP1462472A1 (en) * 2003-03-26 2004-09-29 Sigma Kalon Services B.V. A process for the protection of acid groups in polymers
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
TWI374886B (en) * 2006-08-14 2012-10-21 Sicor Inc Processes for preparing intermediates of pemetrexed
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101423524B (en) * 2007-10-30 2010-12-22 齐鲁制药有限公司 Diglutamate derivates and application thereof in preparation of pemetrexed
US8252804B2 (en) 2008-10-01 2012-08-28 Duquesne University Of The Holy Spirit Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same
US20110082158A1 (en) * 2008-10-01 2011-04-07 Aleem Gangjee Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
CA2887727A1 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
AU2014214325B2 (en) * 2013-02-06 2018-06-07 Merck Patent Gmbh Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
CN104341427A (en) * 2014-10-01 2015-02-11 山东铂源药业有限公司 Synthesis method of pemetrexed disodium impurity
US9481678B2 (en) * 2015-02-09 2016-11-01 Duquesne University Of The Holy Ghost Substituted pyrrolo[2,3-D]dipyrimidines for selectively targeting tumor cells with FR-alpha and FR-beta type receptors
GB2553716B (en) 2015-04-17 2020-06-17 Univ Holy Ghost Duquesne Pyrrolopyrimidines as antitumor agents
CN110305135B (en) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 Pemetrexed disodium intermediate and preparation method thereof
CN110305134B (en) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 Pemetrexed disodium intermediate and preparation method thereof
CN110305136A (en) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 A kind of pemetrexed disodium intermediate and preparation method thereof
CN110305137A (en) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 A kind of pemetrexed disodium intermediate and preparation method thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334636A2 (en) * 1988-03-24 1989-09-27 Takeda Chemical Industries, Ltd. Pyrrolopyrimidine derivatives, their production and use
EP0400562A1 (en) * 1989-05-29 1990-12-05 Takeda Chemical Industries, Ltd. Pyrrolopyrimidines, their production and use as tumoricidal agents
EP0402903A1 (en) * 1989-06-14 1990-12-19 Takeda Chemical Industries, Ltd. Production of pyrrolopyrimidines and intermediates therefor
US4996206A (en) * 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
EP0418924A2 (en) * 1989-09-21 1991-03-27 Takeda Chemical Industries, Ltd. Pyrrolopyrimidines, their production and use
EP0431953A2 (en) * 1989-12-08 1991-06-12 Takeda Chemical Industries, Ltd. Pyrrolopyrimidine derivatives, their production and use
EP0434426A1 (en) * 1989-12-20 1991-06-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
EP0438261A2 (en) * 1990-01-16 1991-07-24 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
EP0530537A1 (en) * 1991-08-12 1993-03-10 Takeda Chemical Industries, Ltd. Condensed pyrimidine derivatives, their production and use as antitumor agents
JPH0565286A (en) * 1990-12-14 1993-03-19 Takeda Chem Ind Ltd Determination of anti-malignant tumor agent and reagent therefor
EP0549291A1 (en) * 1991-12-27 1993-06-30 Takeda Chemical Industries, Ltd. Thymidylate synthase inhibitors
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
EP0567223A1 (en) * 1992-03-24 1993-10-27 Eli Lilly And Company Glutamic acid derivatives as antineoplastic agents
JPH069637A (en) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd Condensed pyrimidine derivative, its production and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661148A (en) * 1989-09-19 1997-08-26 Teijin Limited Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and pharmaceutical preparation comprising the same as active ingredient
CZ283281B6 (en) * 1992-09-25 1998-02-18 Eli Lilly And Company PROCESS FOR PREPARING PYRROLO(2,3-d)PYRIMIDINES SUBSTITUTED IN POSITION 5
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US5650511A (en) * 1995-12-12 1997-07-22 Biocryst Pharmaceuticals, Inc. Process for the preparation of 9-deazaguanine derivatives

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334636A2 (en) * 1988-03-24 1989-09-27 Takeda Chemical Industries, Ltd. Pyrrolopyrimidine derivatives, their production and use
EP0400562A1 (en) * 1989-05-29 1990-12-05 Takeda Chemical Industries, Ltd. Pyrrolopyrimidines, their production and use as tumoricidal agents
EP0402903A1 (en) * 1989-06-14 1990-12-19 Takeda Chemical Industries, Ltd. Production of pyrrolopyrimidines and intermediates therefor
EP0418924A2 (en) * 1989-09-21 1991-03-27 Takeda Chemical Industries, Ltd. Pyrrolopyrimidines, their production and use
EP0431953A2 (en) * 1989-12-08 1991-06-12 Takeda Chemical Industries, Ltd. Pyrrolopyrimidine derivatives, their production and use
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
US4996206A (en) * 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
EP0434426A1 (en) * 1989-12-20 1991-06-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
EP0438261A2 (en) * 1990-01-16 1991-07-24 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
JPH0565286A (en) * 1990-12-14 1993-03-19 Takeda Chem Ind Ltd Determination of anti-malignant tumor agent and reagent therefor
EP0530537A1 (en) * 1991-08-12 1993-03-10 Takeda Chemical Industries, Ltd. Condensed pyrimidine derivatives, their production and use as antitumor agents
EP0549291A1 (en) * 1991-12-27 1993-06-30 Takeda Chemical Industries, Ltd. Thymidylate synthase inhibitors
EP0567223A1 (en) * 1992-03-24 1993-10-27 Eli Lilly And Company Glutamic acid derivatives as antineoplastic agents
JPH069637A (en) * 1992-04-17 1994-01-18 Takeda Chem Ind Ltd Condensed pyrimidine derivative, its production and use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 017, no. 376 (C-1084), 15 July 1993 (1993-07-15) & JP 05 065286 A (TAKEDA CHEM IND LTD), 19 March 1993 (1993-03-19) *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 209 (C-1190), 13 April 1994 (1994-04-13) & JP 06 009637 A (TAKEDA CHEM IND LTD), 18 January 1994 (1994-01-18) *
See also references of WO9808382A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002232181B2 (en) * 2001-02-15 2004-03-04 Rheon Automatic Machinery Co., Ltd. Food dough rolling apparatus

Also Published As

Publication number Publication date
EP0923287A4 (en) 2001-08-01
CA2263907A1 (en) 1998-03-05
WO1998008382A1 (en) 1998-03-05
JP2000516961A (en) 2000-12-19
AU4163197A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
WO1998008382A1 (en) Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
FI76791B (en) PROCEDURE FOR FRAMSTATION OF AV 2-AMINO-4-HYDROXIKINAZOLINE PRODUCTS WITH ANTICANCER ACTIVITIES.
CN113307811B (en) Tetrahydropyranyl amino-pyrrolopyrimidinones and methods of use thereof
US20170057972A1 (en) Lactam kinase inhibitors
TW201943712A (en) Multifunctional compound, preparation method therefor, and application thereof in pharmaceuticals
RU2633694C2 (en) Dyetherned phenylaminopyrimidine and pharmaceutical composition containing such connection
WO1995028387A1 (en) Benzamide compound and medicinal use thereof
JP2001501216A (en) Pyrimidine derivative and method for producing the same
US5110818A (en) Anticonvulsive substituted-9-benzyl-9h-purines
AU2020413997A1 (en) Pyridazinyl-thiazolecarboxamide compound
EP2008210A1 (en) Modulation of phosphoryl transferase activity of glutamine synthetase
AU2019414550A1 (en) Fak inhibitor and drug combination thereof
CA2799764A1 (en) Mtor selective kinase inhibitors
AU2019372121A1 (en) Heterocyclic compounds as BET inhibitors
KR20200089219A (en) Aryl or heteroaryl derivatives, and pharmaceutical composition thereof for use in preventing or treating kinase-related disease
JP7201800B2 (en) 3,9-diazaspiro[5,5]undecane-based compounds as inhibitors of FLT3 and AXL
CZ195293A3 (en) PROCESS FOR PREPARING IN 5-POSITION SUBSTITUTED PYRROLO(2,3-d) PYRIMIDINES
CA3037971A1 (en) New benzimidazoles derivatives as tec kinases family inhibitors
AU2020214351A1 (en) Indolo heptamyl oxime analogue as PARP inhibitor
AU2021394411A1 (en) Novel camptothecin derivative, composition containing same, and use thereof
AU2006281359B2 (en) Condensed pyrimidine derivatives as inhibitors of folic acid-dependent enzymes
WO2020077944A1 (en) Purine derivative, preparation method therefor and use thereof
IE60038B1 (en) 4(3H)-oxo-5, 6, 7, 8-tetrahydropyrido-[2, 3-d]pyrimidine derivatives
JP2023503133A (en) Sulfonamide compounds and adenosine receptors targeting CD73
EP4087845A1 (en) Btk inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 20010615

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 43/54 A, 7A 61K 31/505 B, 7C 07D 239/70 B, 7C 07D 487/00 B, 7C 07D 487/04 B, 7A 61P 35/00 B, 7C 07D 487/04 J, 7C 07D 239:00 J, 7C 07D 209:00 J

18D Application deemed to be withdrawn

Effective date: 20010301

RTI1 Title (correction)

Free format text: NONCLASSICAL PYRROLO 2,3-D PYRIMIDINE ANTIFOLATES